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 The gram-positive prokaryotes of the Streptomyces genus are prolific producers of 
secondary metabolites including a plethora of complex polyketide compounds.  These natural 
products are constructed through decarboxylative Claisen condensations of simple malonic acids 
from primary metabolism by multidomain, modular enzymes called polyketide synthases (PKS) in 
a manner analogous to an industrial assembly line.  A prominent example of one such pathway is 
the pikromycin (Pik) cluster from S. venezuelae ATCC 15439, which biosynthesizes a suite of 12- 
and 14-membered macrolide antibiotics.  This pathway has been a workhorse in the Sherman lab 
for in vivo work, in vitro biochemistry, and more recently, biocatalysis and in depth structural 
analysis. 
 This dissertation describes synthetic chemistry, in vitro biochemistry, and in vitro 
biocatalysis focused on the final two PKS modules from the Pik cluster, PikAIII and PikAIV.  First, 
the native pentaketide from the Pik pathway was chemically synthesized and employed to 
optimize in vitro biochemistry/biocatalysis with PikAIII-TE and PikAIII/PikAIV, culminating in a 
biocatalytic platform for macrolide production in 13 linear steps.  Next, the native hexaketide from 
the Pik pathway was synthesized from fermentation derived 10-deoxymethynolide and employed 
to optimize in vitro biochemistry of PikAIV and excised Pik thioesterase (TE) domain, revealing 
the ability to control the catalytic cycle of PikAIV and gain entry to 12- or 14-membered 
macrolactones with greater than 10:1 selectivity for either ring size.  Finally, we simulated 
“combinatorial biosynthesis” in a controlled in vitro environment with PikAIII-TE and PikAIII/PikAIV 
to identify catalytic bottlenecks using unnatural pentaketide substrates that mimic engineering 
early in the pathway. Analyses of results generated to date indict the TE domain as the bottleneck 



















Type I Polyketide Synthases and Polyketide Natural Products 
1.1 Introduction 
Polyketide natural products have been clinical mainstays for over sixty years, with prominent 
examples employed in the treatment of an impressively diverse range of diseases (Figure 1.1). 
Pharmacological properties ranging from antimicrobial, antiparasitic, anticancer, to 
immunosuppressive activities are attributed to polyketides, and many are indispensible to human 
and veterinary medicine.1 These intricate natural products have garnered wide spread attention 
from medical, chemical, pharmacological, and biological scientific communities, each attracted to 
different facets of these compounds; therapeutic potential, structural complexity, synthetic 
construction (total synthesis and method development), pharmacological target elucidation, 
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 The story of the macrolide antibiotics begins in 1950 with the isolation of pikromycin,3 
which was quickly overshadowed by the more efficacious erythromycin A4 entering the clinic in 
the mid 1950s.  R.B. Woodward coined the term macrolide in 1957 as a portmanteau of 
macrolactone glycoside, the essential components of this class of antibiotics.4a Macrolides are 
potent antibacterial agents that disrupt protein synthesis by selectively binding to the 50S subunit 
of the prokaryotic ribosome.5  
Recent studies implicate macrolides as sequence selective allosteric modulators of the 
ribosomal peptidyl transferase center (PTC), and as physical impediments for the growing peptide 
chain in the nascent peptide exit tunnel (NPET).5 In addition, macrolides are known to disrupt the 
process of ribosome assembly by binding to the 50S subunit before full particle assembly.6 While 
erythromycin is still commonly prescribed 60 years after its introduction, the macrolide class has 
evolved substantially over time to afford dramatically improved properties.4a  
Erythromycin, fermented industrially from improved strains of Saccharopolyspora 
erythraea, is considered a first generation macrolide.  While erythromycin is a potent antibiotic, it 
suffers from a number of shortcomings, including acid catalyzed degradation in the human 
stomach to a spiroketal motilin agonist, yielding painful stomach cramps.4a As such, erythromycin 
is administered orally with an enteric coating, which allows the drug be released in more 
hospitable intestinal environment. 
 
The class evolved to second generation macrolides with the introduction of clarithromycin 
and azithromycin (Figure 1.1) which enjoy improved pharmacokinetic (PK) and pharmacodynamic 
(PD) properties. Clarithromycin differs from erythromycin by a single methyl group installed on the 
C-6 hydroxyl group, which improves the acid stability of the drug. Azithromycin is an expanded 
15-membered macrolide, which is synthesized from erythromycin though an oxime mediated 
Beckmann rearrangement and subsequent methylation of the installed secondary amine.  
Azithromycin, distributed as the “Z-Pak,” is one of the most prescribed drugs of all time as it is 
able to treat many types of infections when taken just once daily for 3-5 days. As with all classes 










































Figure 1.2 Representative macrolides  
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macrolides.  While the second generation mainly sought to improve PK/PD properties, the third 
generation addressed acquired resistance.  
Macrolide resistance is conferred through methylation of the RNA bases within the 
ribosome to decrease binding efficacy, efflux of the macrolide out of the cell, and less commonly, 
by direct modification of the macrolide through hydrolysis of the macrolactone, phosphorylation, 
or glucosylation.4a MLSB (macrolide, lincosamides, streptogramin B) resistance is conferred 
through mono- or dimethylation of A2058 in 23S ribosomal RNA.  MLSB is most commonly 
encountered though induction of erm (erythromycin resistance methylase) genes, though there 
are examples of constitutively expressed erm genes.  Induction of ermC occurs when mRNA 
coding for a 19-amino acid peptide preceding the ermC gene stalls after 9-amino acids have been 
translated (in the presence of erythromycin.)7 This leads to a change in the mRNA secondary 
structure and allows the ribosome to bind to the previously inaccessible ermC ribosome binding 
site (RBS) and translate ermC.  This process requires the presence of the L-cladinose sugar of 
erythromycin, as such, third generation macrolides are known as “ketolides” where L-cladinose 
has been cleaved and the resulting C3 hydroxyl group is oxidized to a ketone.  
 
Pikromycin is naturally a ketolide, and while pikromycin and ketolides derived from 
erythromycin display only weak antibacterial activity, the induction of MLSB genes is greatly 
diminished. Screening of heterocyclic side chains to improve binding efficacy generated 
telithromycin (approved 2004), cethromycin, and solithromycin and conferred another benefit, 
evasion of efflux pumps. Telithromycin and other ketolides are able to bind to two or more sites 
on the ribosome, and have been observed to overcome even constitutively expressed erm genes 
in some cases.8 While the evolution of the macrolide class is a triumph of modern medicine, 
further exploration of macrolide chemical space is extremely limited.  
While briefly mentioned above, all clinically employed macrolides are furnished through 
semi-synthesis of fermentation-derived erythromycin limiting modification of deep-seated 
functionality.  Furthermore, performing chemistry on a complex natural product requires intensive 
synthetic efforts.  Installing a single methyl group onto the C6 hydroxyl group requires a multi-step 













































sequence to generate clarithromycin, and conversion of clarithromycin to telithromycin requires 8 
more steps.9 Total synthesis of macrolides is achievable10 but is constrained to academic interest, 
as the complexity of these compounds requires understandably long synthetic schemes and low 
overall yields. Though total synthesis is unlikely to provide metric tons of designer macrolides in 
the foreseeable future, the biosynthetic machinery used to satisfy clinical demand for macrolides 
could yield macrolide libraries through direct fermentation if the natural products community can 
understand and manipulate these complex pathways.  Furthermore, following identification of a 
lead unnatural macrolide, industrial fermentation to produce the API (or starting material thereof) 
would fall within existing workflows. 
 Isolation and utilization of polyketide natural products predates identification of the 
biosynthetic machinery responsible for the biogenesis of these compounds by several decades.  
The early 1990’s enjoyed a polyketide renaissance, with identification and subsequent cloning of 
type I polyketide synthases.11 The genes coding for PKS proteins were aligned with domains 
known in type I modular fatty acid synthases (FAS, Figure 1.4).12 The homology between PKS 
and FAS genes supported the long held hypothesis that polyketides were biosynthesized in a 
manner analogous to fatty acids,12 with a few key differences. 
  
Type I FAS enzymes biosynthesize fatty acids in an iterative manner, where malonyl-Coenzyme 
A (M-CoA) delivers malonate and iterative rounds of decarboxylative Claisen condensations and 
β-keto tailoring yield a mature chain, which is then released from the synthase. PKS modules, on 
the other hand, only perform a single decarboxylative Claisen condensation from a specified 
malonate, and β-keto tailoring domains need not reduce to the alkane (though possible), before 
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Figure 1.4 Fatty acid and polyketide synthases   
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polyketide chain, allowing for precise biosynthesis of natural products. 
 
The catalytic cycle of a generic type I PKS module (Scheme 1.1) can involve as little as 
three requisite domains.13 The smallest functional module must contain ketosynthase (KS), 
acyltransferase (AT), and acyl carrier protein (ACP) domains, where the AT is first acylated by 
KS AT ACP
HS HO HS
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  domain	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6.	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2
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Scheme 1.1 Type 1 polyketide synthase catalytic cycle(s)          
10.	  TE	  offloads	  
mature	  polyketide 
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malonyl(or methylmalonyl, ethylmalonyl, etc.)CoA.  The ACP accepts the malonate from the AT 
domain, and the KS domain accepts a growing polyketide from the upstream ACP and catalyzes 
a stereospecific Claisen condensation to extend the chain by two carbons.  If the module lacks 
domains responsible for β-keto tailoring then the chain will be transferred to the next module, if 
ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) domains are present, then the 
β-keto will be processed to a hydroxyl group (KR), alkene (DH), or alkane (ER), respectively.   
The final module of a type I pathway will posses a thioesterase (TE) domain at the C-
terminus, and this domain is responsible for off loading the mature polyketide as a hydrolyzed 
carboxylic acid or lactonized as a ring.  In the case of macrolide antibiotics such as methymycin, 
erythromycin, pikromycin, and methymycin, the TE offloads a 12- or 14- membered macrolactone 
ring.  Such macrolactonization events are commonly performed in biomimetic total syntheses,14 
though such reactions are notoriously difficult to perform10b requiring high dilution to prevent 
dimerization/polymerization and often elevated temperatures and extended reactions times to 
overcome entropic barriers.  Biomimetic ring closings have lost favor in recent years to ring 
closing metathesis (RCM) and other metal-based methods that are able to coordinate distal 
functionality and promote efficient cyclization. In contrast, TE domains excel at 
macrolactizations15 employing extremely mild reaction conditions (buffered H2O as solvent, room 
temperature, high dilution not required). 
 
The pikromycin biosynthetic cluster (Pik) was first reported in 1998 from S. venezuelae 
ATCC 15439 (Figure 1.5).16 A generic type I PKS probe revealed two PKS pathways, though a 
more specialized DNA probe tylAI involved in dososamine biosynthesis from the tylosin pathway 
Figure 1.5 The pikromycin (Pik) biosynthetic pathway24   
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was used to locate the Pik pathway. Genetic knockouts of the other Type I PKS pathway had no 
effect on the biosynthesis of pikromycin or methymycin.  A cosmid library was generated, 
resulting in complete coverage of the ~60 kilobase Pik pathway.  Analysis of the assembled DNA 
sequences revealed 18 clustered genes: two ribosomal methyl transferases (pikR1, pikR2), four 
polyketide synthases (pikAI, pikAII, pikAIII, pikAIV), a type II thioesterase (pikAV), nine genes 
involved in desosamine biosynthesis and appendage (desI-desVII and desR), a p450 (pikC), and 
a pathway regulator (pikD) . 
 
A series of knockout experiments verified that this pathway did indeed produce two classes of 
macrolides, the 12-membered methymycins and the 14-membered pikromycins. Disruption of 
pikAI resulted in a mutant that produced neither class of macrolactones or macrolides, while 
disruption of desosamine biosynthesis (desVI and desV) produced macrolactones narbonolide 
and Cthynolide but not macrolides. Disruption of the type II thioesterase (pikAV) resulted in 
dramatically decreased titers though macrolide production remained detectable. Disruption of the 
pikC p450 led to accumulation of reduced macrolides YC-17 and narbomycin (Scheme 1.2). 
The results of this study were groundbreaking as this was the first time a single type I 
PKS pathway demonstrated to produce two different classes of polyketides (12-memebered 
methymycin and 14-membered pikromycin), additionally, the substrate promiscuity of tailoring 


























































as a near ideal model system for combinatorial biosynthesis efforts. 
 
To further elucidate the unique ability of PikAIII and PikAIV to catalyze the formation of 
two different macrolactones, the Sherman lab moved to in vitro analysis.17 Briefly, PikAIII and 
PikAIV as 6xhis constructs were heterologously expressed in E. coli BL21 (DE3) cells co-
expressing an sfp gene from B. subtilis (for post-translational modification of phosphopantetheine 
onto the ACP domain) and purified through nickel affinity chromatography. Four diketide 
substrates possessing the four possible stereochemical configurations were synthesized as N-
acetylcysteamine thioesters and incubated with purified protein, NADPH, and methylmalonyl-
coenzyme A (MM-CoA), where the C2 position of the malonate was radiolabeled with 14C. After 
incubation, the reactions were analyzed by radio-TLC (with verification from authentic standards). 
Multiple outcomes could be envisioned when incubating unnatural substrates with PKS modules 
including 1) substrate not accepted 2) substrate hydrolyzed 3) substrate accepted by PikAIII and 
cyclized spontaneously yielding a reduced triketide product 4) substrate accepted by PikAIII and 
cyclized by PikAIV TE yielding a reduced triketide product 5) substrate accepted by PikAIII and 
passed to PikAIV yielding a tetraketide product 6) substrate accepted by PikAIV and cyclized 
yielding an oxidized triketide product. The (2S,3R) syn-substrate was preferentially accepted 
under all conditions (PikAIII, PikAIV, and PikAIII/PikAIV), though PikAIV could also accept the 



































































(2R,3S) syn-configuration. Neither anti-configured provided detectable conversion to tri- or 
tetraketide products indicating preference for syn diketide substrates. The (2S,3R) syn-substrate 
yielded single (radioactive) products when incubated with PikAIII or PikAIV monomodules, but 
gave all three possible products when incubated with PikAIII/PikAIV with the reduced triketide as 
the predominant product. Of note is the glacial rate (0.0045-0.017 kcat/min) of conversion with 
diketide substrates when compared to chicken liver fatty acid synthase (FAS, 48 kcat/min), a 
difference of four orders of magnitude.18 This incredible difference is rate between the two 
megasynthases could be an inherent (primary vs. secondary metabolism), or perhaps due to 
suboptimal catalysis when employing unnatural diketide substrates. 
 
To test the hypothesis that catalysis is poor with diketide substrates, native substrates 
were synthesized19 and tested in conditions identical to that of aforementioned diketide substrates 
(Scheme 1.4.) While native polyketide substrates represent a significant investment in synthetic 
chemistry, the stark contrast in enzymatic catalysis left no doubt to the necessity of employing 
native substrates when studying these complex enzymes.  Measured rates with native substrates 
Scheme 1.4 In vitro analysis of PikAIII and PikAIV with native substrates 
module substrate product kcat (min-1) 
PikAIII-TE pentaketide 10-dml >0.55 
PikAIV pentaketide nbl - 
AIII/AIV pentaketide 10-dml 3 
AIII/AIV pentaketide nbl 3.3 
























































were 2-3 orders of magnitude faster than with diketide model compounds, approaching that of 
chicken liver FAS [48 vs. 4.4 kcat (min-1)], dispelling the notion that secondary metabolite 
synthases are substantially slower than those from primary metabolism.  
Recent work from a four-group collaboration (Håkansson, Sherman, Smith, and Skinitotis 
laboratories) provided new insights to both PKS structure and catalytic cycle.20 PikAIII from the 
Pik pathway was selected for in depth electron cryo-microscopy, ultimately providing sub-
nanometer-resolution and capture of multiple conformations within the catalytic cycle.  Briefly, a 
PikAIII 6xhis construct was expressed in E. coli Bap1 cells21 (genome incorporation of the sfp 
gene from B. subtilis) and purified through nickel affinity chromatography, and two subsequent 
rounds of gel filtration chromatography. Purified PikAIII was absorbed onto mesh grids followed 
by blotting and vitrification.  Vitrified samples were imaged with a transmission electron 
microscope equipped with a field emission gun. Imaging was conducted at ~20 electrons per Å2 
at a magnification of x66,964. Particles were selected and refined from a sphere-like initial 
reference to provide a structure of PikAIII with a final resolution of 7.3-9.5Å (Figure 1.5). This 
model was fit with X-ray crystal data from homologous domains from the 6-deoxyerythronolide B 
synthase,22 providing a first glimpse into the overall architecture of a PKS module for the first 
time.  PikAIII forms a 328 kilodalton dimer that revealed an internal reaction chamber where the 
ACP is free shuttle the growing polyketide chain to the next catalytic domain as processing 
occurs. This structure is quite different from the anticipated FAS architecture (Figure 1.5).  A 
fused construct of PikAIII where ACP4 was fused to the N-terminus of the KS domain(KS active 
Figure 1.6 Cryo-EM structure of PikAIII 
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site cysteine was mutated to alanine and ACP5 was deleted) elucidated how modules are able to 
pass growing polyketides to the next module. ACP5 was loaded with pentaketide-CoA using SFP 
and Cryo-EM of this construct observed ACP4 docked on top of KS5, where the ACP is poised to 
deliver substrate to the KS domain (Figure 1.6). 
 
Next, the original construct was used to observe how ACP5 oriented relative to the KS domain 
when loaded with MM-CoA. When loaded with methyl-malonate, ACP5 oriented itself far from 
where pentaketide loaded ACP4 positioned itself to KS5. This observation, supported with 
mutagenesis coupled with biochemical assays, suggests a second entrance tunnel into the KS, 
where the Claisen condensation occurs (Figure 1.7). 








































Incubation of PikAIII with the thiophenol-thioester of the Pik pentaketide (see chapter 2) loaded 
the active site cysteine 209 of the KS domain with high fidelity leading to global conformational 
shifts including AT moving closer to the KS domain, 
several loops shifiting in the KS domain, and repositioning of the ACP.  Most dramatically, the KR 
has undergone an end-to-end flip of roughly 180° (Figure 1.8.) To observe the module after the 




















































Figure 1.9 Cryo-EM structure of PikAIII with Pik pentaketide 
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Claisen condensation has occurred, PikAIII was incubated with MM-CoA and the thiophenol 
thioester pentaketide (Figure 1.9.) 
 
In this structure, the KR remains proximal to the AT, and the AT is shifted toward the KS by 8Å, 
possibly preventing intermediate transfer from the upstream PikAII ACP4 to the KS5 active site.  
Given the long, 43 amino acid linker between the KR and ACP, it is unclear whether the KR acts 
on the same or opposite monomer. In any event, this conformational change allows the β-
ketohexaketide access to a KR domain for the final reduction before being passed to PikAIV. 
 For the final catalytic step, PikAIII was incubated with the thiophenol pentaketide, MM-
CoA, and NADPH to generate the reduced β-hydroxyhexaketide (Figure 1.10) which generated 
three independent conformational states for the final round of catalysis. In all conformers, the 
catalytic domains are identically positioned, with the KS side entrance occluded and the KR 
domain oriented with its active site proximal to the AT.  Strikingly, the ACP domains are below the 
KR domain and completely outside the catalytic chamber is each conformer. In all conformers, 
Ser 1438 is pointing away from PikAIII, appearing poised to transfer the fully processed 
polyketide to PikAIV.  This elucidates how PKS modules maintain directional fidelity, where the 
substrate is sequested within the internal reaction chamber until it has been fully processed. Only 
after complete processing is the polyketide ejected from the reaction chamber allowing transfer to 
the downstream PKS module. 











































1.2 Thesis Outline 
Based on the strong foundation of prior PKS enzymology established in the Pik pathway, we 
sought to build upon existing knowledge and develop PikAIII-TE, PikAIII and PikAIV beyond 
considerable obstacles such as radioactive assays and requirement of cost prohibitive cofactors.  
Ideally, we sought to improve the throughput and cost-per-reaction of in vitro biochemistry to 
levels amenable for studying complex facets of PKS function that would potentially require 
thousands of reactions to elucidate. 
Chapter 2 focuses on developing PikAIII-TE, and PikAIII/PikAIV in vitro biochemistry with the 
synthetic Pik pentaketide through optimizing reaction parameters. During the course of this work, 
nearly every component of in vitro PKS biochemistry was optimized, including 1) thioester handle 
to load the enzyme and initiate catalysis 2) replacement of expensive MM-CoA with inexpensive 
synthetic MM-NAC 4) replacement of stoichiometric NADPH to NADP+ recycling requiring just 10 
mol % of the cofactor 5) deployment of PKS modules as purified or crude cell preparations 6) 
deployment of thiol scavengers to improve product yield through minimizing conjugate addition to 
the starting material or macrolactone products 7) Improved conversion enabled abandoning 
antiquated radioactive assays and introduction of routine, medium throughput HPLC analysis. 
Ultimately, the optimized system(s) enabled preparative production of either 10-
deoxymethynolide or narbonolide in just 12 linear steps. With synthetically useful PKS catalysis 





































Figure 1.11 Cryo-EM structure of PikAIII with Pik pentaketide, methyl malonate, and NADPH 
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biotransformation using engineered variants of ATCC 15439 S. venezuelae.  Through the 
combination of synthetic chemistry, PKS catalysis, and whole cell biotransformations, we 
synthesized a suite of five Pik macrolides in 13 linear steps, and reported these findings in 2013 
(Hansen, D. A.; Rath, C. M.; Eisman, E. B.; Narayan, A. R.; Kittendorf, J. D.; Mortison, J. D.; 
Yoon, Y. J.; Sherman, D. H. J. Am. Chem. Soc. 2013, 135, 11232). These advances have been 
leveraged in three other publications since then, (Whicher, J. R.; Smaga, S. S.; Hansen, D. A.; 
Brown, W. C.; Gerwick, W. H.; Sherman, D. H.; Smith, J. L. Chem. Biol. 2013, 20, 1340. 
 Whicher, J. R.; Dutta, S.; Hansen, D. A.; Hale, W. A.; Chemler, J. A.; Dosey, A. M.; 
Narayan, A. R. H.; Hakansson, K.; Sherman, D. H.; Smith, J. L.; Skiniotis, G. Nature 2014, 510, 
560. Dutta, S.; Whicher, J. R.; Hansen, D. A.; Hale, W. A.; Chemler, J. A.; Congdon, G. R.; 
Narayan, A. R. H.; Hakansson, K.; Sherman, D. H.; Smith, J. L.; Skiniotis, G. Nature 2014, 510, 
512.) highlighting the dividends paid by investing in reaction optimization and assay development. 
Chapter 3 revisits standalone PikAIV using a panel of Pik hexaketide substrates to elucidate 
the influence of substrate ester in determining the outcome of PikAIV catalysis. The Pik 
hexaketide substrates were accessed through chemical degradation of fermentation derived 10-
deoxymethynolide from an engineered variant of ATCC 15439 S. venezuelae. As the Pik 
hexaketide is prone to degradation during routine procedures such as SiO2 chromatography or 
storage at -20 °C, we developed protection strategies to alleviate this experimental bottleneck.  
We pursued two distinct protective groups 1) a small methyl ether that would remain attached 
throughout the catalytic cycle, and 2) a 2-nitrobenzyloxymethyl ether that could be cleaved by 
irradiation with ultraviolet light immediately before use to provide the native hexaketide on 
demand. The advances in substrate stabilization enabled evaluation of substrate esters, where 
we observed dramatic variation in the product distribution provided though PikAIV catalysis, with 
greater than 10:1 selectivity for either the 14 membered macrolactone narbonolide through full 
module catalysis or the 12 membered macrolactone 10-deoxymethyonolide through direct 
macrolactonization.  The findings of this work have been submitted for publication (Hansen, D. A.; 
Koch, A. A.; Sherman, D. H.submitted). 
Chapter 4 explores the complex topic of combinatorial biosynthesis in Type I PKS pathways. 
The linear, modular nature of PKS enzymes could, at least in theory, lead to production of natural 
product analog libraries or direct fermentation of a specific unnatural product through rational 
enzyme engineering or directed evolution efforts. However, combinatorial biosynthesis has been 
largely unsuccessful, where no methods or products from such efforts have yet to reach 
commercial viability.  While some unnatural products have been reported in the literature, the 
overwhelming majority of combinatorial pathways suffer from greatly diminished titers relative to 
WT due to numerous complicating factors when engineering these complex pathways.  As such, 
we chose to explore the tractable Pik pathway and “simulate combinatorial biosynthesis” early in 
the pathway (PikAI) and evaluate how WT PikAIII-TE or PikAIII/PikAIV PKS modules were able to 
process combinatorial polyketides. Accordingly, we synthesized a panel of unnatural pentaketides 
16	  
bearing modifications that would have occurred if the loading module or PikAI possessed a 
mutant AT domain accepting different extender units (malonate vs. methyl malonate) or mutant 
KS domain to construct all possible stereochemical configurations derived from the Claisen 
condensation.  By directly assaying these combinatorial pentaketides with WT PikAIII-TE or 
PikAIII/PikAIV we can evaluate how a downstream PKS module can handle early pathway 
engineering while avoiding protein-centric complications arising from protein engineering or 
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 Total synthesis of macrolide natural products presents a formidable challenge to the 
synthetic chemist. While total synthesis is capable of furnishing minute quantities of macrolides,1 
this approach is at present constrained to academic interest, as the complexity of these 
compounds requires understandably involved synthetic schemes and low overall yields. Although 
total synthesis will not provide metric tons of designer macrolides in the foreseeable future, the 
biosynthetic machinery used to satisfy clinical demand could conceivably furnish designer 
macrolides at industrial scale and within existing workflows if the natural products community can 
understand and manipulate these complex pathways. Toward this end, we sought to optimize in 
vitro PKS catalysis of the final two modules of the Pik macrolide pathway (PikAIII and PikAIV) to 
facilitate higher-throughput analysis and dispense of antiquated radioactivity based assays. While 
PKS optimization was initially envisioned simply as a means to streamline biochemical 
characterization for basic study of these complex enzymes, advances in PKS catalysis ultimately 
allowed for biocatalytic synthesis of Pik macrolides. 
 
2.2 Synthesis of the Pik pentaketide seco-acid 
 
 In order to study the final two modules of the Pik pathway, PikAIII and PikAIV, we first 
needed to synthesize the native pentaketide substrate.  This substrate has been synthesized 
previously during initial characterization of PikAIII (Scheme 2.1).2  
 
Aldrich et al. recognized a disconnection of the central α,β-unsaturated ketone allowing for a 
convergent coupling of two fragments via a barium hydroxide mediated Horner-Wadsworth-
Emmons olefination.3 This approach proved highly effective at constructing the Pik pentaketide, 
1	   2	   3	  














and, as such, we chose to utilize the same central disconnection in a manner more suitable for 
analog synthesis (vide infra, Chapter 4). We envisioned a cross-metathesis union of the two 
fragments using olefin metathesis catalysts such as Grubbs 2nd generation4 or Hoveyda-Grubbs 
2nd generation.5 This would allow for utilizing common α,β-unsaturated ketone left fragment, and 
a variety of monosubstituted olefin right fragments(Scheme 2.2).  
 
According to Grubbs,6 alkenes can be categorized intro four different types based upon reactivity 
under cross-metathesis conditions with 2nd generation catalysts (Figure 2.1). Type I alkenes will 
homodimerize rapidly and the subsequent dimers are still accessible to metathesis catalysts and 
can go on to react with other alkenes. Type II alkenes homodimerize slowly, and homodimers are 
sluggish to react further. Type III alkenes do not homodimerize, but will react participate in 
metathesis reactions with type I and II alkenes. Type IV alkenes are inert to cross-metathesis but 
do not deactivate metathesis catalysts.  
 
When attempting cross-metathesis with two type I alkenes, a statistical mixture of products would 
be expected unless one partner is used in great excess, and E/Z selectivity is often poor. 
However, cross metathesis between a type I and type II alkenes, such as a type II α,β-
unsaturated ketone 4, and type I mono-substituted olefin 5 allow high yielding metathesis to occur 
without considerable excess of either partner and typically greater than 20:1 E/Z selectivity. With 
this straightforward approach in mind, we envisioned a scalable synthesis of 4 through a routine 
sequence involving Myers alkylation,7 which has been successfully employed in the synthesis of 
related DEBS pentaketide.8 Other options were considered, the most attractive being 
desymmetrization of meso-dimethyl glutaric anhydride via [Rh(COD)Cl]2/t-Bu-PHOX controlled 
alkylzinc addition.9 Type I silyl-ether 5 could be accessed through robust Evans aldol 
methodology.10  
 The synthesis of 4 began with commercially available (R)-Roche ester (6), which is a 
product of enantioselective microbial oxidation of isobutyric acid,11 a common starting material for 
polyketide natural products where the initial stereocenter is “bought.”12 A rapid three step 
1	   4	   5	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procedure prepares 6 for the Myers alkylation, TBS protection of the primary hydroxyl group, 
DIBAL-H reduction of the ester to a hydroxyl group which is then iodinated to provide 7 under 
Appel like conditions (Scheme 2.3). This three-step sequence was optimized to avoid 
chromatography until after iodination, and was performed in a single day on several occasions.13  
 
 7 was alkylated initially using (S,S)-pseudoephedrine propionamide to 8,7 though later 
efforts employed (S,S)-pseudoephenamine propionamide14 under similar conditions with identical 
results (dr >20:1) as pseudoephedrine became harder to acquire from commercial suppliers 
(Scheme 2.3).  While the Myers alkylation is a robust and scalable reaction,15 displacement of the 
auxiliary with ethyllithium (EtLi) toward 4 proved to be unexpected bottleneck. EtLi is 
commercially available though expensive, dilute (0.5 M) in benzene:cyclohexane, and often hard 
to acquire, compared to n-BuLi which is widely available as inexpensive, concentrated (2.5-10 M) 
solutions in hexanes. While initial displacement of the pseudoephedrine auxiliary with EtLi was 
indeed successful, we decided to move to n-BuLi displacement to generate 9, which would 
ultimately provide butyl ketoacid 10 (Scheme 2.4) instead of the originally targeted ethyl ketoacid 
towards 4. Upon oxidation to α,β-unsaturated ketone from either either 4 or 10, we expected 
similar reactivity during cross-metathesis to a type I right fragment.  
 
Transformation of silyl ether 9 to ketoacid 10 was accomplished under in a single step with a 
RuO4 oxidation under Sharpless conditions16 which served to both oxidize the silyl ether to a silyl 
ester with concomitant loss of the TBS group and without epimerization of the α 
stereocenter(Scheme 2.4). This direct oxidation contributes to the step economy of this scheme 
when compared to a three step deprotection, alcohol to aldehyde oxidation, and final aldehyde to 
acid oxidation. More importantly, this approach bypasses the unprotected alcohol, which would 
be expected to form a thermodynamically favorable pyran hemiketal17 posing multiple potential 
complications.  With a reliable route to 10 in hand we began to evaluate methods to 
dehydrogenate the saturated ketone. A number of methods exist for such dehydrogenations, the 
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Scheme 2.3 Conversion of (R)-Roche ester (6) to amide 
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Scheme 2.4 Conversion of amide 8 to amide 10 
	  
8	   9	   10	  
TBSO
O    n-BuLi












reaction involves oxidation of silyl-enol ethers with stoichiometric Pd(OAc)2 or 50 mol % Pd(OAc)2 
using p-benzoquinone as a co-oxidant. Of primary concern is exclusively trapping the kinetic 
enolate of 10 (at C6) without concomitant deprotonation of the C2, which would become 
reasonably acidic after the acid is transiently protected as a silyl-ester. Initial attempts were met 
with considerable resistance, where attempting to trap the kinetic enolate with LDA/TMSCl at -78 
°C and subsequent oxidation with Pd(OAc)2 or IBX19 provided variable product mixtures of 
partially epimerized α,β-unsaturated ketone 11, 
 
and partially epimerized recovered starting material 10. Switching from LDA to LHMDS eliminated 
epimerization,20 and implementation of an acetone quench to scavenge excess LHMDS/TMSCl 
prior to aqueous workup improved reproducibility of the process(Scheme 2.5). Dehydrogenation 
to 11 with stoichiometric Pd(OAc)2 resulted in difficulties during purification, while employing the 
inexpensive alternative IBX could be removed more readily by column chromatography.  Trace 
quantities of 10 observed from hydrolysis of the intermediate silyl-enol ether were somewhat 
separable via SiO2 chromatography, though readily separable via AgNO3:SiO2 chromatography. 
With a scalable route to 11 secured we turned our attention to the right fragment 5. 
 Type I olefin 5 was easily secured through routine Evans aldol chemistry,21 reductive 
displacement of the oxazolidinone auxiliary with LiBH4,22 followed by IBX oxidation and Wittig 
olefination (Scheme 2.6). 
 
With both fragments completed, we began to evaluate cross-metathesis conditions to forge 
compound 1. We screened Grubbs 2nd generation4 or Hoveyda-Grubbs 2nd generation5 beginning 
in CH2Cl2 at room temperature with 3 mol % of either catalyst, 1 equiv 11 (0.1 M) and 1.5 equiv 5 
(0.15 M). Only trance conversion was observed at room temperature, and raising the temperature 
reflux (40 °C) improved the rate somewhat but it the reaction was still too slow to be synthetically 
useful. Moving to PhMe and increasing the temperature to 60°C, 70°C, 80°C improved the initial 
rate but led to variable yields with incomplete conversion. Additional optimization ultimately led us 
to run the reaction neat at 50 °C with vigorous stirring. When run neat, catalyst initiation is easily 
Scheme 2.5 Oxidation of saturated 10 to α,β-unsaturated ketone 11 
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Scheme 2.6 Synthesis of olefin 5 
	  









87% over two steps
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observed through visible etheylene gas evolution. After 12 h at 50 °C, only trace 11 can be 
observed by TLC and crude 1H NMR indicates complete conversion to 1(Scheme 2.7).  
 
2.3 Optimization of PKS biochemistry 
 
Just 2 steps are required to prepare the seco-acid 1 for in vitro enzymatic reactions: esterification 
and deprotection. We considered the (thio)ester of the substrate required to load a PKS enzyme 
as a logical place to start our optimization efforts. N-acetylcysteamine (NAC) thioesters have 
been used exclusively (save rare acyl-ACP examples) for studying PKS enzymes in vitro. The 
first instances of using NAC thioesters to study PKS enzymes predates knowledge of the 
enzymes themselves, where isotopically labeled natural product precursors were employed as 
NAC thioesters23 with the aim of penetrating the cell wall of the producing organism before uptake 
by the biosynthetic pathway. These pioneering studies laid the foundation for future in vitro PKS 
biochemistry, and the use of NAC thioesters became universal without evaluation of other means 
to acylate a given module.  With a seemingly obvious experiment is left unexplored in the 
literature, we were suspicious that perhaps deviation from NAC esters was met with failure and 
thus unreported. The use of NAC could be justified as this moiety mimics the terminal portion of 
the phosphopantetheine (ppant) arm that polyketide substrates are tethered to in vitro, however, 
this logic doesn’t withstand scrutiny; there is no evidence that the KS domain recognizes the 
ppant arm of the upstream ACP.  Interaction of two PKS modules is mediated by C and N 
terminal docking domains24 placing the ACP in close proximity to the KS for chain transfer. When 
performing PKS biochemistry with a purified PKS module, this protein-protein interaction is 
absent requiring the substrate to diffuse onto the active site cysteine KS domain.  If we assumed 
no recognition of the NAC moiety, a more reactive ester could potentially enhance the rate of 
acylation, and, in turn improve PKS catalysis. Such effects have been studied in detail within the 
context of native chemical ligation,25 where transthioesterification between a terminal cysteine 
and a synthetic thioester must occur prior to rearrangement to the native amide backbone. Proper 
selection of a thioesters ester can provide complete ligation in a matter a minutes, while improper 
selection can leave a ligation incomplete after multiple days.  Aryl thioesters undergo 
transthioesterification more readily than (most) alkyl thioesters,25 so we sought to generate a 
small panel Pik pentaketide aryl thioesters to assay against the NAC thioester. Aqueous 
hydrogen fluoride deprotection of silyl-ether 1 provided alcohol 13 which was reductively 
thioesterified using commercial aryl disulfides(Scheme 2.8). We synthesized NAC thioester as 
Scheme 2.7 Cross metathesis of 5 and 11 to yield 
1 








described previously,2 and thiophenol thioester 15 from phenyl disulfide and tributylphosphine.  
Initial attempts using triphenylphospine as the reducing agent were sluggish,26 suggesting that 
the nucleophilicity of the phosphine plays a key role in promoting reductive thioesterification.27  
   
16 was synthesized in a similar manner by employing 2,2’-dipyridyldisulfide, though 17 required 
more creative conditions due to the insolubility of 4,’4-bis(2-amino-6-methyl-pyrimidyl)disulfide.  
When attempting to synthesize 17 PhH at 100 °C using PBu3, the second equivalent of 4-(2-
amino-6-methyl-pyrimidyl)sulfide underwent conjugate addition into the α,β-unsaturated ketone.  
Substituting PPh3 for PBu3 provided 17 as an inseparable mixture of O=PPh3, requiring the use of 
solid supported PPh3.   
 With pentaketides in hand we incubated 14-17 with purified PikAIII-TE, methylmalonyl 
extender unit 19 or 23 (vide infra, Schemes 2.9 and 2.10), and biological hydride donor 20 or 
(vide infra, Schemes 2.9) under nonoptimized conditions to get some sense of efficacy. After 
initial frustrations with ultra-low throughput radio-TLC, we attempted more modern analysis via 
sensitive quadrapole time of flight liquid chromatography/mass spectrometry (QTOF LC/MS). 
One-hour incubation of 14-17 with PikAIII-TE revealing significant differences in conversion 
depending on the type of ester employed.  Thiophenol thioester 15 produced ~4 times more 10-
dml (18) relative to traditionally employed NAC thioester 14, while 16 and 17 enjoyed ~2-fold 
increases relative to 14.  As the thiophenol thioester 15 was superior in terms of both enzymatic 
conversion and ease of synthesis, we sought to attain absolute quantification along the reactions 
time course. While high-end LC/MS analysis could potentially replace radio-TLC to analyze PKS 
biochemistry, concerns of variation in ionization efficiency from run-to-run, expense, and limited 
availability of instrument time led us to consider other analysis methods.  10-dml (18) has a weak 
chromophore (α,β-unsaturated ketone) which absorbs at ~236nm making simple HPLC analysis 





































challenging. However, the dramatically improved conversion of 15 to 10-dml (18) allowed us to 
develop a medium-throughput HPLC based work-flow for future optimization(Scheme 2.8). 
Scheme 2.9 illustrates how an in vitro PKS reaction is typically performed,2,8 where a synthetic 
substrate is incubated with a purified module and requisite cofactors.  While aforementioned 
considerations of low conversion were improved through thioester optimization thus enabling 
HPLC based workflow, we next sought to address cofactor considerations of poor atom economy 
and exorbitant expense. 
 
The first cofactor examined was methylmalonyl-coenzyme A (MM-CoA, 19), which is the 
endogenous cofactor responsible for delivering methylmalonate to the AT domain. 19 is 
commercially available and universally used in a stoichiometric manner to study PKS modules in 
vitro. Testing a defined hypothesis with a small number of microscale PKS reactions can justify 
the cost of 19 as only a few milligrams would be required, however, we expected to run 
thousands of reactions where the cost of 19 would quickly become unsustainable.  A lone report 
in the literature suggested truncation of the CoA moiety can still function as a viable 
methylmalonate cofactor28 with DEBS PKS modules, albeit at a higher concentrations.   In the 
case of MM-NAC (23), it is likely that the AT domain does indeed recognize the ppant arm of CoA 
as this transfer is not mediated by protein:protein interactions and the use of a NAC thioester can 
be justified in this manner.  As such, we sought to reproduce this result with the Pik modules. We 
were able to reproduce the reported synthesis of 23 at small scale though the one step synthesis 
from methyl meldrum’s acid 21 was hindered by difficulties in seperation of extremely hydrophillic 
23 from side products formed during the reaction.  As such, we devloped a two step route through 
2229 which is a crystaline solid that can made at decagram scale without chromatography from 
21.  With 22 in hand, we were able to access 23 by simple transthioesterification with N-
~$40,000/g	  
~$1,000/g	  






























































acetylcysteamine in aqueuous sodium bicarbonate.  Purification continued to be a problem as the 
extreme polarity 23 prevents extraction into organic solvent or chromatography on SiO2.  
Ultimately, we devised a scheme to acidify the reaction mixture upon completion with a solid 
supported sulfonic acid resin G26, which is both commercially available and inexpensive.  The 
resin is filtered off along with complexed Na+ ions, and organic purities are extracted from the 
aqueous layer with CH2Cl2 leaving pure 23 in the aqueous layer.  Lyophilization then provided 
pure 23, and this two-step sequence is amenable to decagram synthesis without requiring 
chromatographic purification.  With MM-NAC (23) in hand, we evaluated the concentration 
dependence of this cofactor anaolog with PikAIII-TE and PikAIII/PikAIV in vitro using thiophenol 
pentaketide 15 analyzed by HPLC (Scheme 2.10).  
 
 As the Khosla group had observed in the DEBS pathway, we observed a concentration 
dependence of 23 well above what is required with MM-CoA (19) or when considering required 
requisite methyl malonate stoichiometry, suggesting that the AT domain does not recognize the 
NAC moiety with the same affinity as CoA.  A control experiment using thiophenol 22 in place of 
23 provided only trace conversion, further supporting that AT domain in Pik modules is 
recognizing CoA or truncations thereof.  Nevertheless, the incredible improvement in cost per 
reaction and the synthetically accessibility of 23 motivated us to forgo the use of expensive 19 in 
downstream optimization.  We next explored NADPH recycling systems, beginning with the use 
of less expensive and more stable NADP+ (25). The first tested was the Wong/Whitesides 
glucose-6-phosphate/glucso-6-phosphate dehydrogenase recycling system,30 which proved so 
efficient we were able to decrease NADP+ (25) down to 10 mol % relative to penaketide 15 further 
reducing costs.  
With cofactor and thioesters optimization completed, we sought one last improvement to 
scavenge thiols liberated during the reaction (thiophenol or NAC).  This was motivated by a few 













































reasons 1) to boost yields by preventing conjugate addition of thiols into the α,β-unsaturated 
ketone of the substrate or products 2) sequester liberated thiophenol to improve upon the horrific 
odor of the reactions 3) prevent formation of mixed disulfides that can complicate HPLC analysis. 
A screen of electrophiles was largely uninteresting, as mildly electrophilic (α,β-unsaturated acids 
and amides) were poor scavengers and offered little improvement, while stronger electrophiles 
(maleimides, nitrostyrenes) completely inhibited catalysis likely through alkylating the active site 
cysteine of the KS domain.  One compound stood about above the rest, 2-vinylpyridine (26).31 2-
vinylpyridine has been successfully employed as a glutathione scavenger when studying 
glutathione reductase, which, like PKS modules, contains active site cysteine(s) required for 
catalysis.  In our hands, 2-vinylpyridine had no detectable inhibition of PKS catalysis at 8 mM, 
and near instantaneous scavenging of thiophenol.  In fact, the odor of thiophenol could no longer 
be detected during PKS reactions despite the ppb detection threshold of the human nose. 
 
With biochemical parameters began to consider the potential synthetic utility of PikAIII-TE and 
PikAIII/AIV as biocatalysts.  As the pentaketide 15 is synthesized in 11 linear steps, PKS 
processing would yield 10-dml (18) or narbonolide (24) in just 12 linear steps. As such we purified 
larger quantities of PikAIII-TE and PikAIII/PikAIV and tested the scalability of these reactions.  
Initial iterations were scaled up 2000-fold, from 50 µL to 200 mL converting 0.2 millimoles of 
pentaketide 15 (~70 mg) to a theoretical ~60 mg of 10-dml (18) or ~70 mg narbonolide (24).   





























































0.2 1 20 53 47
0.2 1 20 62 55
0.2 4 10 66 55
1.43 4 10 60 49
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Enzymatic reactions were treated as if they were a normal chemical reaction, monitored by TLC, 
extracted when completed, and then macrolactone products 10-dml (18) or narbonolide (24) were 
purified by SiO2 flash chromatography (scheme 2.11, entry 1a) 10-dml (18) tolerated this 
treatment well, though narbonolide (24) appeared to decompose slightly (through possible C5-C9 
hemiketal formation) creating problems for spectroscopic analysis. We hypothesized that 
protecting the hydroxyl group prior to chromatography would prevent degradation.  Esterification 
with Ac2O/NEt3 in the presence of catalytic DMAP worked well and provided stable acetyl-
narbonolide (32) facilitating product characterization. 
During the course of reactions with purifieda PKS modules (scheme 2.11, entry 1a) we observed 
protein precipitation (presumably though denaturation or aggregation), and considered the use of 
PKS modules as crude cell lysate,b a common approach in industrial biocatalysis.  Complications 
can arise if the protein of interest is hydrolyzed by proteases, if other cellular enzymes can 
catalyze side reactions with the starting material or product, and direct extraction becomes 
difficult often requiring an initial miscible organic solvent precipitation, filtration, and evaporation 
before product extraction.  Furthermore, accurate quantification of enzymatic quantification in 
crude cell lysate is no small task, typically resulting in an approximation.  However, many proteins 
display improved stability, activity, and reproducibility in crude cell lysate, and by removing the 
burden of protein purification catalyst preparation becomes a significantly more efficient and 
scalable process.  As such, we evaluated PKS reactions employing the modules in crude cell 
lysate (scheme 2.11, entry 2b-4b) with a slight improvement in macrolactone yield.  Attempts to 
increase the reaction concentration to 4 µM PKS with purified modules led to erratic, lower 
conversion of 15 to either macrolactone with increased protein precipitation (suggesting 
aggregation), though crude cell lysate was operable under these more concentrated 
conditions(scheme 2.11, entry 3b,4b).  Entry 4b was intended to demonstrate the scalability of 
PKS catalysis, employing 0.5 g of pentaketide 15 generating ~250 mg of either macrolactone. 
 
2.4 Biotransformation of macrolactones to macrolides 
 
While the majority of total synthesis efforts towards macrolides terminate with achieving the 
macrolactone core,32 we opted to go a step further and evaluate biotansformations of 
macrolactones to mature macrolide natural products. Abiotic synthetic efforts often stop at 
macrolactones as the post-PKS tailoring steps are extraordinarily hard to perform without 
enzymatic assistance.  In the Pik pathway, the amino-sugar desosamine is biosynthesized from 
glucose and appended onto hindered a hydroxyl group on the macrolactone core. The final 
tailoring step is a C-H oxidation of the macrolactone core mediated by the P450 PikC, where the 
oxidation is directed by the desosamine sugar.33 Without utilizing the desaosamine biosynthetic 
pathway, desosamine requires 9 chemical steps to construct,1d,34 followed by glycosylation and 
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deprotection. The P450 oxidation mediated by PikC presents an even greater synthetic challenge 
as no current C-H method exists to perform such a transformation. When targeting oxidized 
macrolactones or macrolides through total synthesis the hydroxyl group is embedded into the ring 
at an early stage.1a-c,35 
 
 Biotransformation of either macrolactone to macrolides was examined with engineered 
variants of S. venezuelae ATCC 15439 DHS200136 and YJ112.37 Both strains have had the Pik 
PKS genes knocked out through iterative insertions of a hygromycin marker and produce no 
macrolactone or macrolide secondary metabolites, and YJ112 posses an extra copy of pathway 
regulator pikD.  The tailoring genes are intact and biotransformation of both 10-dml (18) and 
narbonolide (24) are known37 though unoptimized for macrolactone to macrolide mass balance. 
Small-scale inoculation of narbonolide (24) to DHS2001 or YJ112 cultures experienced variation 
in initial rate and total conversion pikromycin (28), motivating studies to isolate and evaluate 
growth phase dependence. Addition of narbonolide (24) to high OD600 cultures resulted in rapid, 
but incomplete conversion, while addition to prelog phase cultures were initially slow but afforded 
complete conversion with either strain.  Addition of acetyl-narbonolide (32, 5 µM, vide infra) to 
cultures accelerated the biotransformation, completing the biocatalytic synthesis of pikromycin 
(28) in 13 linear steps from commercially available (R)-Roche ester (Scheme 2.12).  
 Biotransformations of 10-dml (18) to methymycin macrolides proved to be more 
interesting.  Under identifical conditions and in parallel with narbonolide (24) biotransformations, 
neither glycosylation nor oxidation of 10-dml (18) was observed.  Perplexed, this experiment was 
repeated multiple times with the same outcome. To confirm that the problem wasn’t with synthetic 
10-dml (18), we fermented natural 10-dml (18, vide infra, chapter 3) and the purified the 
compound to homogeneity via prep-HPLC. Attempted biotransformation with naturally derived 10-
dml (18) gave the same result, no conversion observed.  We next attempted a mixed 
biotransformation with 10-dml (18) and narbonolide (24) and at last observed conversion of 10-
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dml (18) to YC-17 (29) and methymycins (30, 31), though 10-dml (18) did not covert fully while 
narbonolide (24) did.  Additional experiments where successive doses of narbonolide (24) were 
added provided more complete conversion to (29) and methymycins.  The hypothesis developed 
from these experiments was as follows: the PKS product narbonolide (24) is responsible for 
inducing Pik tailoring genes, while the PKS product 10-dml (18) cannot induce Pik tailoring genes.  
While an interesting insight into complex pathway regulation, this phenomenon was restricting 
access to the methymycin macrolides and required a solution. 
  
Iterative doses of narbonolide (24) was an option but a poor one, as the tailoring genes 24 
induced quickly glycosylated 24 to narbomycin (27) which appeared to have little ability to keep 
the des genes functional.  As such, we considered using acetyl-narbonolide (32) as non-
consumable inducer, where the hydroxyl group required for glycosylation is protected.  If the 
acetate did not interfere with binding to whatever cellular sensor was recognizing narbonolide 
(24), then perhaps only a low concentration would be required to affect complete conversion of 
10-dml (18) to methymycin macrolides.  To our surprise, this strategy not only worked, but worked 
at very low concentrations of acetyl-narbonolide (32), only 5 µM was required to affect complete 
transformation of 10-dml (18) to methymycin macrolides. Figure 2.2 shows a 24 h time point 
LC/MS analysis of DHS2001 cultures, with the trace on the right displaying 10-dml (18) 
conversion without induction, the trace in the middle 10-dml (18) conversion without induced with 
5 µM narbonolide (24), and the trace on the right with 5 µM acetyl-narbonolide (32).  The 
difference in biotransformation efficiency was striking, and allowed effective biotransformation of 






























Scheme 2.13 Biotransformation of 10-dml (18) to methymycins (28) 
	  




 Acetyl-narbonolide induction was more pronounced with strain YJ112, providing 
increased conversion to the doubly oxidized novamethymycin (33), and a previously unknown 
methymycin was detected by LC/MS as well.  Preparative biotransformation and HPLC 
purification yielded a methymycin we named ketomethymycin, presumably arising from a second 
hydroxylation of neomethymycin at the C13 position, generating a transient germinal di-
hydroxylated compound that eliminated water to form the ketone. 
   
LC/MS analysis of WT S. venezuelae ATCC 15439 reveled trace quantities of a compound with 
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Scheme 2.14 Second oxidation of methymycins 
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a trace secondary metabolite made under normal laboratory culture conditions. With functional 
biotransformation conditions in hand, preparative scale conversion smoothly converted 
macrolactones to macrolides, completing the biocatalytic synthesis in 13 steps with divergence at 
the 11th step. 
 
 
2.5 Chemistry Experimental 
 
Reactions were performed in evacuated (<0.05 torr) flame dried glassware containing PFTE 
coated magnetic stir bars fitted with rubber septa backfilled with dry N2 and run under a positive 
pressure of dry N2 provided by a mineral oil bubbler unless stated otherwise (open flask). 
Reactions at elevated temperatures were controlled by IKA RET Control Visc (model RS 232 C), 
room temperature (RT) reactions were conducted at ~23 °C, reactions run cooler than room 
temperature were performed in a cold room (4 °C), an ice bath (0 °C), dry ice/acetone (-78 °C), or 
isopropanol/ThermoNESLAB (model CC100) for all other temperatures. Commercial purification 
system MBraun-MB-SPS # 08-113 provided all dry solvents unless stated otherwise (technical 
grade). Analytical thin-layer chromatography (TLC) was performed with EMD 60 F254 pre-coated 
glass plates (0.25 mm) and visualized using a combination of UV, p-anisaldehyde, KMnO4, and 
Bromocresol green stains. Flash column chromatography was performed using EMD 60 
Gerduran® (particle size 0.04-0.063) silica gel.  NMR spectra were recorded on a Varian 600 
MHz spectrometer. 1H NMR spectra were recorded relative to residual solvent peak (CDCl3 δH 














strain combinedyield (%) methymycin neomethymycin novamethymycin ketomethymycin
YJ112
DHS2001
71 3.5 5 3 1





















Scheme 2.15 Biotransformation of macrolactones to macrolides 
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coupling constant (Hz), and integration. Multiplicity abbreviations are as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, h = hextet, ovlp = overlap, br = broad signal.  13C 
NMR spectra were recorded relative to residual solvent peaks (CDCl3 δC 77.0 ppm, D6-DMSO δc 
39.5 ppm).  High resolution mass spectrometry was performed on an Agilent quadrapole time-of-
flight spectrometer (Q-TOF 6500 series) by electrospray ionization (ESI). 
 
 
7: An open 500-mL flask was charged with (R)-Roche ester 6 (TCI, 10.00 g, 84.65 mmol, 1.00 
equiv), imidazole (Fisher, 6.34 g, 93.12 mmol, 1.10 equiv), technical grade CH2Cl2, (170 mL, 
0.5M) and cooled to 0 °C.  Tertbutyldimethylsilyl chloride (Oakwood, 14.03 g, 93.12 mmol, 1.10 
equiv) was added in 5 portions.  The resulting solution was stirred for 1 h at 0 °C and became 
cloudy with white precipitate.  A half-saturated NH4Cl solution was added until the precipitate was 
completely dissolved.  The organic layer was separated and the aqueous layer extracted 2x with 
CH2Cl2.  The combined organic extracts were washed with brine and filtered through a sodium 
sulfate plug, which was subsequently rinsed 2x with CH2Cl2.  Concentration and subsequent high 
vacuum yielded the silyl-ether as colorless oil (19.65 g, 84.55 mmol) that was carried onto the 
next step without further purification. 
A 500-mL flask containing the silyl-ether (19.65 g, 84.55 mmol) was added CH2Cl2 (170 mL, 
0.5M) and cooled to -78 °C.  A second bath was prepared and cooled to -42 °C. DIBAL-H (Sigma, 
25.25 g, 31.64 mL, 177.56 mmol, 2.10 equiv) was added slowly down the side of the flask and 
stirred for 5 min at   -78 °C.  The flask was placed in the -42 °C bath for 1 h and then recooled to -
78 °C.  Methanol (100 mL) was added slowly and the solution was stirred for 15 min at -78 °C.  
The reaction was decanted into of vigorously stirring CH2Cl2 (200 mL) at RT, layered with 
saturated Na/K tartrate (300 mL) and stirred until the layers became clear.  The organic layer was 
separated and the aqueous layer was extracted 2x with CH2Cl2. The combined organic extracts 
were washed with brine and filtered through a sodium sulfate plug, which was then rinsed 2x with 
CH2Cl2.  Concentration and subsequent high vacuum yielded the alcohol as acolorless oil (16.66 
g, 81.51 mmol) that was carried onto the next step without further purification.   
To an open 500-mL flask wrapped in foil containing the alcohol (16.66 g, 81.51 mmol) was added 
technical grade CH2Cl2 (163 mL, 0.5 M) and cooled to 0 °C.  Imidazole (Fisher, 8.33 g, 122.27 
mmol, 1.50 equiv) and triphenylphospine (AK, 27.79 g, 105.96 mmol, 1.30 equiv) were added in 
single portions and stirred until dissolved.  Iodine (Fisher, 27.93 g, 110.03 mmol, 1.35 equiv) was 
added in 10 portions while maintaining internal temperature <5 °C.  Complete addition of iodine 
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The reaction was quenched by addition of a cold saturated sodium thiosulfate solution resulting in 
a colorless bi-phasic mixture.  The organic layer was separated and washed once with saturated 
sodium thiosulfate, and filtered through a sodium sulfate plug, which was then rinsed 2x with 
CH2Cl2 and concentrated.  Flash chromatography: Et2O/hexanes (5:95) gave 7 as a colorless oil 
(22.50 g, 71.60 mmol, 84% yield over three steps).  
1H NMR (CDCl3, 599 MHz) δ 3.52 (dd, J = 10.0, 5.0 Hz, 1H), 3.40 (dd, J = 10.0, 6.9 Hz, 1H) 3.30 
(dd, J = 9.5, 5.1 Hz, 1H), 3.25 (dd, J = 9.5, 5.7 Hz, 1H), 1.67-1.60 (m, 1H), 0.95 (d, J = 6.7 Hz, 
3H), 0.90 (s, 9H), 0.06 (s, 6H). 
13C NMR (CDCl3, 151 MHz) δ 66.7, 37.4, 25.9, 18.2, 17.2, 13.7, -5.4. 
HRMS: Calculated [M+H]+ 315.0636, found 315.0656.  
 
8:  To a 500-mL flask containing (S,S)-pseudoephedrine propionamide7 (25.34 g, 114.66 mmol, 
1.60 equiv) was added THF (300 mL) and stirred at RT until the solid dissolved completely.  The 
flask was then cooled to -78 °C. 
A 1000-mL flask containing LiCl (Fisher, 36.45 g, 859.92 mmol, 12.00 equiv) was flame dried 
under vacuum iteratively until the inline monometer no longer responded to the flame.  THF (150 
mL) was added by cannula, followed by diisopropylamine (Sigma, distilled from activated sieves 
(4 Å), 33.15 mL, 23.93 g, 236.48 mmol, 3.30 equiv) and the flask was cooled to -78 °C.  Slow 
addition of n-BuLi (Sigma, 2.46M in hexanes, 90.30 mL, 221.15 mmol, 3.10 equiv) at -78 °C, 
warmed to 0 °C and held for five minutes before recooling to -78 °C.    
The entire contents of the 500-mL flask containing (S,S)-pseudoephedrine propionamide solution 
was added to the 1000 mL flask by cannula.  The resulting solution was stirred for 1 h at -78 °C, 
30 min at 0 °C, and 5 min at RT before it was recooled to 0 °C.  7 (22.50 g, 71.66 mmol) was 
dissolved in THF (20 mL) and added dropwise to the solution, which was allowed to warm to RT 
and stirred for 12 h.  The reaction was quenched with saturated NH4Cl (300 mL), and poured into 
a 2 L separatory funnel containing H2O (500 mL), and the aqueous layer was extracted 3x with 
CH2Cl2. The combined organic extracts were washed with brine and filtered through a sodium 
sulfate plug, which was then rinsed 2x with CH2Cl2.  Concentration and flash chromatography: 
EtOAc/Hexanes (30:70) afforded pale yellow solid 8 (27.46 g, 67.36 mmol, 94% yield). 
1H NMR (CDCl3, 599 MHz): δ 7.37-7.20 (m, 5H), 4.62-4.52 (m, 2H), 4.35 (s, 1H), 3.43 (dd, J = 
9.8, 4.8 Hz, 2H), 3.36 (dd, J = 9.9, 5.9 Hz, 2H), 2.83 (s, 3H), 2.78-2.70 (m, 1H), 1.70-1.62 (m, 
1H), 1.60-1.52 (m, 1H), 1.14 (d, J = 7.1 Hz, 3H) 1.15-1.04 (m, 1H), 1.07 (d, J= 6.7 Hz, 3H), 0.87 
(s, 9H), 0.81 (d, J = 6.6 Hz, 3H), 0.01 (s, 6H). 
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13C NMR (CDCl3, 151 MHz) δ 179.1, 142.6, 128.7, 128.2, 127.4, 126.9, 126.2, 76.5, 67.9, 37.6, 
34.2, 33.1, 25.9, 18.3, 17.5, 17.3, 14.4, -5.5, -5.4. 
HRMS: Calculated [M+Na]+ 430.2748, found 430.2740.  
 
9: To a 1000-mL flask containing 8 (27.46 g, 67.36 mmol) was added THF (275 mL, final 
concentration ~0.2M) and stirred at RT until the solid dissolved, then cooled to -78°.  A second 
flask charged with n-BuLi (Sigma, 2.46M in hexanes, 60.24 mL, 148.19 mmol, 2.20 equiv) was 
cooled to -78 °C, and added to the solution of 8 via cannula. The reaction was stirred for 10 min 
at -78 °C, and 30 min at 0 °C before addition of diisopropylamine (Sigma, 20.77 mL, 15.00 g, 
148.19 mmol, 2.20 equiv), and stirred for 15 min at 0 °C.  The reaction was quenched with 
AcOH/Et2O (20:80, 200 mL).  The organic layer was carefully washed 2x with saturated sodium 
bicarbonate, brine, subsequently filtered through a sodium sulfate plug, which was then rinsed 2x 
with Et2O.  Concentration and flash chromatography: EtOAc/Hexanes (5:95) afforded colorless oil 
9 (18.62 g, 61.97 mmol, 92% yield). 
1H NMR (CDCl3, 599 MHz) δ 3.40 (dd, J = 9.7, 5.6 Hz, 1H), 3.37 (dd, J = 9.8, 6.0 Hz, 1H), 2.64 
(h, J = 6.9 Hz, 1H), 2.48-2.36 (m, 1H), 1.80-1.74 (m, 1H), 1.59- 1.50 (m, 4H), 1.29 (h, J = 7.4 Hz, 
2H), 1.06 (d, J = 6.8 Hz, 3H), 1.07-1.00 (ovlp m, 1H), 0.92-0.86 (ovlp m, 6H), 0.8 (s, 9H), 0.03 (s, 
6H). 
13C NMR (CDCl3, 151 MHz): δ 214.9, 67.9, 44.1, 40.4, 36.8, 33.5, 25.9, 25.8, 22.4, 18.3, 17.2, 
17.1, 13.9, -5.46, -5.48. 
HRMS: Calculated [M+Na]+ 323.2377, found 323.2378.  
 
10:  To an open 1000 mL flask containing 9 (18.62 g, 61.97 mmol) was added CCl4/CH3CN/H2O 
(1:1:2, 300 mL, 0.2M), NaIO4 (AK, 66.27 g, 309.85 mmol, 5.00 equiv), and RuCl3*H2O (Fisher, 
0.13 mg, 0.62 mmol, 1 mol%).  The flask was fitted with a reflux condenser and heated to 70 °C 
with vigorous stirring.  The solution turned yellow and vigorous stirring at 70 °C was contiued until 
the solution turned black (~2 d), cooled to RT and filtered through celite (celite washed 2x with 
MeCN).  The biphasic solution was concentrated and resuspended in hexanes.  The organic layer 
was carefully extracted with saturated sodium bicarbonate until gas evolution ceased (~5x), and 
back washed with 1x with hexanes.  The aqueous layer was carefully brought to pH 3 with 
phosphoric acid and extracted 5x with CH2Cl2.  Subsequent filtration through a sodium sulfate 
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plug then rinsed 2x with CH2Cl2 and concentration provided 9 as a pale yellow oil (10.30 g, 51.44 
mmol, 83% yield). 
1H NMR (CDCl3, 599 MHz) δ 2.61 (h, J = 7.0 Hz, 1H), 2.55- 2.38 (m, 3H), 2.08 (ddd, J = 14.5, 8.8, 
6.1 Hz, 1H), 1.54 (p, J = 7.4 Hz, 2H), 1.40-1.32 (m, 1H),  1.29 (h, J = 7.3 Hz, 2H), 1.19 (d, J = 7.0 
Hz, 3H), 1.09 (d, J = 7.0 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H). 
13C NMR (CDCl3, 151 MHz) δ 214.0, 182.4, 44.00, 40.6, 37.2, 36.0, 25.7, 22.3, 17.5, 16.4, 13.8. 
HRMS: Calculated [M+H]+ 201.1485, found 201.1485.  
 
11:  To a 500 mL flask containing 10 (6.01 g, 30 mmol) in THF (30 mL) at -78 °C was added 
TMSCl (Sigma, 15.23 mL, 13.00 g, 120.00 mmol, 4 equiv) down the side of the flask.  A second 
flask was charged with LHMDS solution (Sigma, 1M in THF, 120.00 mL, 120.00 mmol, 4 equiv) 
and cooled to -78 °C, then added to the 10 solution by cannula and stirred at -78 °C for 30 min, 
followed by dropwise addition of acetone (10 mL) with 10 min additional stirring.  The solution 
was quenched at -78 °C with phosphate buffer (1M, pH 7, 120 mL) and layered with Et2O.  The 
aqueous layer was extracted 3x Et2O, combined organic layers washed with brine.  Filtration 
through a sodium sulfate plug, which was then rinsed 2x with Et2O and concentration gave the 
crude trimethylsilyl enol ether of 10 (contaminating (isopropenyloxy)trimethylsilane was mostly 
removed under subsequent high vacuum).  
IBX38 (0.4M in DMSO, 150 mL, 60.00 mmol, 2.00 equiv) was added to the crude silyl enol ether 
and  stirred for 12 h (the solution turns yellow and a white precipitate forms).  The reaction was 
diluted with H2O (300 mL) and extracted 3x Et2O, with combined organic extracts washed 1x with 
brine, subsequently filtered through a sodium sulfate plug, which was then rinsed 2x with Et2O.  
Concentration gave crude silyl enol ether.  The crude material was suspended in hexanes 
(allowing a white precipitate to settle) before transfer onto the flash column: 
AcOH/EtOAc/Hexanes (1:10:89) to yield 11 as a pale yellow oil (4.80 g, 24.21 mmol, 81% yield). 
1H NMR (CDCl3, 599 MHz) δ 6.96 (dt, J = 15.7, 6.4 Hz, 1H), 6.16 (d, J = 15.7 Hz, 1H), 2.86 (h, J 
= 7.0 Hz, 1H), 2.54 (h, J = 7.0 Hz, 1H), 2.25 (p, J = 6.8 Hz, 1H), 2.12 (ddd, J = 14.4, 8.3, 6.6 Hz, 
1H), 1.44-1.38 (m, 1H), 1.20 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.08 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 151 MHz): δ 203.3, 182.0, 149.5, 127.6, 41.4, 37.1, 36.3, 25.6, 17.5, 16.5, 12.2. 
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The following two procedures were performed concurrently: 
5: A 250 mL flask containing MePPh3Br (AK, 8.25 g, 23.10 mmol, 1.10 equiv) was placed in an oil 
bath, and heated to 110  °C under high vacuum for 4 h.   The flask was cooled to RT and 
backfilled with N2, THF (100 mL, 0.2M) and cooled to 0 °C.  n-BuLi (Sigma, 2.35M, 9.83 mL, 
23.10 mmol, 1.10 equiv) was added dropwise and the reaction was allowed to warm to RT and 
stirred for a minimum 1 h.  
To an open 500 mL flask was added 1221-22 (4.88 g, 21.00 mmol), DMSO (80 mL, 0.25M) and IBX 
(8.82 g, 31.50 mmol, 1.50 equiv) in a single portion.  The reaction was monitored by TLC, and 
after consumption of 12 (~4 h) Et2O (100 mL) was added. The reaction was quenched with a cold 
solution of sodium thiosulfate (100 mL), and stirred for 30 min.  The aqueous layer was separated 
and the organic layer was washed 2x with saturated thiosulfate, brine, dried with sodium sulfate, 
filtered, rinsed 2x with Et2O and concentrated to give crude aldehyde of S12, which was dissolved 
in THF (20 mL) and used immediately.   
Both flasks were cooled to -78 °C and crude 12 was added by cannula to the prepared ylide.  The 
solution was stirred at -78 °C for 30 min, warmed to RT and stirred for an additional 30 min.  The 
reaction was quenched with half saturated NH4Cl (200 mL) and extracted 3x with pentane, filtered 
through a sodium sulfate plug, rinsed 2x with CH2Cl2 and concentrated to give the crude alkene 
product. Flash chromatography: Et2O/pentane (2:98) afforded 5 as a clear oil (4.20 g, 18.38 
mmol, 87% over two steps.) 
1H NMR (CDCl3, 599 MHz)  δ  5.84 (ddd, J = 17.5, 10.5, 7.2 Hz, 1H), 5.03-4.95 (m, 2H), 3.46 (q, J 
= 5.5 Hz, 1H), 2.31 (h, J = 6.7 Hz, 1H), 1.49-1.36 (m, 2H), 0.97 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 
0.86 (t, J = 7.4 Hz, 3H), -0.14 (s, 6H). 
13C NMR (CDCl3, 151 MHz): 141.7, 113.6, 77.00, 42.28, 26.49, 25.91, 18.16, 14.97, 9.44, -4.34, -
4.46. 
EI MS: Calculated [M-C(CH3)3]+ 171.1, found 171.1. 
 
S11: A 25 mL recovery flask was charged with 11 (0.99 g, 5.00 mmol), 5 (1.71 g, 7.50 mmol, 1.50 
equiv.) and HG-II (Sigma, 94 mg, 0.15 mmol, 3 mol%) under a stream of N2.  An 18 gauge needle 
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the flask was heated to 50 °C for 12 h.  After cooling to RT, the solution was dissolved in CH2Cl2 
(20 mL) and transferred to a 250 mL flask, further diluted with CH2Cl2 (20 mL) and cooled to 0 °C.  
Remaining catalyst was destroyed by careful addition of H2O2 (15 % by volume, 20 mL) and 
vigorous stirring for 1 h at 0 °C.39 The organic layer was separated and the aqueous layer was 
extracted 2x with CH2Cl2, filtered through a sodium sulfate plug, rinsed 2x with CH2Cl2 and 
concentrated. Flash chromatography: AcOH/EtOAc/hexanes (1:10:89) to yield 1 (1.62 g, 4.37 
mmol, 87% yield). 
1H NMR (CDCl3, 599 MHz) δ 6.94 (dd, J = 15.9, 7.5 Hz, 1H), 6.14 (dd, J = 16.0, 1.3 Hz, 1H), 
3.59-3.53 (m, 1H), 2.87 (h, J = 6.9 Hz, 1H), 2.58-2.44 (m, 2H), 2.17-2.07 (m, 1H), 1.52-1.44 (m, 
1H), 1.43-1.34 (m, 2H), 1.20 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 
0.88 (s, 9H), 0.86 (ovlp t, J = 7.0Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (CDCl3, 151 MHz): δ 203.0, 181.5, 150.8, 127.9, 76.4, 41.5, 41.3, 37.0, 36.2, 26.8, 25.8, 
21.3, 18.1, 17.5, 16.7, 14.2, 9.6, -4.4, -4.9. 
HRMS: Calculated [M+H]+ 371.2616, found 371.2641.  
 
13: To an open 25 mL polyethylene bottle was added 1 (0.20 g, 0.54 mmol) and MeCN (0.44 mL, 
0.5M) and aq. HF (48%, 0.1 mL).  The reaction was monitored by TLC and diluted with 
H2O/CH2Cl2 upon completion.  The organic layer was separated and the aqueous layer (plastic 
separatory funnel) was extracted 2x with CH2Cl2 followed by filtration through a sodium sulfate 
plug, then rinsed 2x with CH2Cl2 and concentrated. Flash chromatography: 
AcOH/EtOAc/Hexanes (1:25:74) to yield 13 as a colorless oil (0.12 g, 0.47 mmol, 87% yield).  
The aqueous layer was brought to pH=10 before disposal. 
1H NMR (CDCl3, 500 MHz) δ 6.94 (dd, J = 16.0, 7.3 Hz, 1H), 6.17 (dd, J = 16.0, 1.1 Hz, 1H), 3.55 
(p, J =5.4 1H), 2.90 (h, J = 6.9 Hz, 1H), 2.60-2.44 (m, 2H), 2.15-2.06 (m, 1H), 1.59-1.50 (m, 1H), 
1.49-1.32 (m, 2H), 1.20 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H), 0.98 
(t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 101 MHz): δ 203.1, 180.8, 149.8, 128.5, 76.05, 42.2, 41.4, 37.31, 36.9, 27.0, 
17.8, 16.4, 13.6, 10.4. 
HRMS: Calculated [M+H]+ 257.1747, found 257.1750.  
 















15: To a 25 mL flask was added 13 (20 mg, 0.078 mmol) and Ph2S2 (Fisher, 19 mg, 0.086 mmol, 
1.10 equiv.) dissolved in CH2Cl2  (0.78 mL, 0.1M) and cooled to 0 oC.  PBu3 (Sigma, distilled neat, 
21 µL, 17 mg, 0.085 mmol, 1.10 equiv) was added slowly while keeping the solution <5 oC, the 
reaction mixture was stirred for 10 min before it was quenched with CuSO4 impregnated silica gel 
and concentrated.  Flash chromatography: EtOAc/hexanes (25:75) to yield 15 (25 mg, 24.2 mmol, 
92%). 
1H NMR (CDCl3, 500 MHz) δ 7.41 (s, 5H), 6.87 (dd, J = 15.9, 7.6 Hz, 1H), δ 6.17 (dd, J = 15.9, 
1.2 Hz, 1H), 3.50-3.42 (m, 1H), 2.93-2.80 (m, 2H), 2.48-2.39 (m, 1H), 2.20 (ddd, J = 14.4, 8.8, 5.9 
Hz, 1H), 1.59-1.31 (m, 3H), 1.25 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.8 Hz, 
3H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 101 MHz): δ 202.6, 201.3, 149.8, 134.4, 129.4, 129.2, 128.3, 127.6, 75.9, 46.0, 
42.3, 41.3, 36.7, 27.4, 18.5, 16.4, 13.9, 10.33. 
HRMS: Calculated [M+H]+ 349.1832, found 349.1853. 
 
16: To a 25 mL flask was added 13 (24 mg, 0.094 mmol) and 2,2’-dipyridyldisulfide (TCI, 22 mg, 
0.10 mmol, 1.10 equiv.) dissolved in CH2Cl2  (0.94 mL, 0.1M) and cooled to 0 oC.  PBu3 (Sigma, 
distilled neat, 26 µl, 21 mg, 0.10 mmol, 1.10 equiv) was added dropwise keeping the solution <5 
oC, the reaction mixture was stirred for 10 min before it was quenched with CuSO4 impregnated 
silica gel and concentrated.  Flash chromatography: EtOAc/hexanes (25:75) to yield colorless oil 
16 (20 mg, 0.057 mmol, 61% yield). 
1H NMR (CDCl3, 400 MHz) δ 8.62 (d, J = 4.9, 1H), 7.75 (td, J = 7.7, 2.0 Hz, 1H), 7.61 (d, J = 7.8 
Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 6.91 (dd, J = 15.9, 7.4 Hz, 1H), 6.16 (d, J = 15.9 Hz, 1H), 
3.55-3.45 (m, 1H), 2.99-2.80 (m, 2H), 2.51-2.38 (m, 1H), 2.21 (ddd, J = 14.3, 9.0, 5.8 Hz, 1H), 
1.60-1.30 (m, 3H), 1.28 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H),  
0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ 202.7, 200.4, 151.3, 150.4, 150.0, 137.1, 130.3, 128.4, 123.6, 75.8, 
46.6, 42.3, 41.0, 37.0, 27.3, 18.4, 16.4, 13.7, 10.4. 
HRMS: Calculated [M+H]+ 350.1784, found 350.1788.  
 
17: To a 20 mL sealed tube was added 13 (30 mg, 0.117 mmol) and 4,4'-Bis(2-amino-6-
methylpyrimidyl) disulfide (TCI, 49 mg, 0.1755 mmol, 1.5 equiv) suspended in benzene (3 mL, 






















0.04M), followed by solid supported PPh3 (Sigma, 1.36 mmol/g, 130 mg, .1755 mmol, 1.50 
equiv.).  The reaction was heated to 100 oC for 15 min, cooled to RT, filtered through glass wool, 
then rinsed 2x with CH2Cl2 and concentrated: flash chromatography: EtOAc/hexanes (40:60 to 
100:0) to yield 17 (20 mg, 0.052 mmol, 45% yield). 
1H NMR (CDCl3, 400 MHz) δ 6.93 (s, 1H) 6.92 (dd, J = 7.6 Hz, 1H), 6.16 (dd, J = 16.0, 1.3 Hz, 
1H), 5.18 (br s, 2H), 3.53 (p, J = 6.6 Hz, 1H), 2.91 (h, J = 6.8, 1H), 2.98-2.74 (m, 1H), 2.54-2.40 
(m, 1H), 2.36 (s, 3H), 2.32-2.13 (m, 1H), 1.60-1.31 (m, 3H), 1.26 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 
6.9 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3 H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ 202.5, 199.1, 179.2, 168.9, 150.0, 128.4, 114.8, 76.7, 75.9, 47.1, 
42.3, 40.9, 36.9, 27.3, 24.0, 18.3, 16.6, 13.6, 10.4. 
HRMS: Calculated [M+H]+ 380.2002, found 380.2003.  
 
 
15:  To a 100 mL flask containing 15 (1.59 g, 4.29 mmol) was added Ph2S2 (Fisher, 1.03 g, 4.72 
mmol, 1.10 equiv) and divinylsulfone (Oakwood, 0.50 mL, 0.56 g, 4.72 mmol, 1.10 equiv) 
dissolved in CH2Cl2 (22 mL, 0.2M) and cooled to 0 °C.  PBu3 (Sigma, distilled neat, 1.38 mL, 1.13 
g, 5.58 mmol, 1.30 equiv.) was added dropwise keeping the solution <5 oC. The reaction was 
stirred for 20 min and quenched with saturated sodium bicarbonate (50 mL). The aqueous layer 
was extracted 2x with CH2Cl2, filtered through a sodium sulfate plug, which  then rinsed 2x with 
CH2Cl2 and concentrated.  Flash chromatography: EtOAc/hexanes (5:95) gave the crude 
thioester of 15, which was used immediately in the following step. 
To an open 25 mL polyethylene bottle was added crude thioester of 15 and MeCN (4 mL, 1M) 
and aq. HF (48%, 1 mL).  The reaction was monitored by TLC and upon completion it was diluted 
with CH2Cl2 (10 mL) and carefully quenched with saturated sodium bicarbonate. The aqueous 
layer was extracted 2x with CH2Cl2. Filtration through a sodium sulfate plug then rinsed 2x with 
CH2Cl2 and concentrated.  Flash chromatography: EtOAc/hexanes (15:85) gave 15 (1.37 g, 3.93 
mmol, 91% yield over two steps). 
1H NMR (CDCl3, 500 MHz) δ 7.41 (s, 5H), 6.87 (dd, J = 15.9, 7.6 Hz, 1H), δ 6.17 (dd, J = 15.9, 
1.2 Hz, 1H), 3.50-3.42 (m, 1H), 2.93-2.80 (m, 2H), 2.48-2.39 (m, 1H), 2.20 (ddd, J = 14.4, 8.8, 5.9 
Hz, 1H), 1.59-1.31 (m, 3H), 1.25 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.8 Hz, 
3H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 101 MHz): δ 202.6, 201.3, 149.8, 134.4, 129.4, 129.2, 128.3, 127.6, 75.9, 46.0, 
42.3, 41.3, 36.7, 27.4, 18.5, 16.4, 13.9, 10.33. 













23: To an open 500 mL flask containing H2O (220 mL, 1M) sparged with N2 for 30 minutes 
(sparging maintained through course of reaction) was added 2229 (60 g, 285 mmol, 1.3 equiv.) 
followed by NaHCO3 (177.4 g, 2 mol, 2.5 equiv.).  HSNAC40 (23.264 mL, 26 g, 219 mmol) was 
added dropwise over 30 min and stirred for 4 h and monitored by TLC for the loss of 22.  The 
solution was carefully acidified with G26 resin (Sigma, washed 2x 1M HCl prior to use) until a pH 
of 2-3 was achieved, the solution was filtered through glass wool, and the aqueous layer was 
washed 3x with CH2Cl2 [organic layer was placed in an Erlenmeyer and stirred with bleach 
(added slowly) before disposal].  The aqueous layer was flash frozen and lyophilized to yield 23 
(40.4 g, 184.26 mmol, 84% yield) as a white solid.  
For use in enzymatic reactions, 23 was suspended in H2O (500mM) aliquots, the pH was raised 
to 7.2 through careful addition of NaHCO3, flash frozen and stored at -20 °C.  
Note: 23 rapidly decarboxylates in DMSO-D6. MeCN-D3 proved acceptable for both 1H and 13C 
NMR, though complete decarboxylation was observed after ~7 days when stored on the bench at 
RT.   
1H NMR (CD3CN, 400 MHz) δ 6.71 (s, 1H), 3.67 (q, J = 7.1 Hz, 1H), 3.38-3.23 (m, 2H), 3.06-2.91 
(m, 2H), 1.85 (s, 3H), 1.34 (d, J = 7.1 Hz, 3H). 
13C NMR (CD3CN, 101 MHz) δ 197.9, 172.2, 171.5, 55.3, 39.4, 29.5, 22.9, 14.7. 
HRMS: Calculated [M+H]+ 220.0638, found 220.0646. 
 
2.6 Polyketide Synthase Experimental 
 
PKS Protein Preparation 
 
All H2O was obtained from a Millipore Milli-Q system (serial P3MNO3809A) using Millipore Q-
Gard 2/Quantum Ex Ultrapure organex cartridges.  LB broth Miller was obtained from EMD and 
autoclaved before use.  Glycerol was obtained from EMD, HEPES was obtained from 
Calbiochem (Omnipur grade), Isopropyl-b-D-thiogalactopyranoside (IPTG) was obtained from 
Gold Biotechnology.  Kanamycin Sulfate (Kan) was obtained from Amresco.  ACS grade 
imidazole and NaCl were obtained from Fisher Scientific.  pH was determined on a Symphony 
SB70P pH meter (serial SN005695) calibrated according to manufacturer’s specifications.  Ni-
NTA agarose was purchased from Qiagen and pre-equilibrated with five column volumes of lysis 
buffer.  PD-10 columns were purchased from GE and pre-equilibrated with five column volumes 














of storage buffer.   Cells were lysed using a 550 Sonic Dismembrator purchased from Fisher 
Scientific.  Optical density (OD600) was determined using an Eppendorf Biophotometer. 
 
Cloning, expression and purification of all proteins (PikAIII, PikAIV, PikAIII-TE) has been 
previously reported,2,41 and expression and purification optimized for activity and reproducibility.  
Buffers:  (lysis) HEPES (50 mM), NaCl (300 mM), imidazole (10mM), glycerol (10% v/v), pH 8.0 
(wash) HEPES (50 mM), NaCl (300 mM), imidazole (30mM), glycerol (10% v/v), pH 8.0 (elution) 
HEPES (50 mM), NaCl (300 mM), imidazole (300mM), glycerol (10% v/v), pH 8.0 (storage) 
HEPES (50 mM), NaCl (150 mM), EDTA (1 mM), glycerol (20% v/v), pH 7.2.   Bap42 cells bearing 
plasmids for expression of respective PKS modules were taken from glycerol cell stocks stored at 
-80°C and grown in LB (10mL) with Kan (50 mg/L), and grown overnight at 37°C.  The following 
morning, LB (1L) containing Kan (50 mg/L) was inoculated with the entire overnight culture, and 
shaken at 37°C until they reached an OD600 of 0.25 - 0.3 at which point they were removed and 
allowed to cool to RT.  When an OD600 of 0.4 was reached, the cultures were induced with IPTG 
(300µM) and shaken at 180RPM at 20°C for 18 hours.  Cells were pelleted at 5000g (4 °C) for 10 
minutes. 
 
Purification of PKS Proteins 
 
The following steps were conducted in <2 hours for maximum and reproducible enzymatic 
activity.  Cells were suspended in 15 mL of lysis buffer per liter of culture broth via vortex, and 
sonicated on ice at 60% power 6 x 10s with 60s rest periods.  Cellular debris was pelleted in a 
precooled (4°C) centrifuge at 40,000g for 10 min, and the supernatant was applied to 3 mL of Ni-
NTA resin and allowed to drip through.  15 mL of wash buffer was added, the column was gently 
pressurized with a syringe, and the enzyme of interest was eluted with 15 mL of elution buffer 
with gentle syringe pressure.  Protein containing fractions were determined via Bradford assay 
and pooled.  Buffer exchange was performed using a PD-10 column, and protein containing 
fractions were determined via Bradford assay and pooled, aliquoted, flash frozen in liquid N2, and 
stored at -80 °C. 
 
Analytical PKS Reactions 
 
Glucose-6-phosphate was purchased from Biosynth, glucose-6-phosphate dehydrogenase 
(yeast) was purchased from Alpha Aesar, and NADP+ was obtained from Amresco. 2-
vinylpyridine (Sigma) was added as a thiol scavenger to reactions monitored by HPLC without 
discernible loss of enzymatic activity.  All reactions were conducted in triplicate at 50 µL scale, 
initiated by addition of PKS enzyme(s), quenched when designated by addition of MeOH (3x by 
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vol, 150 µL) and clarified by centrifugation at 20800g for 2 minutes.  The resulting solution was 




Analytical liquid chromatography/mass spectrometry (LC/MS) was performed on an Agilent LC 
system (1290 series) coupled to an Agilent QTOF mass spectrometer (6500 series) using a 
Phenomenex Synergi 4µ Hydro RP 100 x 2 mm column (serial 48836-5) at 50°C.   Method: 0.4 
mL/min, A: H2O 0.1% formic acid, B: MeCN 0.1% formic acid, 0% B 0-2 min, 0-100% B linear 
gradient 1-9 min, 100% 9-10 min, 100-0% B 10-10.5 min linear gradient re-equilibration, 0-4 min 
were diverted to waste. The mass spectrometer was operated in profile mode in the positive ion 
mode with automatic lock mass infusion at 121.0508 and 922.0098 m/z using Agilent HP-Mix. 
The source temperature was 325°C with drying gas at 5 L/min and nebulizing gas at 30 Psig. The 
capillary was set to 3500 V, the fragmenter was set to 175 V, the skimmer was set to 65 V, and 
the octapole RF was set to 750 V peak to peak. Spectra were measured from 100-1,500 m/z with 
500 ms/spectrum. 
 
HPLC analysis  
 
Analytical high performance liquid chromatography (HPLC) was performed on a Beckman Coulter 
system (model 366 serial 385-1160) using a Phenomenex Luna 5µ C18 250 x 4.6mm column 
(serial 466013-1) monitoring at 250nM.  Method: 1.5mL/min, A: H2O 0.1% formic acid, B: MeCN 
0.1% formic acid, 5% B 0-1 min, 5-100% B linear gradient 1-12 min, 100% B 12-15 min, 5% 15-
17.5 min re-equilibration.  
 
Standard curves were constructed in triplicate at five concentrations, with concentration (0.5mM-
0.03125mM) corresponding to conversion to macrolactone products (200%-12.5% conversion), 
for example: 0.25mM corresponds to 100% theoretical conversion.  (0.5mM/200%, 
0.25mM/100%, 0.125mM/50%, 0.0625mM/25%, 0.03125mM/12.5%) immediately before or after 
reaction analysis. 
 
Crude Cell Lysate Preparation 
 
Expression of all modules was performed as described in the Protein Purification section.  Cells 
were pelleted at 5000g (4°C) for 10 minutes, and resuspended in 10mL of storage buffer  
[HEPES (50 mM), NaCl (150 mM), EDTA (1 mM), glycerol (20% v/v), pH 7.2] per liter of pelleted 
culture broth via vortex and sonicated on ice at 60% power 6 x 10s with 60s rest periods.  Cellular 
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debris was pelleted in a precooled (4 °C) centrifuge at 40,000g for 10 min.  Crude cell lysate was 
either used immediately or flash frozen in N2 and thawed on ice without discernible loss in 
activity.  Protein concentration was crudely normalized to that of purified protein though 
densitometry, and used without further manipulation. 
 
Representative semi-preparative and preparative PKS reactions 
 
All reactions were performed once, initiated by addition of PKS enzyme(s), quenched after 4 h by 
addition of 2x volume of acetone, placed in a -20 °C freezer for one hour and filtered through a 
celite plug.  Remaining insoluble material was suspended in acetone and this solution was used 
to rinse the celite plug.    Acetone was removed through rotary evaporation and the aqueous layer 
was 3x with CH2Cl2. Filtration through a sodium sulfate plug was performed then rinsed 2x with 
CH2Cl2 and concentrated.  Flash chromatography: EtOAc/Hexanes (30:70) afforded 10-dml.  
Flash chromatography: EtOAc/Hexanes (30:70) afforded narbonolide though yields varied as did 
complexity of spectra associated with the isolated macrolactone.  Acetylation of narbonolide after 
workup but before chromatography stabilized yields and purity of the product. Acetylation 
conditions: CH2Cl2 (0.1M) at 0°C for 20 min with Ac2O (10 equiv), NEt3 (12 equiv), DMAP (cat).  
The reaction was quenched with half saturated NH4Cl, the organic layer was separated and the 
aqueous layer was 2x extracted with CH2Cl2.  Filtration through a sodium sulfate plug, which was 
then rinsed 2x with CH2Cl2 and concentrated.  Flash chromatography: EtOAc/Hexanes (20:80) 
afforded acetyl-narbonolide. 
 
Representative semi-preparative and preparative PKS reactions 
 
All reactions were performed once, initiated by addition of PKS enzyme(s), quenched after 4 h by 
addition of 2x volume of acetone, placed in a -20 °C freezer for one hour and filtered through a 
celite plug.  Remaining insoluble material was suspended in acetone and this solution was used 
to rinse the celite plug.  Acetone was removed through rotary evaporation and the aqueous layer 
was 3x with CH2Cl2. Filtration through a sodium sulfate plug was performed then rinsed 2x with 
CH2Cl2 and concentrated.  Flash chromatography: EtOAc/Hexanes (30:70) afforded 10-dml.  
Flash chromatography: EtOAc/Hexanes (30:70) afforded narbonolide though yields varied as did 
complexity of spectra associated with the isolated macrolactone.  Acetylation of narbonolide after 
workup but before chromatography stabilized yields and purity of the product. Acetylation 
conditions: CH2Cl2 (0.1M) at 0°C for 20 min with Ac2O (10 equiv), NEt3 (12 equiv), DMAP (cat).  
The reaction was quenched with half saturated NH4Cl, the organic layer was separated and the 
aqueous layer was 2x extracted with CH2Cl2.  Filtration through a sodium sulfate plug, which was 
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then rinsed 2x with CH2Cl2 and concentrated.  Flash chromatography: EtOAc/Hexanes (20:80) 
afforded acetyl-narbonolide (32). 
 
Reaction 1: semi-preparative scale up of analytical reactions 
 
Conditions: sodium phosphate buffer (400mM, 20% v/v glycerol, 200mL, pH = 7.2), Pik 
pentaketide 15 (70 mg, 0.2 mmol, 1mM), MM-NAC (20 equiv, 20mM), NADP+ (0.1 equiv, 0.1mM), 
glucose-6-phosphate (2.5 equiv, 2.5mM), glucose-6-phosphate dehydrogenase (0.5 unit/mL), 2-
vinylpyridine (8mM), purified PikAIII-TE or PikAIII/PikAIV (1 uM, 0.1 mol%), 4 hours, stationary, 
RT. The aforementioned purification protocol gave 10-dml (18) (31.5 mg, 0.11 mmol, 53%) as a 
viscous colorless oil that foams under high vacuum, or acetyl-nbl (32) (37.5 mg, 0.094 mmol, 
47%), that crystalizes upon standing. 
 
Reaction 2: semi-preparative crude cell lysate evaluation 
 
Conditions: sodium phosphate buffer (400mM, 20% v/v glycerol, 200mL, pH = 7.2), Pik 
pentaketide 15 (70 mg, 0.2 mmol, 1mM) MM-SNAC (20 equiv, 20mM), NADP+ (0.1 equiv, 
0.1mM), glucose-6-phosphate (2.5 equiv, 2.5mM), glucose-6-phosphate dehydrogenase (0.5 
unit/mL), 2-vinylpyridine (8mM), cell free PikAIII-TE or PikAIII/PikAIV (1 uM, 0.1 mol%), 4 hours, 
stationary, RT. The aforementioned purification protocol gave 10-dml (18) (36.8 mg, 0.124 mmol, 
62%) as a viscous colorless oil, which foams under high vacuum or acetyl-nbl (32) (43.4 mg, 
0.11 mmol, 55%) that crystalizes upon standing. 
 
Reaction 3: semi-preparative crude cell lysate buffer/concentration evaluation 
Conditions: sodium phosphate buffer (50mM, 2.5% v/v glycerol, 50mL, pH = 7.2), pentaketide 15 
(70 mg, 0.2 mmol, 4mM) MM-SNAC (10 equiv, 40mM), NADP+ (0.1 equiv, 0.4mM), glucose-6-
phosphate (2.5 equiv, 10mM), glucose-6-phosphate dehydrogenase (2 unit/mL), 2-vinylpyridine 
(8mM), cell free PikAIII-TE or PikAIII/PikAIV (4µM, 0.1 mol%), 4 hours, stationary, RT. The 
aforementioned purification protocol gave 10-dml (18) (39.2 mg, 0.124 mmol, 66%) as a viscous 
colorless oil that foams under high vacuum, or acetyl-nbl (32) (43 mg, 0.11 mmol, 55%) that 
crystalizes upon standing. 
 
Reaction 4: preparative PKS catalysis, and scale up of reaction 3. 
 
Conditions: sodium phosphate buffer (50mM, 2.5% v/v glycerol, 375mL, pH = 7.2), pentaketide 
15 (500 mg, 1.43 mmol, 4mM) MM-SNAC (10 equiv, 40mM), NADP+ (0.1 equiv, 0.4mM), glucose-
6-phosphate (2.5 equiv, 10mM), glucose-6-phosphate dehydrogenase (2 unit/mL), 2-vinylpyridine 
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(8mM), cell free PikAIII-TE or PikAIII/PikAIV (4µM, 0.1 mol%), 4 hours, stationary, RT. The 
aforementioned purification protocol gave 10-dm(18) (256 mg, 0.86 mmol, 60%) as a viscous 
colorless oil that foams under high vacuum, or acetyl-nbl(31) (277 mg, 0.7 mmol, 49%) which 
crystalizes upon standing. 
 
10-dml (18) 
1H NMR (CDCl3, 599 MHz)  δ 6.74 (dd, J = 15.7, 5.4 Hz, 1H), 6.42 (d, J = 15.7 Hz, 1H), 5.00 
(ddd, J = 8.2, 5.4, 2.1 Hz, 1H), 3.55 (d, J = 10.4 Hz, 1H), 2.68-2.48 (m, 3H), 1.76-1.50 (m, 4H), 
1.36-1.24 (ovlp m, 2H), 1.30 (d, J = 6.8 Hz, 3H), 1.22 (d, J = 7.0 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 
1.00 (d, J = 6.2 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 151 MHz) δ 205.1, 174.9, 147.1, 125.6, 78.0, 73.7, 45.1, 43.3, 38.0, 33.2, 33.2, 
25.1, 17.6, 17.4, 16.4, 10.3, 9.5. 
HRMS: Calculated [M+H]+ 297.2060, found 297.2055 
 
Acetyl-narbonolide (31) 
1H NMR (CDCl3, 599 MHz)  δ 6.75 (dd, J = 15.8, 6.0 Hz, 1H), 6.14 (d, J = 15.8 Hz, 1H), 5.36 (d, J 
= 8.2 Hz, 1H), 4.91 (ddd, J = 8.3, 5.9, 2.9 Hz, 1H), 3.77 (q, J = 7.0 Hz, 1H), 2.91 (p, J = 7.5 Hz, 
1H), 2.74-2.62  (m, 2H), 2.07 (s, 3H), 2.00 (s, 1H), 1.71-1.65 (m, 1H), 1.64-1.57 (m, 3H), 1.35 (d, 
J = 7.0 Hz, 3H), 1.16 (d, J = 7.4 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 7.0 Hz, 3H), 0.97 
(d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 151 MHz) δ 206.0, 202.6, 170.3, 169.0, 147.8, 126.5, 78.5, 74.98, 50.5, 47.7, 
43.0, 38.3, 35.5, 34.7, 23.1, 20.7, 17.4, 16.4, 14.7, 13.5, 12.1, 10.4. 
HRMS: Calculated [M+H]+ 395.2428, found 395.2436 
 
Narbonolide (24) 
1H NMR (CDCl3, 599 MHz)  δ 6.89 (dd, J = 16.3, 4.9 Hz, 1H), 6.10 (dd, J = 16.4, 1.8 Hz, 1H), 
5.16-5.11 (m, 1H),  3.91-3.83 (m, J = 4.9 Hz, 1H), 3.71 (q, J = 7.0 Hz, 1H), 3.05-2.97 (m, 1H), 
2.73-2.65 (m, 2H), 2.61 (s, 1H), 1.73-1.58 (m, 4H), 1.53-1.44 (m, 1H), 1.35 (d, J = 7.0 Hz, 3H), 
1.25 (s, 2H), 1.14 (d, J = 6.8 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H) 1.40-0.78 
(ovlp m, 4 H)  
13C NMR (CDCl3, 151 MHz) δ 207.6, 204.9, 170.9, 148.5, 128.9, 78.1, 72.6, 50.3, 50.2, 39.8, 
38.8, 36.4, 35.1, 24.2, 18.6, 18.2, 14.3, 10.9, 10.8, 10.4. 
HRMS: Calculated [M-H2O+H]+ 335.2217, found 335.2225 
 
2.7 Biotransformation Experimental 
 
Spore stock preparation from Streptomyces venezuelae strains 
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All H2O used was obtained from a Millipore Milli-Q system (serial P3MNO3809A) using Millipore 
Q-Gard 2/Quantum Ex Ultrapure organex cartridges.  Yeast extract, meat extract, glucose, agar 
was obtained from EMD.  N-Z amine was obtained from Sigma Aldrich.  Soytone and soluble 
starch were obtained from BD.  MOPS was purchased from AK Scientific.  CaCl2 and NaCl2 were 
obtained from Fisher Scientific.  pH was determined on a Symphony SB70P pH meter (serial 
SN005695) calibrated according to the manufacturer’s specifications.  Optical density (OD600) 
was determined using an Eppendorf Biophotometer.  All solutions are autoclaved unless stated 
otherwise and manipulations occurred in a sterile laminar flow hood. 
 
Engineered variants of Streptomyces venezuelae ATCC 15439 designated DHS2001 and YJ112 
were grown on Bennett’s agar (1L = 1 g yeast extract, 1 g meat extract, 2 g N-Z amine, 10 g 
glucose, 15 g agar, pH 7.3) plates (30 mL) at 28°C until reaching a high spore density (~4-6 
days).  H2O (9 mL) was added to the plate, and the spores were suspended by scraping with an 
inoculation loop.  This solution was added to a 15 mL sterile tube, vortexed vigorously for 1 min, 
and filtered through cotton into another 15 mL sterile tube.  The spores were pelleted by 
centrifugation (2000g, 5 min), the supernatant decanted, and the spores were resuspended in 
20% glycerol solution (1 mL), transferred to a sterile screw top vial and flash frozen in N2. 
 
Biotransformation of 10-dml to methymycins 
 
Twelve baffled 250 mL flasks containing SCM media (1 L = 15 g soluble starch, 20 g soytone, 0.1 
g calcium chloride, 1.5 g yeast extract, 10.5 g MOPS, pH 7.2) (100 mL), each inoculated with 
spore stock (10 µl) and incubated at 28°C, 180 RPM until reaching an OD600 = 0.1 (~12-15 h).  
10-dml (120 mg, 0.405 mmol, 0.34mM, 10 mg per flask, 100 mg/L) was added as a DMSO 
solution (50 mg/mL) followed by acetyl-nbl (5uM, ~2.5 mg/L), and the flasks continued incubation 
at 28°C, 180 RPM for 48 h.  Combined culture broth was concentrated by rotary evaporation to 
1/3 of the original volume followed by 2x volume of acetone, placed in a -20°C freezer for one 
hour and filtered through a celite plug.  Remaining insoluble material was suspended in acetone 
and used to rinse the celite plug.    Acetone was removed through rotary evaporation and the 
aqueous layer was saturated with NaCl, pH was adjusted to 11, and the solution 3x extracted with 
EtOAc. The organic layer was dried with sodium sulfate, filtered, and concentrated.  Macrolides 
were purified directly by preparatory HPLC using a Phenomenex Luna 5u C18 250 x 21.2mm 
column (serial 444304-4) at a flow rate of 9 mL/min with an isocratic mobile phase of H2O/MeCN 
(45/55) and a 0.1% NEt3 modifier.   
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DHS2001: Methymycin (30) (39 mg, 0.083 mmol, 20.5% yield) Neomethymycin(31) (75 mg, 
0.160 mmol, 39.5% yield) Novamethymycin (33) (11 mg, 0.023 mmol, 5.7%) Ketomethymycin 
(34) (2 mg, 0.004 mmol, 1%) 
Total: methymycins (0.27 mmol, 66%, 
Methymycin:Neomethymycin:Novamethymycin:Ketomethymycin  = 3.5:7:1:trace)  
YJ112: Methymycin (30) (37 mg, 0.079 mmol, 19.5%  yield) Neomethymycin (31) (58 mg, 
0.123 mmol, 30% yield) Novamethymycin (33) (32 mg, 0.065 mmol, 16%) Ketomethymycin  
(34) (11 mg, 0.023 mmol, 6%) 
33
21
34 31 30 
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Total: methymycins (0.29 mmol, 71%, 
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Methymycin  
1H NMR (CDCl3, 599 MHz) δ 6.58 (d, J = 15.9 Hz, 1H), 6.32 (d, J = 15.9 Hz, 1H), 4.75 (dd, J 
=10.8, 2.2 Hz, 1H), 4.23 (d, J = 7.3 Hz, 1H), 3.59 (d, J = 10.4 Hz, 1H), 3.51-3.43 (m, 1H), 3.40 (br 
s, 1H), 3.20 (dd, J = 10.2, 7.3 Hz, 1H), 2.85 (dq, J = 13.8, 6.9 Hz, 1H), 2.60-2.50 (m, 1H), 2.50-
2.43 (m, 1H), 2.25 (s, 6H), 1.98-1.89 (m, 1H), 1.72-1.61 (m, 2H), 1.56-1.39 (m, 2H), 1.42 (d, J = 
6.9 Hz, 3H), 1.34 (s, 3H), 1.28-1.19 (ovlp m, 2H) 1.21 (d, J = 6.1 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 
1.00 (d, J = 6.7 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 
 
13C NMR (CDCl3, 151 MHz) δ 204.5, 175.2, 148.9, 125.6, 105.1, 85.5, 76.3, 74.3, 70.3, 69.5, 
65.8, 45.1, 44.2, 40.2, 33.9, 33.6, 28.2, 21.2, 21.1, 19.4, 17.6, 17.4, 16.1, 10.7. 
 
HRMS: Calculated [M+H]+ 470.3112, found 470.3152. 
 
Neomethymycin 
1H NMR (CDCl3, 599 MHz) δ 6.73 (dd, J = 15.7, 5.5 Hz, 1H), 6.42 (dd, J = 15.7, 1.3 Hz, 1H), 4.77 
(dd, J = 9.0, 2.0 Hz, 1H), 4.21 (d, J = 7.3 Hz, 1H), 3.86 (dq, J = 12.3, 6.1 Hz, 1H), 3.57 (d, J = 
10.5 Hz, 1H), 3.50-3.42 (m, 1H), 3.41 (ovlp br s, 1H), 3.19 (dd, J = 10.2, 7.3 Hz, 1H), 3.07-3.0 (m, 
1H), 2.86 (dq, J = 11.0, 6.9 Hz, 1H), 2.56-2.46 (m, 1H), 2.49-2.41 (m, 1H), 2.24 (s, 6H), 1.71-1.60 
(m, 2H), 1.48-1.37 (m, 1H), 1.39 (d, J = 6.9 Hz, 3H), 1.28-1.19 (ovlp m, 2H), 1.21 (d, J = 6.1 Hz, 
3H), 1.18 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 7.4 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.6 
Hz, 3H). 
 
13C NMR (CDCl3, 151 MHz) δ 205.2, 174.8, 147.1, 126.2, 105.0, 85.6, 75.4, 70.3, 69.5, 66.2, 
65.8, 45.1, 43.9, 40.2, 35.4, 34.1, 33.4, 28.2, 21.1, 21.0, 17.6, 17.4, 15.8, 9.8. 
 
HRMS: Calculated [M+H]+ 470.3112, found 470.3137. 
 
Novamethymycin   
1H NMR (CDCl3, 599 MHz) δ 6.63 (d, J = 16.0 Hz, 1H), 6.31 (d, J = 16.0 Hz, 1H), 4.65 (d, J = 9.2 
Hz, 1H), 4.22 (d, J = 7.3 Hz, 1H), 4.12 (dq, J = 12.3, 6.1 Hz, 1H), 3.59 (d, J = 10.4 Hz, 1H), 3.47 
(dq, J = 12.5, 6.6 Hz, 2H), 3.20 (dd, J = 9.9, 7.4 Hz, 1H), 2.85 (dq, J = 13.9, 6.9 Hz, 1H), 2.60-
2.51 (m, 1H), 2.50-2.43 (m, 1H), 2.25 (s, 6H), 1.71-1.62 (m, 2H), 1.49 (s, 3H), 1.48-1.40 (ovlp m, 
1H), 1.40 (d, J = 6.9 Hz, 3H), 1.28-1.18 (ovlp m, 2H), 1.22 (d, J = 6.0 Hz, 3H), 1.17 (ovlp d, J = 
7.5 Hz, 3H), 1.16 (ovlp d, J = 7.4 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H). 
 
13C NMR (CDCl3, 151 MHz) δ 204.3, 174.1, 148.2, 125.4, 105.1, 85.3, 75.5, 74.2, 70.3, 69.6, 
67.7, 65.8, 45.2, 44.0, 40.2, 33.8, 33.6, 28.2, 21.1, 20.9, 20.1, 17.5, 17.4, 15.8. 
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HRMS: Calculated [M+H]+ 486.3061, found 486.3074. 
 
Ketomethymycin 
1H NMR (CDCl3, 599 MHz) δ 6.73 (dd, J = 15.7, 5.6 Hz, 1H), 6.51 (d, J = 15.7 Hz, 1H), 5.27 (d, J 
= 2.5 Hz, 1H), 4.26 (d, J = 7.3 Hz, 1H), 3.61 (d, J = 10.5 Hz, 1H), 3.49 (dq, J = 12.0, 6.4 Hz, 1H), 
3.43 (br s,  1H), 3.28-3.19 (m, 2H), 3.04 (dq, J = 13.1, 6.5, 6.1 Hz, 1H), 2.60-2.51 (m, 1H), 2.51-
2.44 (m, 1H), 2.27 (s, 6H), 2.17 (s, 3H), 1.73 (br t, J = 13.3 Hz, 1H), 1.68-1.62 (m, 1H), 1.57-1.47 
(ovlp m, 1H), 1.50 (d, J = 6.9 Hz, 3H), 1.30-1.21 (ovlp m, 1H), 1.23 (d, J = 6.2 Hz, 3H), 1.18-1.12 
(m, J = 13.0, 6.8 Hz, 1H), 1.20 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.7 Hz, 
3H). 
 
13C NMR (CDCl3, 151 MHz) δ 204.9, 204.6, 174.6, 144.6, 127.2, 105.1, 85.5, 77.1, 70.3, 69.6, 
65.9, 45.0, 43.9, 40.2, 36.7, 33.9, 33.7, 28.1, 27.4, 21.1, 17.7, 17.3, 15.6, 10.5. 
 
HRMS: Calculated [M+H]+ 468.2956, found 468.2962. 
 
Biotransformation of narbonolide to pikromycin 
Twenty five baffled 250 mL flasks containing SCM media (1L = 15 g soluble starch, 20 g soytone, 
0.1 g calcium chloride, 1.5 g yeast extract, 10.5 g MOPS, pH 7.2) (100mL), were inoculated with 
spore stock (S. venezuelae strain YJ112, 10 µl) and incubated at 28°C, 180 RPM until OD600 = 
0.1 (~12-15 h).  Crude narbonolide (250 mg, 0.71 mmol, 0.28mM, 10 mg per flask, 100 mg/L, 200 
µl per flask) was added in a DMSO solution (50 mg/mL), followed by acetyl-narbonolide in a 
50mg/mL DMSO solution (5µM, ~2.5 mg/L) and the flasks were incubated at 28°C, 180 RPM for 
48 h.  Combined culture broth was concentrated by rotary evaporation to 1/3 original volume 
followed by 2x volume of acetone, placed in a -20°C freezer for one hour and filtered through a 
celite plug.  Remaining insoluble material was suspended in acetone and this solution was used 
to rinse the celite plug.  Acetone was removed through rotary evaporation and the aqueous layer 
was saturated with NaCl, the pH was adjusted to 11 and the solution was 3x extracted with 
EtOAc. The organic layer was dried with sodium sulfate, filtered, and concentrated.    Pikromycin 
was purified directly by preparatory HPLC using a Phenomenex Luna 5u C18 250 x 21.2mm 
column (serial 444304-4) at a flow rate of 9 mL/min with an isocratic mobile phase of H2O/MeCN 
(45/55) and a 0.1% NEt3 modifier.  After evaporation, pikromycin was dissolved in CH2Cl2 and 
flash chromatography through a short plug of silica gel: MeOH/CH2Cl2 (10/90). 
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Strain YJ112: pikromycin (267 mg, 0.51 mmol, 72%)  
Note: 1H and 13C NMR experiments conducted at 50°C. 
1H NMR (CDCl3, 599 MHz) δ 6.63 (d, J = 15.7 Hz, 1H), 6.30 (d, J = 15.7 Hz, 1H), 5.00 (dd, J = 
11.0, 2.1 Hz, 1H), 4.34 (d, J = 7.2 Hz, 1H), 3.98-3.92 (ovlp m, 1H), 3.97-3.88 (ovlp m, 1H), 3.95 
(ovlp q, J = 7.3 Hz, 1H), 3.59-3.52 (m, 1H), 3.23 (dd, J = 10.1, 7.4 Hz, 1H), 3.19 (t, J = 3.6, 1H), 
2.75-2.65 (m, 1H), 2.48 (m, 1H), 2.28 (s, 6H), 2.18-2.09 (m, 1H), 1.77-1.69 (m, 1H), 1.70-1.64 (m, 
1H), 1.57-1.50 (m, 1H), 1.57-1.50 (m, 1H), 1.47-1.38(ovlp m, 1H), 1.45 (d, J = 7.3 Hz, 3H), 1.32 
(s, 3H), 1.30 (d, J = 7.1 Hz, 3H), 1.24 (d, J = 6.1 Hz, 3H), 1.10 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.9 
Hz, 3H), 1.05-0.96 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H). 
13C NMR (CDCl3, 151 MHz) δ 212.6, 203.5, 170.4, 145.4, 129.2, 104.9, 83.5, 75.1, 70.0, 69.7, 
65.9, 53.2, 46.6, 43.0, 40.2, 37.7, 35.8, 28.4, 23.3, 23.0, 21.1, 17.5, 14.7, 13.2, 10.6. 
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Substrate Controlled Divergence in PikAIV Catalysis with Stabilized Hexaketide Substrates 
 
The work described in this chapter was conducted alongside fellow Sherman lab graduate 
student Aaron A. Koch, who contributed to many aspects of the research herein. 
 
Terminal type I PKS modules typically catalyze the formation of a single product where 
the ketosynthase (KS) domain accepts the growing polyketide chain from an upstream acyl 
carrier protein (ACP), final processing is performed, and the terminal thioesterase (TE) domain 
releases the product.  PikAIV is unique in the ability to accept the Pik hexaketide onto either the 
KS or TE domain, to generate the 14-membered macrolactone narbonolide(16) or 12-membered 
macrolactone 10-dml(1) respectively.   
Advances made in PKS biochemistry (chapter 2) were applied to evaluate the terminal 
Pik module, PikAIV, with a panel of native Pik hexaketide substrates.  The Pik hexaketide 
substrates were accessed through chemical degradation of fermentation derived 10-dml(1) from 
an engineered variant of S. venezuelae ATCC 15439. As the Pik hexaketide is inherently 
unstable due to intramolecular hemiketalization subsequent dehydration,1 we developed 
protection strategies to alleviate this experimental bottleneck.  We pursued two distinct protective 
groups 1) a small methyl ether that would remain attached throughout the catalytic cycle, and 2) a 
2-nitrobenzyloxymethyl ether that could be photolyzed to provide the Pik hexaketide on demand. 
The advances in substrate protection enabled thorough evaluation of substrate control on domain 
loading.  We observed dramatic variation in the product distribution dictated by the type of ester 
employed, with greater than 10:1 selectivity for either the 14-membered macrolactone 
narbonolide (16) through full module catalysis or the 12-membered macrolactone 10-
deoxymethynolide (1) through direct macrolactonization. 
 
3.1 Synthesis of the Pik hexaketide seco-acid 
 
 We considered two options for accessing the Pik hexaketide, 1) fully synthetic2 or 2) 
degradation of fermentation derived 10-dml(1).1 Either strategy was viable as intermediates from 
Pik pentaketide (chapter 2) could be diverted to synthesize the Pik hexaketide and 10-dml(1) 
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fermentation is a practical method to provide grams of the macrolactone.  Ultimately, we decided 
to pursue a second-generation degradation strategy toward the Pik hexaketide.  The first 
generation degradation of 10-dml (Scheme 3.1) exploited the most intuitive disconnection to the 
hexaketide.  As the hexaketide is the seco-acid of 10-dml(1), hydrolysis of the macrolactone and 
subsequent esterification could theoretically yield hexaketide ready for PKS biochemistry in just 
two steps.  Direct hydrolysis fails for two reasons 1) the hexaketide seco-acid is unstable and 
decomposes rapidly through hemiketalization and dehydration pathways and 2) 10-dml(1) is 
exceedingly difficult to hydrolyze requiring forcing conditions, destroying any product formed.
 
 As such, a Leuche reduction of the α,β-unsaturated ketone to an allylic alcohol provided 
2, which, when hydrolyzed would be stable as the hemiketalization degradation pathway would 
be prevented(Scheme 3.1).  2 was then refluxed in LiOH solution for 9 d resulting in partial 
epimerization at the C2 position of 3.  Thioesterification and prep-HPLC was sufficient to separate 
the C2 epimers yielding 4 then just one oxidation away from targeted hexaketide 5. 
  





















































































 The allylic alcohol was returned to the requisite α,β-unsaturated ketone oxidation state with 
MnO2 providing 5 after prep-HPLC as a mixture of linear chain and closed hemiketals.1 While this 
route was able to provide a few milligrams of 5 for functional studies of PikAIV or excised TE 
domain, we sought to develop countermeasures against hemiketal formation, and, in turn, a 
scalable route to Pik hexaketides that avoided prep-HPLC. 
Total synthesis of polyketide natural products routinely employs protecting group arrays 
where the last step is often a deprotection to unveil the final target molecule.  While mature 
natural products possess some measure of implicit stability having survived purification from 
natural sources, polyketide intermediates often degrade rapidly through intramolecular 
hemiketalization and dehydration pathways. Although the structural basis remains unclear, 
polyketide elongation intermediates that are covalently attached to the ACP domain during 
biosynthesis are likely stabilized through sequestration within the PKS module(Figure 3.1).3 
Unsurprisingly, instability of polyketide substrates needed to study PKS modules in vitro is a 
commonly encountered experimental bottleneck where the substrate rapidly decomposes once 
synthesized. Pik pentaketide 6 (chapter 2) has been widely utilized1,4 in the Sherman lab and this 
can be attributed, at least in part, to the inherent stability of the compound.  The lone hydroxyl 
group (highlighted in green) is inert because the α,β-unsaturated ketone renders intramolecular 
hemiketalization disfavorable, allowing for facile final deprotection and long term storage of 6.  
Removing the α,β-unsaturated ketone results in concomitant loss of stability in the case of related 
DEBS pentaketide 7, whose construction was plagued by a problematic final deprotection.4b The 
Pik hexaketide 5 suffers from similar stability problems,1-2 due to similar hemiketalization and 
dehydration pathways. While we were specifically targeting the Pik hexaketide, we sought to 
develop general strategies to overcome this common problem.  Thus, to address the instability 
the Pik hexaketide, we considered two distinct stabilization strategies: (i) a sterically 
undemanding protecting group that would remain attached throughout the catalytic cycle, and (ii) 
a protecting group that could be removed in a controlled manner to provide the native hexaketide 
immediately before use in reactions with PikAIV or the excised Pik TE domain.  Ultimately, a 
methyl ether protecting group was chosen to satisfy (i) and a photocleavable 2-
nitrobenzyloxymethyl ether (NBOM)5 was explored to address objective (ii).   
To synthesize protected Pik hexaketides, we first needed to ferment a 10-dml(1).  We 
utilized an engineered strain of Streptomyces venezuelae ATCC 15439 designated DHS8708 
where desosamine biosynthesis was knocked out through disruption of desI.  DHS8708 no longer 
produces macrolides but does produce either 10-dml (1) or narbonolide (16) depending on media 
employed.6 Soy based media biases fermentation heavily towards 10-dml(1), and fermentation 
optimization indicated aeration to be intimately tied to resulting macrolactone titer, prompting use 
of heavily baffled Fernbach flasks and/or a bioreactor. While the bioreactor typically provided 100-
120 mg/L, shake flasks also performed well (~90-100 mg/L) meaning that 34 L runs would 
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typically provide over 3 g of 10-dml (1).  With an adequate amount of 10-dml (1) secured, we 
initiated the synthetic route to Pik hexaketides by protecting the C3 hydroxyl group. Methylation of 
the C3 hydroxyl group proved extremely challenging, presumably due to steric hindrance arising 
from the two vicinal methyl groups.  Only trace etherification of the hindered C3 hydroxyl group 
was detected in neat MeI/Ag2O at room temperature or when heated in a pressure tube, and 
decomposition to a complex mixture of products was observed with excess Me3OBF4/1,8-
bis(dimethylamino)naphthalene in CH2Cl2 at all temperatures investigated.13 MeOTF and 2,6-Di-t-
butylpyridine provided initial promise, though some decomposition was observed when run at RT 
in CH2Cl2 or when cooled to 4 °C, and attempts to run the reaction at colder temperatures led 
extremely slow conversion.  Switching to less polar PhMe suppressed decomposition but the rate 
was glacial at 4 °C, and epimerization was observed when the reaction mixture was warmed to 
RT.  Ultimately a concentrated, mixed solvent system of CH2Cl2/PhMe (2:1, 2 M) with 1.2 equiv of 
MeOTf and 2,6-Di-t-butylpyridine in CH2Cl2/PhMe (2:1, 2 M) at 4 °C furnished the desired product 
9 in good yield, albeit at an extended reaction time (72 h).  
 
Initially, we attempted to install a 2-nitrobenzyl group onto the C3 hydroxyl group directly 
though this too proved challenging. Attempts to install the 2-nitrobenzyl ether with 2-nitrobenzyl 
bromide, 2-nitrobenzyl trifluoromethanesulfonate, or 2-nitrobenzyl trichloroacetimidate were met 
with met with failure under all surveyed conditions. As such, we moved to a 2-
nitrobenzyloxymethyl (NBOM)5 group which could be appended smoothly by employing 8 with 
stoichiometric CuBr2 to furnish 9.7   Attention was then focused on opening the macrolactone ring 
known to be particularly recalcitrant towards hydrolysis.2,8 We considered a number of 
alternatives including oxidative cleavage of α,β-unsaturated ketone,9 or cross-metathesis with 
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pursued the cross-metathesis approach briefly, though the α,β-unsaturated ketone proved largely 
unreactive, and changing the electronics (reduction/silyl protection of the resulting allylic alcohol) 
faired little better (~15% yield.)  Accordingly, we considered that a two-step global reduction and 
selective oxidation would neatly side-step problematic hydrolysis procedures. A strong reducing 
agent could provide a linear triol, where each hydroxyl group would differ in reactivity: primary, 
secondary allylic, and secondary homoallylic alcohols.  From this triol, we could theoretically 
oxidize in a chemoselective manner to give the hexaketide seco-acid in one or two additional 
steps.  
Excess LiAlH4 in THF at RT proved sluggish and gave a mixture of diastereomers, 
whereas reduction with DIBAL-H proceeded smoothly to provide single stereoisomers. 
Chemoselective oxidation of triols 11 and 12 with TEMPO/PIDA adjusted the oxidation state of 
the primary hydroxyl group to a carboxylic acid, and the allylic alcohol to the desired α,β-
unsaturated ketone without oxidizing the homoallylic hydroxyl group at C11 (Scheme 3.2). With 
desired seco-acids 12 and 14 in hand, we esterified both hexaketides with a variety of alcohols 
and thiols.  
 
3.2 Evaluation of Pik hexaketide Esters 
 
In vitro studies of PikAIV with its native substrate have raised interesting questions about 
studying PKS enzymes in vitro.  For example, when incubated directly with N-acetylcysteamine 
Pik hexaketide 5 PikAIV afforded a 4:1 ratio of macrolactones 10-dml (1) and narbonolide (15).10 
This result contrasts sharply with reaction schemes pairing PikAIII/PikAIV2,4a,11 with Pik 
pentaketide 6 where PikAIII performs an extension and delivers the hexaketide to PikAIV via an 
ACP5 thioester; narbonolide (16) is the major product. These results suggest that the traditionally 
employed N-acetylcysteamine thioester might be a poor choice for loading the KS domain with 
high fidelity, and motivated exploratory studies of substrate ester influence with PikAIV.  We had 
some confidence in this approach as optimization of PikAIII (as an unnatural TE fusion12 or when 
paired with the final module, PikAIV) demonstrated improved catalysis with thiophenol 
thioesters4a over N-acetylcysteamine thioesters (chapter 2). 
 We intended to synthesize a series of NBOM and methyl protected hexaketide esters, 
incubate them PikAIV or excised Pik TE, and then analyze the catalytic outcome in terms of 
conversion to 10-dml (1):narbonolide (15) [or methyl-10-dml (9):methyl-narbonolide (16)] and the 
ratio there-of to empirically evaluate substrate ester influence on in vitro catalysis.  For the first 
round of experiments, we employed a panel of 10 hexaketides (five different esters for both 
methyl and NBOM protected hexaketides) with PikAIV and MM-NAC4a,13 (Table 3.1). 
We had initially hoped to achieve deprotection in situ where an NBOM protected 
substrate could be photolyzed in the presence of enzyme, though we observed pH dependence 
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on photolysis14 requiring a two step procedure where photolysis occurs before the deprotected 
hexaketide is administered to PikAIV or the excised Pik TE domain.  For NBOM protected 
substrates, 4-nitrophenol (Table 3.1, entry 6) and N-hydroxysuccinimide (entry 8) substrates 
decomposed rapidly upon photolysis and subsequently gave generally low conversion to 
macrolactones. In contrast, the corresponding hexaketide thiophenol, benzyl mercaptan and N-
acetylcysteamine thioesters photolyzed smoothly, though benzyl mercaptan thioesters (entry 4) 
gave lower overall conversion to either macrolactone. Remarkably, we observed significant 
selectivity in product formation depending on the type of ester employed, where the thiophenol 
thioester (entry 2) demonstrated greater than 10:1 selectivity for narbonolide (15). On the other 
hand, the corresponding hexaketide N-acetylcysteamine thioester (entry 10) showed greater than 
10:1 selectivity for 10-dml (1). 
  
 Initial results clearly demonstrated that the type of ester employed is of utmost 
importance.15 In our hands, NAC had a preference for direct TE loading to generate 10-dml (1), 
as did NHS (entries 7 and 8.)  Unfortunately, benzyl mercaptan was ineffective at loading either 
domain though we had anticipated it to be a competent handle for enzyme acylation.  
In parallel experiments (Table 3.1), methylated substrates were converted to methyl 
protected 10-dml (9) or methyl protected narbonolide (16) albeit with selectivity shifted toward 
methyl 10-dml (9) and reduced overall conversions relative to native substrates furnished through 































































































NBOM photolysis.  To further elucidate the macrocycle product distribution imparted by the thio- 
or oxoester employed, we altered the reaction conditions by excluding MM-NAC in PikAIV 
reactions,10 and also by examining the excised Pik TE domain, eliminating the possibility of 
narbonolide (15) or methyl protected narbonolide (16) formation (Table 3.2).  
 
 Incubation of hexaketides with PikAIV in the absence of MM-NAC or with the excised TE 
domain demonstrated variation in macrolactonization efficiency to 10-dml (1) or methyl 10-dml 
(15) dictated by the ester employed (Table 3.2). Consistent with PikAIV reactions where MM-NAC 
was present, the N-acetylcysteamine thioester (Table 3.2, entries 16-20) gave the highest 
conversion to 10-dml (1) or methyl protected 10-dml (9) under all conditions tested, with N-
hydoxysuccinimide esters providing moderate conversion to methyl protected 10-dml (15) (Table 







































































































Conv to 2 or 7(%)
4 ± 0.2,a 6 ± 0.15b
10 ± 0.6
17 ± 0.8,a 29 ± 3.5b
36 ± 0.8
trace,a 3 ± 0.5b
4 ± 0.3
5 ± 0.5a,4 ± 0.5b
14 ± 0.5
4 ± 0.2,a 12 ± 0.7b
11 ± 0.3
15 ± 0.5,a 11± 0.6b
16 ± 0.6
22 ± 4.2,a 35 ± 1.3b
55 ± 6.2
5 ± 0.5 a, 4 ± 0.7b
6 ± 0.18
29 ± 2.7,a 66 ± 4.7b
66 ± 4.7
61 ± 5.6,a 90 ± 2.1b
90 ± 1.9





Table 3.2 Evaluation of stabilized Pik hexaketides with PikAIV and Pik TE  
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direct macrolactonization utilizing either PikAIV or the excised TE domain (Table 3.2, entries 1-4).  
The slow conversion of thiophenol thioesters with the TE domain explains, at least in part, the 
superiority of this handle over traditionally employed NAC with Pik PKS modules. 
In vivo, chain transfer is mediated through C and N terminal docking domains16 placing 
the ACP in close proximity to the downstream KS for chain transfer. The Pik pathway is unusual 
in the ability to make two macrolactone through differential modes of catalysis with PikAIV.11 
Narbonolide (15) is the major product when PikAIII and PikAIV are incubated with Pik pentaketide 
6, where chain transfer from PikAIII ACP to PikAIV KS is the predominant pathway. 10-dml (1) 
can be detected as a minor product, presumably though yet undefined protein:protein interaction 
between PikAIII ACP and PikAIV TE.  Mutagenesis of the KS or ACP domains of PikAIV 
exclusively gives 10-dml (1), indicating direct transfer from PikAIII KS to the TE domain. 
 
 
When performing PKS biochemistry with a purified, standalone PKS module, this 
protein:protein interaction between modules is absent requiring the substrate to diffuse onto the 
active site cysteine KS domain.  An apparently universal assumption that runs through the PKS 
literature is that substrate will exclusively load the KS domain despite studies demonstrating that 
excised PKS TE domains function as promiscuous hydrolases.17 While PikAIV is an unusual 
terminal PKS module as direct cyclization is possible if the native KS substrate loads the TE 
domain,11 a more common outcome when studying other PKS modules would entail hydrolysis of 
starting material and decreased conversion to desired product.  An additional complication of 
directly acylating the TE would be hijacking the catalytic cycle, possibly resulting in 
conformational change18 suppressing desired full module catalysis.  Ultimately, understanding the 











effect of direct TE acylation will require structural studies to see what conformational changes are 
occurring, if any, and subsequent effect on catalysis.  
 
 An explanation as to why the thiophenol hexaketide is poor at loading the TE domain 
compared to the NAC hexaketide despite enhanced electrophilicity may lie in substrate 
preference of the TE.  The Pik TE domain appears to preferentially accept alkyl thioesters (NAC) 
over aryl thioesters (thiophenol), though the reasonably small substrate panel examined here is 
not sufficient to empirically conclude that the Pik TE prefers alkyl esters, and substrate preference 
from amino acid sequence is problematic even with well studied esterases/lipases.19 Whatever 
the origin of this shift in catalysis, the implications cannot be overstated if general to other type I 
pathways.  Up until very recently (the beginning of the authors graduate studies), PKS 
enzymology was studied using 14C labeled extender units, meaning that potential side reactions 
not incorporating 14C, such as rapid TE hydrolysis, could not be observed.  As such, the PKS 
community as a whole might be reporting artificially slow enzymatic rates and conversions (% 
conversion is rarely if ever reported) due to utilization of NAC thioesters in virtually every study to 
date.  Indeed, this excerpt from two preeminent PKS enzymologists when studying PikAIV with 
NAC hexaketide 5 highlights this concern: “The observed 4:1 ratio of lactonization to chain 
elongation for the processing of 5 may represent the intrinsic ratio of these two processes that 





















leads to the characteristic formation of 12- and 14-membered-ring macrolides”10 where this ratio 
was attributed to intrinsic protein function and not an artifact arising from poor emulation of in vivo 
PKS function.  The Sherman lab itself has made the same error in the past, in fact, when we 
studied PikAIV previously using 5 and 14C labeled extender units we did not even know that 10-
dml(1) was the major product, or even made at all!2 Whatever experimental oversights can be 
observed in the literature, it is our hope that the work describe here can help remedy past pitfalls 
when studying these complex enzymes. 
  
A series of reactions to explore substrate flexibility were conducted with NBOM protected 
hexaketides and PikAIV (excluding MM-NAC) or Pik TE without photolysis, and yielded surprising 
conversion to NBOM protected 10-dml 10 (Table 3.3). The same general trends were observed 
with N-acetylcysteamine giving the highest levels of conversion, followed by N-
hydroxysuccinimide, with aryl and benzyl thio- and oxoesters giving uniformly low levels of 
product formation.  Further exploration with PikAIV and (MM-NAC included) failed to generate 
NBOM protected narbonolide, and heat inactivated enzymes also failed to produce either NBOM 
protected macrolactone. 
 The results described in Table 3.3 are surprising; we did not expect such a large 
protecting group to be accommodated within the Pik TE.  This highlights the utility of performing 












































































Based on the dramatic selectivity in catalytic outcome observed between esters in this 
chapter and chapter 2, we conclude that substrate engineering is a previously unappreciated but 
critical component of in vitro PKS biochemistry and biocatalysis.  Further exploration of these 
strategies will certainly assist in downstream work with PikAIV of the Pik TE. While structural 
studies of PikAIV with native hexaketides will further elucidate the basis for substrate selectivity, 
perhaps a more important future direction is to apply this same approach to other type I PKS 
pathways.  If similar outcomes are observed in related pathways (DEBS, Tyl, etc.), then future 
biocatalytic development could be optimized, at least in part, though substrate engineering 
approaches described in this chapter and chapter 2. 
 
3.3 Chemistry Experimental 
 
Streptomyces venezuelae ATCC 15439 Δdes1 (DHS8708, aph kanamycin resistance gene 
insertion) spore stock and fermentation 
Purified H2O from a Millipore Milli-Q system with Millipore Q-Gard 2/Quantum Ex Ultrapure 
organex cartridges was used for spore stock generation and subsequent fermentation.  
Fermentation was conducted in a New Brunswick BioFlo 3000 fermenter (10 L vessel fitted with 
stainless steel baffles with temperature maintained by a Neslab RTE-111 circulator) and Corning 
Fernbach flasks (2.8 L) with deep baffles (3x) fitted with 16” stainless steel springs.  Agar, meat 
and yeast extracts, and glucose were purchased from EMD.  Soluble starch and soytone were 
obtained from BD.  N-Z amine, soybean flour, antifoam 204, XAD-16 resin, and CoCl2 6H2O 
were obtained from Sigma Aldrich.  MOPS was purchased from AK Scientific.  NaCl and CaCl2 
were obtained from Fisher Scientific. A Symphony SB70P pH meter was calibrated according to 
the manufacturer’s specifications and used to monitor the pH of all solutions during adjustment.  
Optical density (OD600) was determined using an Eppendorf Biophotometer.  All solutions were 
autoclaved and manipulations were carried out in a UV sterilized laminar flow hood. 
 
An engineered variant of Streptomyces venezuelae ATCC 15439 designated DHS8708 was 
grown on Bennett’s agar (1 L = 1 g meat extract, 1 g yeast extract, 10 g glucose, 2 g N-Z amine, 
15 g agar, pH 7.3) plates (~30 mL) at 28 °C until reaching a high spore density (~4-6 days).  
Spores were suspended by addition of H2O (9 mL) to the plate followed by scraping with an 
inoculation loop.  This solution was decanted into a 15 mL sterile tube, vortexed vigorously for 1 







were pelleted by centrifugation (2000 x g, 5 min) and the supernatant was discarded. The 
pelleted spores were resuspended in 20% glycerol solution (1 mL), transferred to a sterile screw 
top vial, flash frozen in N2 and stored at -80 °C. 
 
Seed culture media: 1 L = 20 g soytone, 15 g soluble starch, 1.5 g yeast extract, 0.1 g calcium 
chloride, 10.5 g MOPS, pH 7.2. 
10-dml production media: 1 L = 20 g glucose, 15 g soybean flour, 5 g CaCl2, 1 g NaCl, 0.002 g 
CoCl2!6H2O, (0.5 mL antifoam 204 was added to media used in the fermenter).  Note: the 
fermenter was autoclaved at 1/3 volume with 2/3 volumes of H2O (containing 0.5 mL/L antifoam 
204) added after sterilization. 
Seed culture: A 250 mL Erlenmeyer flask with deep baffles (3x) and a 6” stainless steel spring 
was inoculated with DHS8708 spore stock (10 µL) and incubated at 28 °C, 180 RPM until OD600 = 
~1 (~13-16 h).  Note: Inoculation of production media with high OD600 seed culture results in 
decreased titers of 1. 
1: 24 Fernbach flasks (2.8 L) containing 1 L production media and capped with a milk filter were 
inoculated with 1/500 v/v of the seed culture and incubated at 28 °C, 180 RPM. 2.5 cm orbit, for 
60 h.  Concurrently, the fermenter containing 10 L production media was inoculated with 1/500 
v/v of the seed culture and incubated at 28 °C, 400 RPM, 15 L/min aeration (air passed through a 
0.2 µm inline filter) for 60 h.  Cells were pelleted at 5000 x g (4 °C) for 10 min and subsequently 
discarded. The supernatant was extracted with XAD-16 resin (Sigma, 15 g/L, used as received) 
with gentle agitation.  XAD-16 extraction efficiency was analyzed by extracting 5 mL of resin-free 
supernatant with 5 mL CH2Cl2, which was evaporated and resuspended in 250 µL MeOH. TLC 
(30% EtOAc/hexanes, visualized with p-anisaldehyde) indicated complete extraction after 4-6 h.  
The resin was collected by vacuum filtration though a porous polyethylene filter before loading 
into a glass flash column previously fitted with a plug of glass wool.  The resin was washed with 
H2O (~1 L) and allowed to dry under air pressure for 1 h.  The resin was extracted with acetone 
(1x 500 mL) followed by EtOAc (500 mL) until no 1 could be detected in eluting EtOAc by TLC 
(~2-3x).  The combined organic extracts were washed with brine and filtered through a sodium 
sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  Flash 
chromatography: EtOAc/hexanes (20:80) gave 1 as an oil (3.56 g, 12.01 mmol, 0.105 g/L) that 
foamed under high vacuum, and slowly crystalized upon standing.   
Spectroscopic data matched that reported previously.4a  
 
Chemistry 
Reactions were performed in evacuated (<0.05 torr) flame dried glassware containing PFTE 
coated magnetic stir bars fitted with rubber septa backfilled with dry N2 and run under a positive 
pressure of dry N2 provided by a mineral oil bubbler unless stated otherwise (open flask). 
67	  
Reactions at elevated temperatures were controlled by IKA RET Control Visc (model RS 232 C), 
room temperature (RT) reactions were conducted at ~23 °C, reactions run cooler than room 
temperature were performed in a cold room (4 °C), an ice bath (0 °C), dry ice/acetone (-78 °C), or 
isopropanol/ThermoNESLAB (model CC100) for all other temperatures. Commercial purification 
system MBraun-MB-SPS # 08-113 provided all dry solvents unless stated otherwise (technical 
grade). Analytical thin-layer chromatography (TLC) was performed with EMD 60 F254 pre-coated 
glass plates (0.25 mm) and visualized using a combination of UV, p-anisaldehyde, KMnO4, and 
Bromocresol green stains. Flash column chromatography was performed using EMD 60 
Gerduran® (particle size 0.04-0.063) silica gel.  NMR spectra were recorded on a Varian 600 
MHz spectrometer. 1H NMR spectra were recorded relative to residual solvent peak (CDCl3 δH 
7.26 ppm, D6-DMSO δH 2.50 ppm) and reported as follows: chemical shift (ppm), multiplicity, 
coupling constant (Hz), and integration. Multiplicity abbreviations are as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, h = hextet, ovlp = overlap, br = broad signal.  13C 
NMR spectra were recorded relative to residual solvent peaks (CDCl3 δC 77.0 ppm, D6-DMSO δc 
39.5 ppm).  High resolution mass spectrometry was performed on an Agilent quadrapole time-of-
flight spectrometer (Q-TOF 6500 series) by electrospray ionization (ESI). 
 
8: Adapted from literature procedure,20 an open 1 L roundbottom flask was charged with 17 (AK, 
20 g, 131 mmol, 1 equiv), acetic acid (Fisher, glacial, 314 g, 299 mL, 5220 mmol, 40 equiv) and 
stirred at RT until dissolved.  DMSO (EMD, technical grade, 204 g, 185 mL, 2612 mmol, 20 equiv) 
was added in one portion, followed by slow addition of Ac2O (Fisher, 267 g, 246 mL, 2612 mmol, 
20 equiv).  The flask was capped with a rubber septum and flushed with N2, with a positive 
pressure of N2 maintained thereafter.  The reaction was monitored by loss of starting material 
(TLC) indicating completion at ~72 h.  The solution was decanted into an addition funnel and 
added dropwise into a stirring solution of 10 M KOH (1.2 L, 90 equiv) at 0 °C.  After complete 
addition, the solution was warmed to RT and allowed to stir for 2 h before it was extracted Et2O 
(3x).  The combined organic extracts were washed with brine and filtered through a sodium 
sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  Flash 
chromatography: EtOAc/hexanes (5:95) and subsequent rotary high vacuum (4 h) gave 8 as a 
bright yellow oil (21.6 g, 101 mmol, 77% yield).  
 












9: A 4 dram vial was charged with 1 (3 x PhMe azeotrope, 0.40 g, 1.35 mmol, 1.00 equiv), 
CH2Cl2:PhMe (2:1, 0.69 mL, 2 M) and cooled to 4 °C.  2,6-di-t-butylpyridine (TCI, 0.31 g, 0.36 mL, 
1.62 mmol, 1.20 equiv) was added followed by methyl trifluoromethanesulfonate  (Oakwood, 
fractionally distilled neat [collected ~100 °C at atmospheric pressure], 0.27 g, 0.18 mL, 1.62 
mmol, 1.20 equiv) and stirred for 72 h at 4 °C. The reaction was quenched with a saturated NH4Cl 
solution and extracted with CH2Cl2 (3x).  The combined organic extracts were washed with brine 
and filtered through a sodium sulfate plug, which was subsequently rinsed with CH2Cl2 (2x) and 
concentrated.  Flash chromatography: EtOAc/hexanes (5:95 to 25:75) gave 9 (0.34 g, 1.09 mmol, 
81%) as a colorless crystalline solid.  
1H NMR (599 MHz; CDCl3): δ 6.65 (dd, J = 15.7, 5.5 Hz, 1H), 6.35 (dd, J = 15.7, 1.1 Hz, 1H), 4.91 
(ddd, J = 8.5, 5.8, 2.5 Hz, 1H), 3.45 (s, 3H), 3.08 (dd, J = 10.5, 0.9 Hz, 1H), 2.61-2.55 (m, 2H), 
2.46 (dqd, J = 12.9, 6.6, 3.9 Hz, 1H), 1.68-1.61 (m, 1H), 1.56 (t, J = 13.2 Hz, 1H), 1.53-1.46 (m, 
1H), 1.31-1.26 (m, 1H), 1.23 (d, J = 6.9 Hz, 3H), 1.18-1.13 (ovlp m, 1H), 1.14 (d, J = 7.0 Hz, 3H), 
1.05 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 204.8, 174.8, 146.7, 125.6, 88.4, 73.5, 62.8, 45.0, 43.4, 37.8, 33.8, 
33.7, 25.0, 17.9, 17.5, 16.0, 10.2, 9.5. 
HRMS: Calculated [M+H]+ 311.2217, found 311.2223. 
 
10: Adapted from literature procedure,7 a 100 mL round bottom flask was charged with 1 (0.80 g, 
2.70 mmol, 1.00 equiv) and 10 (2.30 g, 10.80 mmol, 4.00 equiv) and CH2Cl2 (27.0 mL, 0.1 M).  4Å 
molecular sieves (Sigma, powdered, activated at 180 °C under high vacuum overnight, 8.00 g) 
were added in a single portion and the solution was cooled to -20 °C.  CuBr2 (Sigma, 2.41 g, 
10.80 mmol, 4.00 equiv) was added in a single portion and the solution was stirred vigorously at -
20 °C for 12 h, warmed to RT and stirred 2 h, and quenched by the addition of glycerol (6.21 g, 
4.92 mL, 67.48 mmol, 25.0 equiv) and 4 h additional stirring.  The solution was diluted with EtOAc 
and vacuum filtered though a fritted glass filter. The solid was subsequently washed with EtOAc 
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through a sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated. 
Flash chromatography: EtOAc/hexanes (15:85) afforded 10 (1.14 g, 2.47 mmol, 91%) as a pale 
yellow oil. 
1H NMR (599 MHz; CDCl3): δ  8.08 (d, J = 8.2 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.64 (t, J = 7.5 
Hz, 1H), 7.44-7.42 (m, 1H), 6.72 (dd, J = 15.7, 5.5 Hz, 1H), 6.41 (d, J = 15.7 Hz, 1H), 5.03 (q, J = 
12.3 Hz, 2H), 4.96 (ddd, J = 8.5, 5.7, 2.5 Hz, 1H), 4.87 (q, J = 10.1 Hz, 2H), 3.53 (d, J = 10.5 Hz, 
1H), 2.71 (dq, J = 10.5, 6.9 Hz, 1H), 2.64-2.60 (m, 1H), 2.50 (dqd, J = 12.9, 6.6, 3.9 Hz, 1H), 
1.73-1.64 (m, 2H), 1.57-1.50 (m, 1H), 1.36-1.31 (m, 1H), 1.27-1.23 (ovlp m, 1H), 1.25 (d, J = 6.9 
Hz, 3H), 1.20 (d, J = 7.0 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 7.4 
Hz, 3H). 
13C NMR: (151 MHz; CDCl3): δ 204.8, 174.8, 146.9, 146.9, 134.7, 133.8, 128.4, 127.9, 125.7, 
124.7, 98.0, 87.3, 73.7, 67.0, 45.0, 43.1, 37.9, 33.9, 33.6, 25.1, 17.8, 17.6, 16.4, 10.3, 9.5. 
HRMS: Calculated [M+Na]+ 484.2306, found 484.2322.  
 
11: A 100 mL round bottom flask was charged with 9 (0.51 g, 1.64 mmol, 1.00 equiv), CH2Cl2 
(16.4 mL, 0.1 M) and cooled to -78 °C.  DIBAL-H (Sigma, 1.03 g, 1.29 mL, 7.20 mmol, 4.40 
equiv) was added down the side of the flask.  The solution was stirred for 1 h before it was 
warmed to RT for 10 min, and recooled to -78 °C. MeOH (5 mL) was added dropwise and the 
mixture was stirred for 15 min before removal of the cooling bath and addition of a saturated Na/K 
tartrate solution.  Stirring was continued until the layers became clear, followed by extraction with 
EtOAc (3x).  The combined organic extracts were washed with brine and filtered through a 
sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  Flash 
chromatography: EtOAc/hexanes (70:30 to 100:0) afforded 11 (0.49 g, 1.53 mmol, 93%) as a 
colorless gum.  
1H NMR (599 MHz; D6-DMSO): δ  5.47-5.37 (m, 2H), 4.44 (t, J = 5.1 Hz, 1H), 4.36 (d, J = 4.7 Hz, 
1H), 4.27 (d, J = 5.7 Hz, 1H), 3.77 (q, J = 4.9 Hz, 1H), 3.32-3.29 (ovlp m, 1H), 3.29 (s, 3H), 3.26-
3.22 (m, 1H), 3.10 (dtd, J = 8.7, 5.9, 2.9 Hz, 1H), 2.95 (dd, J = 6.3, 3.4 Hz, 1H), 2.06 (h, J = 7.0 
Hz, 1H), 1.83-1.76 (m, 1H), 1.74-1.67 (m, 1H), 1.67-1.62 (m, 1H), 1.56-1.50 (m, 1H), 1.44 (dqd, J 
= 14.0, 7.1, 3.4 Hz, 1H), 1.24 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.84 (t, J = 7.4 Hz, 3H), 0.81 (m, 
6H), 0.76 (d, J = 6.9 Hz, 3H). 
13C NMR (151 MHz; D6-DMSO): δ 133.0, 132.2, 84.8, 75.0, 73.4, 64.3, 59.7, 42.2, 37.2, 36.3, 
36.1, 32.5, 27.1, 17.0, 16.4, 15.8, 11.5, 10.2. 












Note: For configuration of the allylic hydroxyl group see the X-Ray Crystallography section. 
 
12: A 250 mL round bottom flask was charged with 10 (1.66 g, 3.60 mmol, 1.00 equiv), CH2Cl2 
(36 mL, 0.1 M) and cooled to -78 °C.  DIBAL-H (Sigma, 2.25 g, 2.82 mL, 15.86 mmol, 4.40 equiv) 
was added down the side of the flask and the solution was stirred for 1 h, warmed to 0 °C briefly 
(~1 min), and recooled to -78 °C. MeOH (5 mL) was added dropwise and stirring was continued 
for 15 min before removal of the cooling bath and addition of a saturated Na/K tartrate solution.  
Stirring was continued until the layers became clear, followed by extraction with CH2Cl2 (3x).  The 
combined organic extracts were washed with brine and filtered through a sodium sulfate plug, 
which was subsequently rinsed with CH2Cl2 (2x) and concentrated.  Flash chromatography: 
EtOAc/hexanes (50:50 to 100:0) afforded 12 (1.28 g, 2.73 mmol, 76%) as a light yellow gum.  
1H NMR (599 MHz; D6-DMSO): δ 8.09 (m, 1H), 7.79-7.75 (m, 2H), 7.59-7.55 (m, 1H), 5.44-5.32 
(m, 2H), 4.93 (q, J = 18.9 Hz, 2H), 4.79 (s, 2H), 4.48 (t, J = 5.1 Hz, 1H), 4.36 (d, J = 4.6 Hz, 1H), 
4.26 (d, J = 5.6 Hz, 1H), 3.73 (q, J = 4.8 Hz, 1H), 3.46 (dd, J = 5.7, 3.0 Hz, 1H), 3.30-3.23 (m, 
2H), 3.09 (dtd, J = 8.6, 5.9, 2.8 Hz, 1H), 2.04 (h, J = 7.0 Hz, 1H), 1.87-1.81 (m, 1H), 1.77-1.71 (m, 
1H), 1.65-1.59 (m, 1H), 1.54-1.47 (m, 1H), 1.42 (dqd, J = 14.0, 7.1, 3.4 Hz, 1H), 1.23-1.15 (m, 
1H), 0.93 (d, J = 6.8 Hz, 3H), 0.85-0.82 (m, 6H), 0.80 (d, J = 6.8 Hz, 3H), 0.78-.75 (ovlp m, 1H), 
0.73 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz; D6-DMSO): δ 147.5, 134.5, 134.3, 133.5, 132.5, 129.2, 128.9, 124.9, 96.2, 
82.4, 75.4, 73.8, 66.3, 64.7, 42.7, 37.0, 36.6, 36.4, 33.6, 27.6, 17.3, 16.8, 16.0, 12.2, 10.6. 
HRMS: Calculated [M+Na]+ 490.2775, found 490.2790. 
Note: Configuration of the allylic hydroxyl group was assigned by analogy with 11. 
 
13: A 9 dram vial was charged with 11 (0.59 g, 1.86 mmol, 1.00 equiv) and H2O:MeCN (1:1, 18.6 
mL, 0.1 M) and cooled to 4 °C.  TEMPO (Sigma, 0.29 g, 1.86 mmol, 1.00 equiv) and PIDA (AK 
scientific, 2.39 g, 7.43 mmol, 4.00 equiv) were added in single portions. The reaction was 
monitored by 1H NMR spectroscopy after 12 h (small aliquot added to excess MeOH, 
concentrated, and dissolved in CDCl3) for loss of the intermediate aldehyde. After 20 h, the 





















extracted with half saturated sodium bicarbonate solution (3x).  The combined aqueous layers 
were backwashed with Et2O:hexanes (1:1), carefully acidified to pH 2-3 with phosphoric acid and 
extracted with EtOAc (3x).  The combined organic extracts were washed with brine and filtered 
through a sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  
Flash chromatography: AcOH/EtOAc/hexanes (1:25:75 to 1:50:50) to yield 13 (0.53 g, 1.61 mmol, 
86%) as a pale yellow oil.  
1H NMR (599 MHz; CDCl3): δ  6.95 (dd, J = 15.8, 6.5 Hz, 1H), 6.26 (dd, J = 15.7, 1.4 Hz, 1H), 
3.68 (dt, J = 8.3, 4.2 Hz, 1H), 3.44 (s, 3H), 3.23 (dd, J = 7.4, 4.0 Hz, 1H), 2.84-2.78 (m, 1H), 2.67 
(quint, J = 7.1 Hz, 1H), 2.50-2.45 (m, 1H), 1.88 (ddd, J = 13.9, 9.9, 4.1 Hz, 1H), 1.62-1.46 (ovlp 
m, 3H), 1.27-1.22 (ovlp m, 1H), 1.21 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.9 
Hz, 3H), 0.97 (ovlp m, 6H). 
13C NMR (151 MHz; CDCl3): δ 203.8, 178.5, 149.6, 126.8, 87.1, 76.0, 61.1, 42.7, 42.0, 41.2, 34.8, 
34.2, 27.4, 17.6, 17.0, 13.3, 11.9, 10.4. 
HRMS: Calculated [M+Na]+ 351.2142, found 351.2146. 
 
14: A 9 dram vial was charged with 12 (0.81 g, 1.74 mmol, 1.00 equiv) and H2O:MeCN (1:1, 17.4 
mL, 0.1 M) and cooled to 4 °C.  TEMPO (Sigma, 0.27 g, 1.74 mmol, 1.00 equiv) and PIDA (AK 
scientific, 2.24 g, 6.96 mmol, 4.00 equiv) were added in single portions. The reaction was 
monitored by 1H NMR spectroscopy (small aliquot added to excess MeOH, concentrated, and 
dissolved in CDCl3) after 12 h for loss of the intermediate aldehyde. After 17 h, the solution was 
decanted into MeOH (100 mL) and concentrated. Flash chromatography: AcOH/EtOAc/hexanes 
(1:25:75 to 1:50:50) to yield 14 (0.73 g, 1.52 mmol, 87%) as a pale yellow oil. 
1H NMR (599 MHz; CDCl3): δ 8.08 (dd, J = 8.2, 1.1 Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.64 (td, J = 
7.6, 0.8 Hz, 1H), 7.45-7.42 (m, 1H), 6.96 (dd, J = 15.8, 6.4 Hz, 1H), 6.23 (dd, J = 15.8, 1.4 Hz, 
1H), 5.06-5.01 (m, 2H), 4.87 (s, 2H), 3.71-3.67 (m, 2H), 2.86-2.80 (m, 1H), 2.71 (quint, J = 7.1 
Hz, 1H), 2.50-2.46 (m, 1H), 1.87 (ddd, J = 14.0, 9.4, 4.7 Hz, 1H), 1.69-1.63 (m, 1H), 1.57-1.44 (m, 
2H), 1.24-1.19 (ovlp m, 1H), 1.21 (d, J = 7.0 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 
3H), 0.98-0.95 (ovlp m, 6H). 
13C NMR (151 MHz; CDCl3): δ 204.0, 179.1, 149.8, 147.0, 134.6, 133.6, 128.6, 127.9, 127.4, 
124.6, 96.7, 84.2, 76.0, 67.0, 41.9, 41.7, 41.4, 35.2, 34.4, 27.1, 17.5, 16.6, 13.2, 12.4, 10.4. 











17: A 4 dram vial was charged with 11 (0.030 g, 0.091 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.026 g, 0.137 mmol, 1.500 equiv), and HOBT (Sigma, 0.015 g, 0.109 mmol, 1.200 equiv).  
The solids were dissolved in DMF (0.9 mL, 0.1 M) and stirred 30 min at RT.  HSNAC (0.013 g, 
0.012 mL, 0.109 mmol, 1.200 equiv) was added, stirred 10 min, followed by DMAP (Sigma, ~ 1 
mg, cat) and stirred 12 h.  The solution was diluted with EtOAc, washed with H2O, and the 
aqueous layer was extracted with EtOAc (2x). The combined organic extracts were filtered 
through a sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  
Flash chromatography: EtOAc to yield 18 (0.031 g, 0.072 mmol, 79%) as a colorless oil. 
1H NMR (599 MHz; CDCl3): δ  7.14 (br s, 1H), 6.87 (dd, J = 15.9, 7.7 Hz, 1H), 6.15 (d, J = 15.9 
Hz, 1H), 3.65-3.58 (m, 1H), 3.50 (dt, J = 8.8, 4.4 Hz, 1H), 3.44 (s, 3H), 3.25 (dd, J = 8.6, 2.9 Hz, 
1H), 3.20-3.15 (m, 2H), 2.95-2.88 (m, 2H), 2.86-2.81 (m, 1H), 2.47-2.41 (m, 1H), 1.95 (s, 3H), 
1.90 (ovlp ddd, J = 13.7, 10.4, 3.5 Hz, 1H), 1.54-1.47 (m, 2H), 1.42-1.35 (m, 1H), 1.24 (d, J = 6.9 
Hz, 3H), 1.24-1.20 (ovlp m, 1H), 1.12 (d, J = 7.0 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.96 (ovlp t, J = 
7.5 Hz, 3H), 0.93 (ovlp d, J = 6.9 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 204.8, 202.8, 170.6, 150.2, 128.7, 87.5, 75.7, 61.9, 51.5, 42.2, 
40.9, 39.0, 33.8, 33.6, 29.2, 27.4, 23.0, 18.9, 17.6, 15.2, 13.7, 10.3. 
HRMS: Calculated [M+Na]+ 452.2441, found 452.2459. 
 
19: A 4 dram vial was charged with 11 (0.030 g, 0.091 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.026 g, 0.137 mmol, 1.500 equiv), and HOBT (Sigma, 0.015 g, 0.109 mmol, 1.200 equiv).  
The solids were dissolved in DMF (0.9 mL, 0.1 M) and stirred 30 min at RT.  Benzyl mercaptan 
(Sigma, 0.014 g, 0.013 mL, 0.109 mmol, 1.200 equiv) was added, stirred 10 min, followed by 
DMAP (Sigma, ~ 1 mg, cat) and stirred 12 h.  The solution was diluted with EtOAc, washed with 
H2O, and the aqueous layer was extracted with EtOAc (2x). The combined organic extracts were 
filtered through a sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and 
concentrated.  Flash chromatography: EtOAc/hexanes (20:80 to 30:70) to yield 19 (0.033 g, 
0.076 mmol, 83%) as a colorless oil. 
1H NMR (599 MHz; CDCl3): δ  7.28-7.27 (m, 4H), 7.22 (dq, J = 8.7, 4.3 Hz, 1H), 6.85 (dd, J = 
15.8, 7.7 Hz, 1H), 6.20 (d, J = 15.8 Hz, 1H), 4.10 (s, 2H), 3.50-3.46 (m, 1H), 3.32-3.31 (ovlp m, 
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4.1 Hz, 1H), 1.60-1.48 (ovlp m, 2H), 1.38 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H), 1.13 (ddd, J = 14.0, 
9.3, 4.9 Hz, 1H), 1.09-1.07 (ovlp m, 6H), 0.95 (t, J = 7.4 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 203.7, 202.1, 149.2, 137.4, 128.8, 128.5, 128.3, 127.2, 86.7, 75.8, 
60.6, 50.7, 42.3, 42.0, 35.6, 34.5, 33.1, 27.4, 18.0, 17.0, 13.9, 12.6, 10.3. 
HRMS:  Calculated [M+Na]+ found 457.2383, found 457.2380. 
 
20: A 4 dram vial was charged with 11 (0.030 g, 0.091 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.026 g, 0.137 mmol, 1.500 equiv).  The vial was cooled to 0 °C and solids were dissolved 
in DMF (0.9 mL, 0.1 M) and stirred 10 min at 0 °C.  N-hydroxysuccinimide (Sigma, 0.013 g, 0.109 
mmol, 1.200 equiv) was added, stirred 10 min at 0 °C and 10 min at RT, followed by addition of 
DMAP (Sigma, ~ 1 mg, cat). The reaction mixture was stirred 4 h.  The solution was diluted with 
EtOAc, washed with H2O, and the aqueous layer was extracted with EtOAc (2x).  The combined 
organic extracts were filtered through a sodium sulfate plug, which was subsequently rinsed with 
EtOAc (2x) and concentrated.  Flash chromatography: EtOAc/hexanes (40:60 to 50:50) to yield 
20 (0.031 g, 0.073 mmol, 80%) as a colorless oil. 
1H NMR (599 MHz; CDCl3): δ  6.86 (dd, J = 15.8, 7.7 Hz, 1H), 6.20 (dd, J = 15.8, 1.0 Hz, 1H), 
3.49 (dt, J = 8.8, 4.4 Hz, 1H), 3.43 (s, 3H), 3.40 (dd, J = 5.8, 5.0 Hz, 1H), 2.99-2.94 (m, 1H), 2.91-
2.85 (m, 1H), 2.81 (br d, J = 7.3 Hz, 4H), 2.42 (dq, J = 12.2, 6.3 Hz, 1H), 2.01 (ddd, J = 13.6, 9.5, 
3.9 Hz, 1H), 1.68-1.61 (m, 1H), 1.54-1.47 (m, 1H), 1.42-1.36 (m, 1H), 1.28 (d, J = 7.0 Hz, 3H), 
1.16 (ddd, J = 14.0, 9.3, 4.8 Hz, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.96-0.92 
(ovlp m, 6H). 
13C NMR (151 MHz; CDCl3): δ 203.6, 170.8, 169.1, 149.3, 128.4, 85.9, 75.7, 60.6, 42.1, 42.0, 
39.4, 35.8, 34.7, 27.3, 25.6, 18.1, 16.9, 13.6, 11.2, 10.3. 
HRMS: Calculated [M+Na]+ 448.2306, found 448.2315. 
 
21: A 4 dram vial was charged with 11 (0.030 g, 0.091 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.026 g, 0.137 mmol, 1.500 equiv).  The vial was cooled to 0 °C and solids were dissolved 
in CH2Cl2 (0.9 mL, 0.1 M) and stirred for 30 min at 0 °C.  4-nitrophenol (0.015 g, 0.109 mmol, 
1.200 equiv) was added and stirred for 10 min at 0 °C. The mixture was warmed to RT and stirred 
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chromatography: EtOAc/hexanes (20:80) to yield 21 (0.025 g, 0.056 mmol, 61%) as a colorless 
oil. 
1H NMR (599 MHz; CDCl3): δ 8.28-8.26 (m, 2H), 7.35-7.32 (m, 2H), 6.86 (dd, J = 15.8, 7.7 Hz, 
1H), 6.20 (dd, J = 15.8, 1.1 Hz, 1H), 3.50-3.47 (ovlp m, 1H), 3.47 (s, 3H), 3.39 (dd, J = 6.3, 5.2 
Hz, 1H), 2.97 (quint, J = 6.9 Hz, 1H), 2.91 (dqd, J = 10.5, 6.9, 3.8 Hz, 1H), 2.45-2.39 (m, 1H), 
2.03 (ddd, J = 13.6, 10.3, 3.3 Hz, 1H), 1.67-1.60 (m, 2H), 1.51 (dqd, J = 14.3, 7.3, 3.9 Hz, 1H), 
1.41-1.32 (ovlp m, 1H), 1.35 (d, J = 7.0 Hz, 3H), 1.20 (ddd, J = 13.8, 10.0, 3.9 Hz, 1H), 1.14 (d, J 
= 7.0 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 203.6, 173.2, 155.5, 149.5, 145.3, 128.5, 125.2, 122.6, 86.7, 75.8, 
61.1, 42.4, 42.2, 41.7, 35.0, 34.4, 27.4, 18.6, 17.1, 13.8, 12.6, 10.3. 
HRMS: Calculated [M+Na]+ 472.2306, found 472.2315. 
 
22: A 9 dram vial was charged with 11 (0.050 g, 0.152 mmol, 1.000 equiv) and Ph2S2 (Sigma, 
0.037 g, 0.167 mmol, 1.100 equiv).  The solids were dissolved in CH2Cl2 (1.52 mL, 0.1 M) and 
cooled to -42 °C.  PBu3 (Sigma, 0.040 g, 0.049 mL, 0.198 mmol, 1.300 equiv) was added 
dropwise and the solution was stirred 20 min at -42 °C.  The reaction was quenched at -42 °C 
with a saturated CuSO4 solution and allowed to warm to RT.  The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (2x).  The organic layer was washed with 
saturated EDTA (disodium salt, 2x) and filtered through a sodium sulfate plug, which was 
subsequently rinsed with CH2Cl2 (2x) and concentrated. Flash chromatography: EtOAc/hexanes 
(25:75) afforded 22 (0.035 g, 0.083 mmol, 55%) as a colorless oil. 
1H NMR (599 MHz; CDCl3): δ 7.40 (s, 5H), 6.85 (dd, J = 15.8, 7.7 Hz, 1H), 6.22 (d, J = 15.8 Hz, 
1H), 3.46 (dt, J = 8.9, 4.4 Hz, 1H), 3.41 (s, 3H), 3.36 (t, J = 5.6 Hz, 1H), 2.95 (quint, J = 6.7 Hz, 
1H), 2.92-2.86 (m, 1H), 2.43-2.37 (m, 1H), 1.98 (ddd, J = 13.7, 9.6, 4.0 Hz, 1H), 1.68-1.60 (m, 
2H), 1.50 (dqd, J = 14.3, 7.3, 3.9 Hz, 1H), 1.40-1.33 (m, 1H), 1.29 (d, J = 7.0 Hz, 3H), 1.22 (ddd, 
J = 14.0, 9.5, 4.7 Hz, 1H), 1.13 (d, J = 6.9 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.96-0.93 (ovlp m, 
6H). 
13C NMR (151 MHz; CDCl3): δ 203.7, 200.7, 149.2, 134.5, 129.3, 129.1, 128.4, 127.6, 86.7, 75.8, 
60.9, 50.8, 42.3, 41.9, 35.4, 34.5, 27.4, 18.2, 17.0, 13.8, 13.2, 10.3. 
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23: A 4 dram vial was charged with 12 (0.050 g, 0.104 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.030 g, 0.156 mmol, 1.500 equiv), and HOBT (Sigma, 0.017 g, 0.125 mmol, 1.200 equiv).  
The solids were dissolved in DMF (1 mL, 0.1 M) and stirred 30 min at RT.  HSNAC (0.015 g, 
0.014 mL, 0.125 mmol, 1.200 equiv) was added, stirred 10 min, followed by DMAP (Sigma, ~ 1 
mg, cat) and stirred 12 h.  The solution was diluted with EtOAc, washed with H2O, and the 
aqueous layer was extracted with EtOAc (2x). The combined organic extracts were filtered 
through a sodium sulfate plug, which was subsequently rinsed with EtOAc (2x) and concentrated.  
Flash chromatography: EtOAc/hexanes (70:30 to 80:20) to yield 23 (0.051 g, 0.088 mmol, 84%) 
as a pale yellow oil. 
1H NMR (599 MHz; CDCl3): δ 8.08 (dd, J = 8.2, 1.1 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.66-7.63 
(m, 1H), 7.46-7.43 (m, 1H), 6.99 (br s, 1H), 6.88 (dd, J = 15.9, 7.7 Hz, 1H), 6.15 (dd, J = 15.9, 1.1 
Hz, 1H), 5.03 (q, J = 14.0 Hz, 2H), 4.84 (s, 2H), 3.71 (dd, J = 8.0, 3.0 Hz, 1H), 3.60-3.55 (m, 1H), 
3.51 (dq, J = 8.6, 4.3 Hz, 1H), 3.21-3.12 (m, 2H), 2.98-2.87 (ovlp m, 2H), 2.86-2.81 (m, 1H), 2.46-
2.41 (m, 1H), 1.94 (s, 3H), 1.93-1.90 (ovlp m, 1H), 1.58 (m, J = 10.3, 6.9, 3.5 Hz, 1H), 1.54-1.46 
(m, 1H), 1.42-1.35 (m, 1H), 1.25-1.20 (ovlp m, 4H), 1.11 (d, J = 7.0 Hz, 3H), 1.07 (d, J = 6.8 Hz, 
3H), 0.95 (t, J = 7.4 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 204.5, 202.6, 170.6, 150.3, 147.1, 134.6, 133.7, 128.6, 128.0, 
124.7, 97.1, 85.1, 75.7, 67.1, 51.0, 42.2, 40.8, 38.9, 34.0, 33.8, 29.1, 27.4, 23.0, 18.8, 17.3, 15.2, 
13.7, 10.3. 
HRMS: Calculated [M+Na]+ calculated 603.2711, found 603.2736. 
 
24: A 4 dram vial was charged with 12 (0.030 g, 0.063 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.018 g, 0.094 mmol, 1.500 equiv), and HOBT (Sigma, 0.010 g, 0.076 mmol, 1.200 equiv).  
The solids were dissolved in CH2Cl2 (0.63 mL, 0.1 M) and stirred for 30 min at RT.  Benzyl 
mercaptan (Sigma, 0.009 g, 0.076 mmol, 1.200 equiv) was added and stirred for 10 min, followed 
by addition of DMAP (Sigma, ~ 1 mg, cat). The reaction mixture was stirred for 2 h.  The solution 
was diluted with EtOAc, washed with H2O, and the aqueous layer was extracted with EtOAc (2x). 
The combined organic extracts were filtered through a sodium sulfate plug, which was 
subsequently rinsed with EtOAc (2x) and concentrated.  Flash chromatography: EtOAc/hexanes 
(30:70) to yield 24 (0.031 g, 0.053 mmol, 84%) as a pale yellow oil. 





















1H NMR (599 MHz; CDCl3): δ 8.07-8.06 (m, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.65-7.61 (m, 1H), 7.42 
(t, J = 7.6 Hz, 1H), 7.27-7.19 (m, 5H), 6.83 (dd, J = 15.8, 7.7 Hz, 1H), 6.16 (dd, J = 15.8, 0.8 Hz, 
1H), 4.98 (q, J = 15.0 Hz, 2H), 4.76-4.71 (m, 2H), 4.04 (s, 2H), 3.78 (t, J = 5.2 Hz, 1H), 3.46 (dt, J 
= 8.8, 4.4 Hz, 1H), 2.88-2.79 (ovlp m, 2H), 2.39 (dq, J = 12.7, 6.4 Hz, 1H), 1.92 (ddd, J = 13.7, 
9.5, 4.1 Hz, 1H), 1.66-1.59 (m, 2H), 1.49 (dqd, J = 14.3, 7.2, 3.9 Hz, 1H), 1.40-1.32 (m, 1H), 1.20 
(d, J = 7.0 Hz, 3H), 1.10 (ddd, J = 14.1, 9.4, 4.9 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.9 
Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 203.5, 201.8, 149.4, 147.1, 137.3, 134.8, 133.6, 128.8, 128.8, 
128.7, 128.5, 128.3, 127.9, 127.2, 124.7, 96.3, 83.7, 75.8, 66.9, 50.3, 42.3, 41.7, 35.7, 34.7, 33.1, 
27.4, 18.0, 16.6, 13.8, 13.1, 10.3. 
HRMS: Calculated [M+Na]+ calculated 608.2652, found 608.2658. 
 
25: A 4 dram vial was charged with 12 (0.030 g, 0.063 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.018 g, 0.094 mmol, 1.500 equiv).  The vial was cooled to 0 °C and the solids were 
dissolved in DMF (0.63 mL, 0.1 M) and stirred 10 min at 0 °C.  N-hydroxysuccinimide (Sigma, 
0.011 g, 0.094 mmol, 1.500 equiv) was added, stirred 10 min at 0 °C and an additional 10 min at 
RT, followed by DMAP (Sigma, ~ 1 mg, cat) and stirred 4 h.  The solution was diluted with EtOAc, 
washed with H2O, and the aqueous layer was extracted with EtOAc (2x).  The combined organic 
extracts were filtered through a sodium sulfate plug, which was subsequently rinsed with EtOAc 
(2x) and concentrated.  Flash chromatography: EtOAc/hexanes (40:60 to 50:50) to yield 25 
(0.026 g, 0.045 mmol, 72%) as a pale yellow oil. 
1H NMR: (599 MHz; CDCl3): δ  8.08 (dd, J = 8.2, 0.9 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.66-7.63 
(m, 1H), 7.43 (t, J = 7.5 Hz, 1H), 6.86 (dd, J = 15.8, 7.6 Hz, 1H), 6.17 (dd, J = 15.8, 0.9 Hz, 1H), 
5.11-5.00 (m, 2H), 4.90 (dd, J = 25.3, 6.9 Hz, 2H), 3.85 (t, J = 5.1 Hz, 1H), 3.49 (dt, J = 8.8, 4.4 
Hz, 1H), 3.07-3.02 (m, 1H), 2.90-2.76 (ovlp m, 5H), 2.44-2.39 (m, 1H), 2.02 (ddd, J = 13.7, 9.7, 
3.9 Hz, 1H), 1.80-1.68 (m, 2H), 1.50 (dqd, J = 14.2, 7.2, 4.0 Hz, 1H), 1.42-1.35 (m, 1H), 1.32 (d, J 
= 7.0 Hz, 3H), 1.15 (ddd, J = 14.0, 9.5, 4.7 Hz, 1H), 1.06-1.05 (ovlp m, 6H), 0.96-0.93 (ovlp m, 
6H). 
13C NMR: (151 MHz; CDCl3): δ 203.4, 170.6, 169.1, 162.0, 149.4, 147.0, 134.9, 133.7, 128.6, 
128.4, 127.8, 124.7, 96.5, 83.1, 75.7, 67.0, 42.1, 41.7, 39.4, 35.7, 34.8, 29.7, 27.2, 25.6, 18.1, 
16.6, 13.5, 12.1, 10.4. 


















25: A 4 dram vial was charged with 12 (0.030 g, 0.063 mmol, 1.000 equiv), EDC!HCl (Chem-
Impex, 0.018 g, 0.094 mmol, 1.500 equiv).  The vial was cooled to 0 °C and the solids were 
dissolved in CH2Cl2 (0.63 mL, 0.1 M) and stirred for 30 min at 0 °C.  4-nitrophenol (0.011 g, 
0.0756 mmol, 1.200 equiv) was added, stirred 10 min at 0 °C, and an additional 12 h at RT.  The 
solution was added directly onto a flash column. Flash chromatography: EtOAc/hexanes (30:70) 
to yield 25 (0.023 g, 0.038 mmol, 60%) as a pale yellow oil. 
1H NMR (599 MHz; CDCl3): δ  8.17-8.15 (m, 2H), 8.01 (dd, J = 8.1, 1.0 Hz, 1H), 7.62 (d, J = 7.7 
Hz, 1H), 7.54 (td, J = 7.5, 1.0 Hz, 1H), 7.43-7.40 (m, 1H), 7.27-7.25 (m, 2H), 6.87 (dd, J = 15.8, 
7.7 Hz, 1H), 6.20 (dd, J = 15.8, 1.0 Hz, 1H), 4.97 (s, 2H), 4.88 (q, J = 6.5 Hz, 2H), 3.85 (t, J = 5.4 
Hz, 1H), 3.49 (dt, J = 8.8, 4.4 Hz, 1H), 3.04-2.98 (m, 1H), 2.94-2.88 (m, 1H), 2.45-2.40 (m, 1H), 
2.07 (ddd, J = 13.6, 10.4, 3.3 Hz, 1H), 1.69-1.48 (ovlp m, 3H), 1.41-1.35 (m, 1H), 1.32 (d, J = 7.0 
Hz, 3H), 1.16 (ddd, J = 13.8, 10.0, 3.9 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 
0.98 (ovlp m, 6H). 
13C NMR: (151 MHz; CDCl3): δ 203.4, 172.8, 155.4, 149.7, 147.6, 145.2, 133.9, 133.3, 129.1, 
128.4, 128.2, 125.0, 124.7, 122.6, 97.2, 84.9, 75.8, 67.4, 42.2, 42.1, 41.7, 35.6, 34.6, 27.4, 18.6, 
16.7, 13.8, 11.7, 10.3. 
HRMS: Calculated [M+Na]+ calculated 623.2575, found 623.2573. 
 
26: A 9 dram vial was charged with 12 (0.055 g, 0.115 mmol, 1.00 equiv) and Ph2S2 (Sigma, 
0.028 g, 0.121 mmol, 1.100 equiv).  The solids were dissolved in CH2Cl2 (1.15 mL, 0.1 M) and 
cooled to -42 °C.  PBu3 (Sigma, 0.030 g, 0.037 mL, 0.150 mmol, 1.300 equiv) was added 
dropwise, and the solution was stirred for 20 min at   
- 42 °C.  The reaction was quenched at -42 °C with a saturated CuSO4 solution and allowed to 
warm to RT.  The organic layer was separated and the aqueous layer was extracted with CH2Cl2 
(2x).  The organic layer was washed with a saturated EDTA solution (disodium salt, 2x) and 
filtered through a sodium sulfate plug, which was subsequently rinsed with CH2Cl2 (2x). The 
organic layers were combined and concentrated. Flash chromatography: EtOAc/hexanes (30:70) 
afforded 26 (0.038 g, 0.056 mmol, 58%) as a pale yellow oil. 
1H NMR (599 MHz; CDCl3): δ  8.08-8.07 (m, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.63-7.61 (m, 1H), 
7.44-7.42 (m, 1H), 7.38 (s, 5H), 6.85 (dd, J = 15.8, 7.7 Hz, 1H), 6.19 (dd, J = 15.8, 0.8 Hz, 1H), 
5.03 (q, J = 15.7 Hz, 2H), 4.85 (s, 2H), 3.83 (t, J = 5.3 Hz, 1H), 3.46 (dt, J = 8.8, 4.4 Hz, 1H), 3.01 
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(quint, J = 6.6 Hz, 1H), 2.91-2.85 (m, 1H), 2.42-2.36 (m, 1H), 1.99 (ddd, J = 13.8, 9.6, 4.1 Hz, 
1H), 1.71-1.56 (m, 2H), 1.49 (dqd, J = 14.3, 7.3, 3.9 Hz, 1H), 1.40-1.32 (m, 1H), 1.30 (d, J = 7.0 
Hz, 3H), 1.20 (ddd, J = 14.0, 9.5, 4.7 Hz, 1H), 1.09 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 
0.96 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 203.5, 200.4, 149.4, 147.1, 134.7, 134.5, 134.7, 133.7, 129.3, 
129.1, 128.8, 128.4, 127.9, 127.5, 124.7, 96.6, 83.9, 75.8, 67.1, 50.4, 42.3, 41.6, 35.5, 34.7, 27.4, 
18.2, 16.7, 13.8, 13.7, 10.3. 
HRMS: Calculated [M+Na]+ 594.2496, found 594.2499. 
 
X-Ray Crystallography: 27 was dissolved in a minimum volume of Et2O, diluted with hexanes 
(~5x v/v) and concentrated to half volume under a stream of N2. Colorless block-like crystals of 
S20 were grown from the resulting hexanes solution at -30 °C.  A crystal of dimensions 0.14 x 
0.06 x 0.04 mm was mounted on a Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer 
equipped with a low temperature device and Micromax-007HF Cu-target micro-focus rotating 
anode (λ = 1.54187 A) operated at 1.2 kW power (40 kV, 30 mA).  The X-ray intensities were 
measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A total of 
3842 images were collected with an oscillation width of 1.0° in ω.  The exposure time was 1 sec. 
for the low angle images, 5 sec. for high angle.  The integration of the data yielded a total of 
24668 reflections to a maximum 2θ value of 136.46° of which 3403 were independent and 3309 
were greater than 2σ(I).  The final cell constants (Table 1) were based on the xyz centroids 17310 
reflections above 10σ(I).  Analysis of the data showed negligible decay during data collection; the 
data were processed with CrystalClear 2.0 and corrected for absorption.  The structure was 
solved and refined with the Bruker SHELXTL (version 2008/4) software package, using the space 
group P2(1) with Z = 2 for the formula C18H32O4.  All non-hydrogen atoms were refined 
anisotropically with the hydrogen atoms placed in a mix of idealized and refined positions.  Full 
matrix least-squares refinement based on F2 converged at R1 = 0.0295 and wR2 = 0.0771 
[based on I > 2sigma(I)], R1 = 0.0305 and wR2 = 0.0781 for all data.  Acknowledgement is made 
for funding from NSF grant CHE-0840456 for X-ray instrumentation. 
 
Sheldrick, G.M. SHELXTL, v. 2008/4; Bruker Analytical X-ray, Madison, WI, 2008. 
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Alternative preparation of 27: An open 25mL round bottom flask was charged with 9 (0.100 g, 
0.322 mmol, 1.000 equiv), CeCl3 7H2O (0.120 g, 0.322 mmol, 1.00 equiv) and MeOH (technical 
grade, 3.2 mL, 0.1 M).  The solution was stirred at RT until the solids had dissolved completely, 
and then cooled to -78 °C.  NaBH4 (0.012 g, 0.322 mmol, 1.00 equiv) was added in a single 
portion and stirred for 10 min.  The solution was decanted cold into 1 M HCl, and the aqueous 
solution was extracted with CH2Cl2 (3x).  The combined organic extracts were filtered through a 
sodium sulfate plug, which was subsequently rinsed with CH2Cl2 (2x) and concentrated.  Flash 
chromatography: EtOAc/hexanes (10:90 to 15:85) afforded 27 (0.096 g, 0.307 mmol, 95%) as a 
colorless oil that crystalized upon standing. 
1H NMR: (599 MHz; CDCl3): δ  5.66 (ddd, J = 15.8, 4.7, 1.7 Hz, 1H), 5.48 (ddd, J = 15.8, 3.5, 1.6 
Hz, 1H), 4.97 (ddd, J = 8.9, 5.3, 3.5 Hz, 1H), 4.09 (br s, 1H), 3.49 (s, 3H), 3.13 (dd, J = 10.3, 1.6 
Hz, 1H), 2.58 (ovlp m, 2H), 1.92 (ttd, J = 10.6, 7.1, 3.4 Hz, 1H), 1.87-1.81 (m, 1H), 1.68-1.58 (ovlp 
m, 2H), 1.58-1.51 (m, 1H), 1.33 (ddd, J = 13.7, 11.0, 2.8 Hz, 1H), 1.24 (d, J = 6.8 Hz, 3H), 1.05 
(ovlp m, 6H), 0.96 (d, J = 7.1 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 175.5, 130.8, 128.5, 88.9, 75.8, 62.8, 43.5, 37.7, 35.3, 33.3, 32.6, 




















HRMS: Calculated [M-H2O+H]+ 295.2268, found 295.2274.  
27 was converted to 11 using conditions identical to direct reduction of 9 to 11, where 11 
produced by either method was identical. 
 
3.4 PKS and TE Biochemistry Experimental 
	  
Purified H2O from a Millipore Milli-Q system with Millipore Q-Gard 2/Quantum Ex Ultrapure 
organex cartridges was used for all cell culture, protein purification, and enzymatic reactions. E. 
coli seed culture was grown in 15 mL sterile tubes, and subsequently grown in Corning Fernbach 
flasks (2.8 L) with 3x deep baffles.  LB broth (Miller) and glycerol were obtained from EMD.  
Isopropyl-β-D-thiogalactopyarnoside (IPTG) and Kanamycin (Kan) sulfate were obtained from 
Gold Biotechnology.  Streptomycin sulfate (Strep) was obtained from AK scientific.  NaCl, CaCl2 
and imidazole were obtained from Fisher Scientific. Lysozyme was purchased from RPI.  
Benzonase was purchased from Sigma Aldrich.  PD-10 colums were purchased from GE 
scientific and equilibrated with 5 column volumes of storage buffer before use.  Ni-NTA agarose 
resin was purchased from Qiagen and pre-equilibrated with five column volumes of lysis buffer 
before use.  
A Symphony SB70P pH meter was calibrated according to the manufacturer’s specifications and 
used to monitor the pH of all solutions during adjustment. Cells were lysed using a 550 Sonic 
Dismembrator purchased from Fisher Scientific.  Optical density (OD600) was determined using an 
Eppendorf Biophotometer.  All solutions were autoclaved or sterile filtered through a 0.2 µm filter.   
 
Buffers: lysis: HEPES (50 mM), NaCl (300 mM), imidazole (10 mM), glycerol (10% v/v), pH 8.0. 
wash: HEPES (50 mM), NaCl (300 mM), imidazole (30 mM), glycerol (10% v/v), pH 8.0. 
elution HEPES (50 mM), NaCl (300 mM), imidazole (300 mM), glycerol (10% v/v), pH 8.0. 
storage: HEPES (50 mM), NaCl (150 mM), EDTA (1 mM), glycerol (20% v/v), pH 7.2. 
PikAIV reactions:  sodium phosphate (400 mM), glycerol (20% v/v), 2-vinylpyridine (8 mM), pH 
7.2. 
Pik TE reactions:  sodium phosphate (400 mM), 2-vinylpyridine (8 mM), pH 7.2. 
 
Stock solutions: hexaketide substrates (50 mM in DMSO), 2-vinylpyridine (500 mM in DMSO), 
ascorbic acid (500 mM in H2O), sodium metabisulfite (100 mM in H2O), PikAIV reaction buffer [2x, 
sodium phosphate (800 mM), glycerol (40% v/v), pH 7.2], Pik TE reaction buffer [2x, sodium 
phosphate (800 mM), pH 7.2], MM-SNAC (500 mM in H2O, neutralized to pH 7.2 with NaHCO3). 
 
Protein Expression 
The cloning, expression and purification of PikAIV21 and the Pik TE22 has been reported 
previously. A starter culture of E. coli (BAP1)23 cells containing the corresponding plasmids for 
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expression of respective proteins was generated by inoculating LB broth Miller (10 mL) containing 
Kan (50 mg/L) and Strep (50 mg/L) with frozen glycerol stocks and grown overnight at 37 ˚C. The 
following morning, LB (1.5 L) containing Kan (50 mg/L) and Strep (50 mg/L) was inoculated with 
the entire overnight culture and grown at 37 ˚C to an OD600 of 0.3-0.4. The cells were then 
cultured at 20 ˚C until an OD600 of 0.7-0.8 was reached; at which point protein expression was 
induced via addition of IPTG (300 µM) and the cultures were incubated at 200RPM, 2.5 cm orbit, 
at 20 ˚C for a minimum of 18 hours.  
Protein Purification   
To retain maximum enzymatic activity, the following purification procedure was performed at 4 ˚C 
in less than 2 hours. Overexpression cultures were harvested by centrifugation (5,500 x g, 10 
min, 4 ˚C) and cell pellets were suspended in 5 mL of lysis buffer per gram of cells via vortex. Cell 
lysis was accomplished by gentle agitation at 4 ˚C with 0.4 mg/ml lysozyme and 8 units/ml 
benzonase for 30 min followed by sonication on ice (6 x 10s with 50s rest periods). Cellular debris 
was pelleted by centrifugation (40,000 x g, 15 min, 4 ˚C), and the supernatant applied to 3 mL of 
Ni-NTA resin. After binding, the column was washed with 25 mL of wash buffer under gentle 
syringe pressure and the target protein was eluted with 15 mL of elution buffer. Protein containing 
fractions were assessed via their absorption at 280 nm, pooled, and buffer exchanged into 
storage buffer using a PD-10 column. Finally, protein containing fractions were determined via 
their absorption at 280 nm, pooled, flash frozen in liquid N2, and stored at -80 ˚C.  
Analytical Enzymatic Reactions 
All enzymatic reactions were performed in triplicate at a volume of 50 µL and were initiated via 
the addition of enzyme. 2-vinylpyridine (Sigma) was employed as a thiol scavenger (8mM final 
concentration) in all reactions. After 4 h stationary incubation at RT, the reactions were quenched 
with 3 volumes of MeOH (150 µL), clarified by centrifugation (17,000 x g, 15 min, 4˚C) and 
analyzed for macrolactone production. In all cases, the reactions were carried out in PikAIV or Pik 
TE reaction buffers.  
Methyl Protected Substrates: 
Reactions employing methylated substrates were performed as one-pot reactions containing 
phosphate buffer, methylated hexaketide (1 mM), with or without MM-SNAC (20 mM). Catalysis 
was initiated via the addition of enzyme, either TE (10 µM) or PikAIV (2.5 µM and 10 µM).  
Conversion to macrolactones was monitored by Method A (HPLC analysis section). 
NBOM Protected Substrates: 
Enzymatic reactions utilizing NBOM protected substrates were performed over two steps. First, a 
solution of ascorbic acid (25mM final concentration), sodium metabisulfite (1mM final 
concentration), NBOM protected substrate (1mM final concentration), and H2O (requisite dead 
volume) was irradiated under a consumer facial tanning lamp at a height of 14 cm (Verseo 
#AH129c) for 20 min to furnish the deprotected Pik hexaketide. NOTE: Irradiation through the 
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side of the microtubes employed (Axygen #MCT-175-C) did not interfere with photolysis, and this 
process was reproducible over the course of this study. After photolysis, the solution was diluted 
with either PikAIV of Pik TE reaction buffer, MM-NAC (20 mM final concentration when included). 
Catalysis was initiated via the addition of enzyme, TE (10 µM) or PikAIV (2.5 µM and 10 µM), and 
incubated for 4 hours.  Conversion to macrolactones was monitored by Method B (HPLC 
analysis section). 
HPLC analysis 
Macrolactone production was monitored via analytical high performance liquid chromatography 
(HPLC) using a Beckman Coulter instrument (model 366 serial 385-1160) and a Zorbax SB-
Phenyl 3.5 µM 4.6 x 150 mm column (part number 863953-912) at a wavelength of 250 nm. 
Method A: For reactions employing methylated substrates, separation was accomplished by the 
following method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 20% B 0-1 min, 20-60% B linear 
gradient 1-10 min, 100% B 10-11 min, 20% B 11-12 min. 
Method B: For reactions employing NBOM protected substrates, separation was accomplished by 
the following method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 10% B 0-1 min, 10-40% B 
linear gradient 1-10 min, 100% B 10-11 min, 10% B 11-12 min. 
Samples were quantified by linear regression using equations derived from fitting the peak areas 
of the corresponding standard curves. Standard curves were generated by analyzing 
macrolactone standards in triplicate at a range of concentrations from 1.0-0.0156 mM, 
representing a range in percent conversions from 400-6.5%, and were linear in all cases.  
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Exploratory Simulated Combinatorial Biosynthesis in the Pik pathway 
 
This chapter explores the complex topic of combinatorial biosynthesis in Type I PKS 
pathways.  As PKS pathways assemble natural products in a manner analogous to an industrial 
assembly line,1 biosynthetic engineers have attempted to manipulate the assembly line to get 
unnatural products through 1) swapping in homologous domains or even whole modules from 
other pathways 2) mutagenesis of KS domains to alter stereochemistry of the Claisen 
condensation 3) mutagenesis of the AT domain to select for various malonates 4) mutagenesis of 
KR domains to change the stereochemistry of the resulting β-hydroxyl group or α-stereocenter 5) 
and mutagenesis of ER domains to change the stereochemistry of the α-stereocenter amongst a 
plethora of other approaches.  These modifications, while seemingly minor and localized if one 
employs an enzyme-centric viewpoint,2 must be considered holistically in terms of the whole 
pathway when one considers the downstream chemistry necessary to yield a final unnatural 
product.  Consider a theoretical macrolide biosynthetic pathway consisting of six PKS 
monomodules, which would ultimately produce a 14-membered macrolactone.  Suppose we 
could mutate the KS domain in module I to WT levels of efficiency where a previously (R)-
selective Claisen was exchanged for a (S)-selective Claisen without any modifications in the rest 
of the pathway.  Let module I also contains a KR domain; what effect would the unnatural (S)-
Claisen product have on the stereoselectivity and rate of the reduction? As KR domains can 
epimerize α-stereocenters in some cases, would the KR simply restore the natural (R)-
configuration?  How would the unnatural (S)-stereocenter affect the rate of the transfer to and the 
subsequent rate of the KS domain in module II? As the unnatural polyketide moved farther down 
the pathway and the unnatural stereocenter became more distal would perturbation of catalytic 
rate decrease?  If the whole pathway processed the unnatural polyketide effectively, would the 
TE domain be able to catalyze macrocyclization to offload the final product?  If so, at what rate?  
Let us suppose that the unnatural polyketide imposed no rate penalties throughout the entire 
pathway save for the final TE domain, how would this affect global pathway flux? If we are 
studying the effect in vivo, how does any one of these scenarios affect the titer of the unnatural 
product with respect to WT? 
These and many more questions aside, enzyme engineering and directed evolution 
efforts could, in theory, lead to production of unnatural product analog libraries or direct 
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fermentation of a specific unnatural product.  If combinatorial biosynthesis could be fully realized 
the reward would be immense; so this intricate web of interlaced problems is worth parsing. 
Combinatorial biosynthesis has been largely unsuccessful, where no methods or 
products from such efforts have yet to reach commercial viability despite 25 years of inquiry.  
While some unnatural products have been reported in the literature, the overwhelming majority of 
combinatorial pathways suffer from greatly diminished titers relative to WT.3  As such, we chose 
to explore the tractable Pik pathway and “simulate combinatorial biosynthesis” early in the 
pathway (PikAI) and evaluate how WT PikAIII-TE or PikAIII/PikAIV PKS modules were able to 
process unnatural (i.e. combinatorial) polyketides. Accordingly, we synthesized a panel of 
unnatural pentaketides bearing modifications that would have occurred if the loading domain or 
module 1 possessed a mutant AT domain accepting different extender units (malonate vs. methyl 
malonate) and mutant KS or KR domains to construct all possible stereochemical configurations 
derived from the Claisen condensation and subsequent reduction/epimerization.  By directly 
assaying these unnatural pentaketides with WT PikAIII-TE or PikAIII/PikAIV we can evaluate how 
a downstream PKS module can handle early pathway engineering while avoiding protein-centric 
complications arising from protein engineering or directed evolution.  In this chemistry-centric 
approach, we are examining substrate flexibility of the final modules of a pathway to perform final 
processing and macrolactonization of unnatural substrates.  




















4.1 Design of unnatural Pik pentaketides 
 
 
The Pik pathway has been studied extensively by the Sherman laboratory and others 
both in vivo and in vitro and serves as an ideal pathway for combinatorial efforts as it naturally 
makes two classes of macrolactones, where the terminal TE is a rare example of a bifunctional 
macrolactone-forming domain.  Furthermore, subsequent tailoring (glycosylation and 
hydroxylation) steps have demonstrated wide substrate flexibility, where unnatural macolactones 
generated from combinatorial PKS modules stand a reasonable chance of being tailored with WT 
glycosyltransferase (desVII/desVIII) and p450 (PikC) enzymes.4 Additionally, S. venezuelae 
ATCC 15439 is a rare example of a fast growing macrolide producer that biosynthesizes during 
log phase, meaning maximum titer is achieved in just over 48 hours as opposed to more common 
stationary phase production resulting in 1-2 week fermentations with related organisms.  Finally, 
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Figure 4.1 The Pik PKS pathway  
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unimproved natural producer, especially when considering the short fermentation time. 
 
 
As such we decided to synthesize a panel of unnatural Pik pentaketides using an 
established synthetic route designed for convergent diversification at a late stage (chapter 2).  
Once in hand, unnatural pentaketides would then be intercepted by the Pik pathway (either 
PikAIII-TE or PikAIII/PikAIV) using previously optimized enzymatic reactions (chapter 2); and the 
outcome of catalysis would be determined by isolating products (if any) and standard NMR (and 
X-ray diffraction if applicable) based structural characterization.   
 The panel of targeted unnatural pentaketides was designed to “simulate combinatorial 
biosynthesis” early in the pathway if modifications occurred in the loading module or module 1 of 
PikAI (Figure 4.3).  1 is the natural diketide from the WT Pik pathway, while 2-4 encompass all 
possible stereoisomers arising from mutated or swapped KS and/or KR domain(s).  5 and 7 
would arise from an acetate starter unit derived from a mutated or swapped AT domain in the 
loading module or PikAI that accepts malonyl-CoA, respectively.  6 would require both acetate 
starter and extender units derived from two malonyl-CoA specific AT domains. 8 would arise from 
loading module capable of utilizing a formyl starter unit. 











































 These unnatural diketides would then be processed to unnatural pentaketides before 
being passed from ACP4 of PikAII to the KS of PikAIII, which is where we intended to intercept the 
pathway with synthetic unnatural pentaketides (Figure 4.4).   
 
4.2 Synthesis of unnatural Pik pentaketides 
 
 The synthesis of unnatural Pik pentaketides follows an identical synthetic scheme to that 
described in chapter 2.  A common α,β-unsaturated ketone 18 is joined with a variety of analogs 
of the natural type I olefin.  
  
Since we already had a scalable route to 18 secured, we simply needed to secure 
relatively simple type I fragments, perform cross metathesis and final esterification/deprotection to 



























Figure 4.3 Combinatorial polyketides on ACP1 from early pathway engineering 
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Figure 4.4 Combinatorial synthetic pentaketides as substrates for PikAIII 
	  
9	   10	  
11	   12	  
13	  
14	  






Scheme 4.1 Central disconnection for Pik pentaketide analogs 
	  










 WT fragment 20 was synthesized as previously described (chapter 2) using Evans aldol 
methodology,5 as were fragments 19 and 23.  A Krische crotylation followed by immediate TBS 
protection provided fragments 21 and 22.6 The homo-allylic alcohol precursor of 24 is 
commercially available, requiring only TBS protection.   Opening (R)-1,2- epoxybutane with 
vinylmagnesium bromide and catalytic CuCl provided the linear homo-allylic alcohol,7 which was 
then converted to the silyl-ether 25. 
   
A three step route to 26 began with (S)-Roche ester, which was TBS protected, DIBAL-H reduced 
the ester to an aldehyde which was directly subjected to Wittig olefination.  
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 With all desired right fragments in hand, we employed slightly modified cross-metathesis 
conditions (chapter 2) to generate all targeted Pik pentaketide analogs.  We found that increasing 
the temperature from 50 °C to 60 °C gave slightly improved yields at smaller scales with the 
additional benefit of near complete catalyst decomposition after 12 h (remaining catalyst was 
occasionally observed by TLC after 12 h, though it could be destroyed by raising the temperature 
to 80 °C for a brief period of time).  Cross-metathesis employing 19-22 was uneventful, with 
isolated yields of ~80% seemingly unaffected by the stereochemical configuration of the right 
fragment (Scheme 4.2).   Cross metathesis with 23-26 was slightly more interesting (Scheme 
4.3), with the highest yields (77%) observed with those fragments lacking α-methyl substitution.  
Fragments 23 and 26 afforded slightly worse yields (66% and 51%, respectively) presumably due 
to α-methyl sterics in combination with the increased volatility relative to 19-22 (Scheme 4.3).   
With seco-acids in hand, we first sought to prepare the stereoisomer panel for enzymatic 
reactions with PikAIII-TE and PikAIII/PikAIV through thioesterification and final deprotection 
(Scheme 4.4).  Anti-analogs 11 and 12 proved acid sensitive requiring milder conditions than 
those previously employed (some elimination observed with excess HF in MeCN/H2O).  Common 
deprotection methods employing TBAF or TASF were unsatisfactory due to observed hydrolysis 
of the thioester.  Moving to substoichiometric H2SiF68 minimized competitive elimination of the 
homo-allylic alcohol, though yields were still lower with anti-pentaketides 11 and 12 than with syn-




































With this first set of analogs in hand, we decided to explore the substrate flexibility of 
PikAIII-TE with 9-12.  Initial runs with PikAIII-TE as previously described (chapter 2) led to 
complete consumption (by TLC) of WT pentaketide 9 as expected, but incomplete consumption of 
10-12 after 4 h along with formation of low levels of possible macrolactone products.  Doubling 
the reaction time to 8 h resulted in complete consumption of 10-12 but the yield of 10-dml with 9 
decreased slightly as a NAC conjugate adduct was observed.  As such, we increased the 
concentration of 2-vinylpyridine (thiol scavenger) from 8 mM to 20 mM, which resorted the ~65% 
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forming with 10-12. 
 
 
As 10-12 were being accepted and elongated by the enzyme but not macrolactonized, we 
hypothesized these substrates were mechanism based inhibitors of the TE domain, resulting in 
substrate stalling in the TE domain and, in turn, increasing residency in the upstream KR domain 
(Scheme 4.6). As such, we turned our attention to studying the Pik TE domain and neglected 30-
33 for the time being.  We chose to pursue a two-prong approach, first with synthesis of the C11 




































































4.3 Synthesis and Evaluation of the Pik C11 epi-hexaketide 
 
Given the success of synthesizing Pik hexaketide substrates (chapter 3) from 10-dml, we hoped 
that we could simply invert the C11 hydroxyl group of 47 through a Mitsunobu inversion or related 
reaction.  Unfortunately, the homo-allylic hydroxyl group was predominantly eliminated under all 
conditions examined, prompting a lengthier synthetic scheme where the α,β-unsaturated ketone 
was subjected to 1,2 reduction under Leuche conditions to raise the pKa of the C10 position 
(Scheme 4.6).  C3 methyl protected 10-dml 40 was reduced and protected to yield 41, which was 
further reduced and again protected to provide 42.  A number of Mitsunobu conditions were 
examined, where DIAD outperformed DEAD in all cases examined and chloroacetic acid9 was 
superior to all other acids examined,10 including 4-nitrobenzoic acid.11  While some elimination 
was observed during the synthesis of 43, the inversion proceeded with an acceptable yield (71%).  
In exploratory deprotections, compound 43 was found to unexpectedly sensitive to mildly acidic 
deprotection (HF) typically used with related compounds, prompting use of TBAF, which was able 
to deprotect both silyl-ethers and hydrolyze chloroacetate12 in a one pot reaction.  The final 
oxidation and thioesterification were operational under previously described conditions (chapter 
3) to yield compound 46.  
 
 With the C11 epi-hexaketide 46 in hand, we sought to compare this compound to the 
natural hexaketide to see what the affect of this epimerized stereocenter had on 
macrolactonization.  An initial 12 h incubation of 46 and 47 with WT Pik TE resulted in substantial 
NAC conjugate addition, resulting in employing the now familiar thiol scavenger 2-vinylpyridine (2-
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Scheme 4.7 Synthesis of the Pik C11 epi-hexaketide 46 
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conversion of 47 to 40, while 46 was quantitatively hydrolyzed, supporting the TE hypothesis.  
  
An identical experiment using the improved Pik TES148C13 yielded surprising results.  In this 
construct, the nucleophilic serine of the catalytic triad has been replaced with cysteine in a 
manner reminiscent of cysteine protease.  This mutation was originally designed to accelerate the 
rate of acylation with little regard to the subsequent macrolactonization, though the mutation 
appears to improve both acylation and subsequent macrolactonization.  A 12 h incubation of 47 to 
resulted in quantitative conversion to 40, and more surprisingly, a 12 h incubation of 46 resulted 
in quantitative conversion to macrolactone hypothesized to be 48, though a homodimer was not 
outside the realm of possibility as neither NMR methods nor ESI-HRMS (detecting masses 



























































Initial attempts to crystalize 48 directly were met with failure under all attempted conditions, 
though Leuche reduction and acylation with 4-nitrobenzoic anhydride did provide crystals suitable 
for X-ray diffraction, indicating the product was indeed a monomer.	    Interestingly, an attempted 
time course of 46 converting to 48 at hour increments failed as complete conversion was 
observed after only 1 h, where conversion of 47 to 40 with WT Pik TE were not yet complete after 
12 h!  These preliminary observations of catalysis with Pik TES148C certainly encourage further 
study into this truly amazing point mutation.  
 
4.3 Synthesis of a Pik heptaketide affinity label 
 
 PKS enzymologists have published a number of excised studies examining excised TE 
domains.  Early work attempted biochemical characterization,14 though difficulty in accessing 
native substrates required the use of non-native thioesters that were simply hydrolyzed rather 
than macrolactonized.  Structural work followed,15 which answered some questions but raised 
many more.  DEBS TE X-Ray structures clearly showed a substrate channel running through the 
enzyme, a Ser-His-Asp catalytic triad commonly observed in esterases, and a wide, concave 
active site.  The active site was surprisingly sparse, with only a few residues capable of 
participating in hydrogen bonding. The Sherman, Smith, and Fecik groups initiated a collaboration 
to examine the Pik TE using combined structural, biochemical, and chemical biology 
approaches.16 This work marks the first time a PKS TE was biochemically characterized with a 
native substrate or structurally characterized with affinity label mimics of a native substrates.  A 
key structural finding with affinity labels was that the compound was observed to curl toward the 
orientation required for macrolactonization while forming only one hydrogen bond with the 
enzyme.  Apparently, a combination of a low energy substrate conformer in combination with a 
seemingly nonspecific active site template is enough to orient the linear chain towards functional 
macrolactonization, providing valuable insight into how these enzymes function.  However, the 
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Scheme 4.10 Derivatization of 48 to 49 
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into the intricacies of the Pik TE.  To rectify this shortcoming, we decided to synthesize a full-
length affinity label mimic of the Pik heptaketide.  This affinity label 50 could potentially be 
captured in two states, one where the active site serine has been labeled and the chain remains 
linear, and a further step where a tetrahedral intermediate could be captured if the terminal 
hydroxyl group cyclizes and forms a narbonolide mimic.  While previous affinity labels where 
diphenyl phosphonates, we hypothesized we could improve inhibition though using alkyl leaving 
groups over aryl(chapter 3). 
 
A short four step sequence from compound 51 (three steps from 10-dml, chapter 3) provided 
compound 50.  TBS protection of the homo-allylic hydroxyl group provided silyl-ether 52, which 
was converted to an acyl chloride with the Ghosez reagent, alkylated,17 and deprotected to 
provide 50 in poor yield (27%) over a three step sequence.18 Compound 50 is currently under 
evaluation. 
   
 
4.4 Chemistry Experimental 
 
Reactions were performed in evacuated (<0.05 torr) flame dried glassware containing PFTE 
coated magnetic stir bars fitted with rubber septa backfilled with dry N2 and run under a positive 
pressure of dry N2 provided by a mineral oil bubbler unless stated otherwise (open flask). 
Reactions at elevated temperatures were controlled by IKA RET Control Visc (model RS 232 C), 
room temperature (RT) reactions were conducted at ~23 °C, reactions run cooler than room 
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temperature were performed in a cold room (4 °C), an ice bath (0 °C), dry ice/acetone (-78 °C), or 
isopropanol/ThermoNESLAB (model CC100) for all other temperatures. Commercial purification 
system MBraun-MB-SPS # 08-113 provided all dry solvents unless stated otherwise (technical 
grade). Analytical thin-layer chromatography (TLC) was performed with EMD 60 F254 pre-coated 
glass plates (0.25 mm) and visualized using a combination of UV, p-anisaldehyde, KMnO4, and 
Bromocresol green stains. Flash column chromatography was performed using EMD 60 
Gerduran® (particle size 0.04-0.063) silica gel.  NMR spectra were recorded on a Varian 600 
MHz spectrometer. 1H NMR spectra were recorded relative to residual solvent peak (CDCl3 δH 
7.26 ppm, D6-DMSO δH 2.50 ppm, D6-acetone δc 2.05 ppm) and reported as follows: chemical 
shift (ppm), multiplicity, coupling constant (Hz), and integration. Multiplicity abbreviations are as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, h = hextet, ovlp = overlap, 
br = broad signal.  13C NMR spectra were recorded relative to residual solvent peaks (CDCl3 δC 
77.0 ppm, D6-DMSO δc 39.5 ppm, D6-acetone δc 29.8 ppm).  High resolution mass spectrometry 
was performed on an Agilent quadrapole time-of-flight spectrometer (Q-TOF 6500 series) by 
electrospray ionization (ESI). 
 
 
18 (modified from chapter 2): To a 500 mL flask containing 53 (8.98 g, 44.8 mmol, 1 equiv) in 
THF (30 mL) at -78 °C was added TMSCl (freshly distilled, Sigma, 22.8 mL, 19.5 g, 179.3 mmol, 
4 equiv) down the side of the flask.  A second flask was charged with LHMDS solution (Sigma, 1 
M in THF, 179.3 mL, 179.3 mmol, 4 equiv) and cooled to -78 °C.  LHMDS solution was added 
dropwise to the 53 solution via by cannula then stirred at -78 °C for 30 min, followed by dropwise 
addition of acetone (11.71 g, 14.8 mL, 201.6 mmol, 4.5 equiv) with 10 min additional stirring.  The 
solution was allowed to warm to RT and concentrated.  The crude solid was suspended in 
hexanes and filtered through a fritted funnel, the solid was then rinsed 2x with hexanes.  The 
filtrate was poured through a sodium sulfate plug, which was then rinsed 2x with hexanes and 
concentration gave the crude trimethylsilyl enol ether of 53 (contaminating 
(isopropenyloxy)trimethylsilane was mostly removed under subsequent high vacuum).  
 
IBX19 (0.4 M in technical grade DMSO, 224 mL, 89.6 mmol, 2.00 equiv) was added to the crude 
silyl enol ether and  stirred for 12 h (the solution turns yellow and a white precipitate forms) in an 
open flask.  The reaction was diluted with H2O (2 volumes) and extracted with Et2O:hexanes (4:1, 
3x) Combined organic extracts washed 1x with brine, subsequently filtered through a sodium 
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EtOAc/Hexanes (10:90) to AcOH/EtOAc/Hexanes (1:10:89) gave 18 as a pale yellow oil (7.55 g, 
38.10 mmol, 85% yield). Matched spectral data from chapter 2. 
 
 
General two-step oxidation/olefination procedure5d for 19, 20, and 23 from Evans aldol 
products5c,20 
A flask containing MePPh3Br (AK, 1.10 equiv) was placed in an oil bath, and heated to 110  °C 
under high vacuum for 4 h.   The flask was cooled to RT and backfilled with N2, THF (0.2 M) and 
cooled to 0 °C.  n-BuLi (Sigma, 1.10 equiv) was added dropwise (solution turns colorless to red 
and solid MePPh3Br dissolves completely) and the reaction was allowed to warm to RT and 
stirred for a minimum 1 h.  
To an open flask was added silyl-ether alcohol (1 equiv), technical grade DMSO (80 mL, 0.25 
M) and IBX (1.50 equiv) in a single portion.  The reaction was monitored by TLC, and after 
consumption of starting material (~4 h) Et2O was added. The reaction was quenched with a cold 
solution of sodium thiosulfate, and stirred for 30 min.  The aqueous layer was separated and the 
organic layer was washed 2x with saturated thiosulfate, brine, dried with sodium sulfate, filtered, 
rinsed 2x with Et2O and concentrated to give the crude aldehyde, which was dissolved in THF (20 
mL) and used immediately.   
Both flasks were cooled to -78 °C and the crude aldehyde was added by cannula to the prepared 
ylide.  The solution was stirred at -78 °C for 30 min, warmed to RT and stirred for an additional 30 
min.  The reaction was quenched with half saturated NH4Cl and extracted 3x with pentane, 
filtered through a sodium sulfate plug, rinsed 2x with pentane and carefully concentrated (rotovap 
bath cooled to 0°C) to give the crude alkene product. Flash chromatography: pentane afforded 
19, 20, or 23 as a clear oil. 
Note: 19, 20, and 23 are volatile under high vacuum. 
19: 87% at 18 millimole scale 
1H NMR (CDCl3, 599 MHz) δ 5.84 (ddd, J = 17.5, 10.4, 7.3 Hz, 4H), 5.07 – 4.91 (m, 2H), 3.47 (dd, 
J = 11.0, 5.4 Hz, 4H), 2.31 (h, 6.7Hz, 1H), 1.49 – 1.36 (m, 2H), 0.97 (d, J = 6.8 Hz, 3H), 0.90 (s, 





























13C NMR (CDCl3, 151 MHz): δ 141.8, 113.2, 77.00, 42.3, 26.5, 25.9, 18.2, 15.0, 9.5, -4.3, -4.4. 
EI HRMS: Calculated [M-CH3]+ 213.1669, found 213.1683. 
 
20: 88% at 6.5 millimole scale 
1H NMR (CDCl3, 599 MHz) δ 5.84 (ddd, J = 17.5, 10.4, 7.3 Hz, 1H), 5.07 – 4.91 (m, 2H), 3.46 (q, 
J = 5.5 Hz, 1H), 2.31 (h, J = 6.7 Hz, 1H), 1.49-1.36 (m, 2H), 0.97 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 
0.86 (t, J = 7.4 Hz, 3H), 0.04 (s, 6H). 
13C NMR (CDCl3, 151 MHz): δ 141.8, 113.6, 77.00, 42.3, 26.5, 25.9, 18.2, 15.0, 9.5, -4.3, -4.4. 
EI HRMS: Calculated [M-CH3]+ 213.1669, found 213.1678. 
 
23: 82% yield at 10 millimole scale. 
1H NMR (CDCl3, 599 MHz)  δ 5.80 (ddd, J = 17.7, 10.5, 7.5 Hz, 1H), 5.03 – 4.95 (m, 2H), 3.63 (p, 
J = 6.1 Hz, 1H), 2.16 (h, J = 6.6 Hz, 1H), 1.07 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.89 
(s, 9H), 0.04 (d, J = 2.9 Hz, 6H). 
13C NMR (CDCl3, 151 MHz): δ 141.6, 113.9, 71.9, 45.5, 25.9, 21.0, 18.1, 15.4, -4.4, -4.8. 
EI HRMS: Calculated [M-CH3]+ 199.1513, found 199.1526. 
 
General two-step crotylation6/silylation procedure for 21 and 22 
 
An oven dried pressure tube was charged with catalyst A or B10 (5 mol %), α-methylallyl acetate 
(TCI, 2 equiv), K3PO4 (EMD, 0.5 equiv), iPrOH (EMD, 2 equiv), H2O (5 equiv), propionaldehyde 
(Sigma, distilled neat, 1 equiv), THF (2M) under a stream of nitrogen.  The tube was sealed and 
placed in a 60 °C oil bath, stirred for 48 hours.  After cooling to RT, 5 volumes of n-pentane were 
added (relative to THF) and the heterogenous mixture was filtered through a plug of sodium 
sulfate, then rinsed 2x with n-pentane.  (Crude catalyst was subsequently recovered by rinsing 3x 































Cat. A or Cat. B              








To the crude crotylation product was added DMF (0.5M) followed by imidazole (Fisher, 5 equiv) 
and tertbutyldimethylsilyl chloride (Oakwood, 5 equiv).  The solution was warmed to 60 °C and 
stirred for 12 hours.  After cooling to RT, the solution was diluted with H2O and extracted 2x n-
pentane, filtered through a plug of sodium sulfate, then rinsed 2x with n-pentane. Careful 
concentration (rotovap bath cooled to 0 °C) and flash chromatography: pentane yields 21 or 22 
as a clear oil.  
 
Note: 21 and 22 are volatile under high vacuum  
 
 21:  64% over two steps at 38 millmole scale (using catalyst B, from (R)-SEGPHOS).  
(dr >20:1; only one diasteromer is observed by 1H-NMR) 
(only one diasteromer is observed by 1H-NMR after cross-metathesis with S3, suggesting er 
>15:1)  
1H NMR (CDCl3, 599 MHz) δ 5.84 – 5.75 (m, 1H), 5.03 – 4.96 (m, 2H), 3.46 (td, J = 6.1, 4.0 Hz, 
1H), 2.39 – 2.23 (m, 1H), 1.45 – 1.37 (m, 1H), 1.12 – 0.94 (m, 4H), 0.94 – 0.77 (m, 13H), 0.03 (d, 
J = 15.6 Hz, 6H). 0.98 (d, J = 6.9 Hz, 1H), 0.89 (s, 9H), 0.04 (s, 6H). 
13C NMR (CDCl3, 151 MHz): δ 141.1, 114.1, 77.2, 42.7, 26.4, 25.9, 18.2, 15.5, 10.1, -4.3, -4.5. 
EI HRMS: Calculated [M-CH3]+ 213.1669, found 213.1679. 
 
 22:  53% over two steps at 19 millimole scale. (Using catalyst A, from (S)-SEGPHOS) 
(dr >20:1; only one diasteromer is observed by 1H-NMR) 
(only one diasteromer is observed by 1H-NMR after cross-metathesis with S3, suggesting er 
>15:1) 
1H NMR (CDCl3, 599 MHz)  δ 5.84 – 5.74 (m, 1H), 5.02 – 4.95 (m, 2H), 3.46 (td, J = 6.0, 4.2 Hz, 
1H), 2.43 – 2.26 (m, 1H), 1.43 – 1.37 (m, 1H), 0.98 (d, J = 6.9 Hz, 1H), 0.89 (s, 9H), 0.84 (t, J = 
7.5 Hz, 1H), 0.04 (s, 6H). 
13C NMR (CDCl3, 151 MHz): δ 141.1, 114.1, 77.2, 42.7, 26.4, 25.9, 18.2, 15.6, 10.1, -4.3, -4.5. 






A 50-mL flask was charged with (R)-4-penten-2-ol (Sigma, 1 g, 11.61 mmol, 1 equiv), DMF (11.6 
mL, 1M), followed by imidazole (Fisher, 0.95 g, 13.96 mmol, 1.2 equiv) and tertbutyldimethylsilyl 




before the solution was loaded onto a flash column: pentane to yield 24 (2.14 g, 10.67 mmol, 
92% yield) as a colorless oil. 
 
Note: 24 is volatile under high vacuum. 
 
1H NMR (CDCl3, 599 MHz) δ 5.81 (ddt, J = 17.3, 10.2, 7.2 Hz, 1H), 5..06 – 4.99 (m, 2H), 3.84 (h, 
J = 6.1 Hz, 1H), 2.30 – 2.09 (m, 2H), 1.13 (d, J = 6.1 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 3H),  0.05 (s, 
3H). 
13C NMR (CDCl3, 151 MHz) δ 135.6, 116.5, 68.4, 44.3, 25.8, 23.38, 18.14, -4.5, -4.7. 
EI HRMS: Calculated [M-CH3]+ 185.1356, found 185.1363. 
 
S10: Adapted from literature procedure7 
To a 250mL flask was added CuCl (Sigma, flame dried under vacuum, 0.55 g, 5.45 mmol, 20 mol 
%), vinylmagnesium bromide (Sigma, 1M in THF, 55.5 mL, 55.5 mmol, 2 equiv), then cooled to -
10 °C.  (R)-1,2-epoxybutane (Sigma, 2 g in 8 mL THF, 27.7 mmol, 1 equiv) was added via 
syringe drive over the course of 1 h.  After complete addition, the solution was allowed to warm to 
0 °C followed by the addition of solid imidazole (Fisher, 3.96 g, 58.2 mmol, 2.1 equiv) and 
tertbutyldimethylsilyl chloride (Oakwood, 8.77 g,  58.2 mmol, 2.1 equiv).  The flask was fitted with 
a reflux condenser and heated to 70 °C for 18 h. After cooling to RT the solution was diluted with 
pentane, washed 2x with H2O, 1x saturated sodium thiosulfate and filtered through a sodium 
sulfate plug then rinsed 2x with pentane.   Careful concentration (rotovap bath cooled to 0°C) and 
flash chromatography: pentane yields 25 (5.16 g, 24.11 mmol, 87% over two steps) as a colorless 
oil. 
Note: 25 is volatile under high vacuum. 
 
1H NMR (CDCl3, 599 MHz) δ 5.81 (ddt, J = 17.3, 10.1, 7.2 Hz, 1H), 5.08 – 4.98 (m, 1H), 3.63 (p, J 
= 5.8 Hz, 1H), 2.26 – 2.15 (m, 2H), 1.54 – 1.38 (m, 2H), 1.34 – 0.98 (m, 1H), 0.89 (s, 9H), 0.87 
(ovlp t, J = 8.0 Hz, 3H), 0.05 (s, 6H). 
 
13C NMR (CDCl3, 151 MHz): δ 135.5, 116.4, 73.1, 41.4, 29.4, 25.9, 18.1, 9.6, -4.5, -4.6. 















26: An open 250-mL flask was charged with (S)-Roche ester (TCI, 3.0 g, 25.40 mmol, 1.00 
equiv), imidazole (Fisher, 1.90 g, 27.94 mmol, 1.10 equiv), technical grade CH2Cl2, (51 mL, 0.5M) 
and cooled to 0 °C.  Tertbutyldimethylsilyl chloride (Oakwood, 4.21 g, 27.94 mmol, 1.1 equiv) was 
added in 5 portions.  The resulting solution was stirred for 1 h at 0 °C and became cloudy with 
white precipitate.  A half-saturated NH4Cl solution was added until the precipitate was completely 
dissolved.  The organic layer was separated and the aqueous layer extracted 2x with CH2Cl2.  
The combined organic extracts were washed with brine and filtered through a sodium sulfate 
plug, which was subsequently rinsed 2x with CH2Cl2.  Concentration and subsequent high 
vacuum yielded colorless oil that was carried onto the next step without further purification. 
 
The following two steps were performed concurrently:   
 
To a 250-mL flask containing MePPh3Br (AK, 9.98 g, 27.94 mmol, 1.10 equiv) was placed in an 
oil bath, and heated to 110  °C under high vacuum for 4 h.   The flask was cooled to RT and 
backfilled with N2, THF (128 mL, 0.2M) and cooled to 0 °C.  n-BuLi (Sigma, 2.48M, 11.26 mL, 
1.10 equiv) was added dropwise (solution turns colorless to red and solid MePPh3Br dissolves 
completely) and the reaction was allowed to warm to RT and stirred for a minimum 1 h.  
 
To a 250-mL flask containing crude silyl ether (~25.4 mmol, 1 equiv) was added CH2Cl2 (51 mL, 
0.5M) and cooled to -78 °C.  DIBAL-H (Sigma, 3.79 g, 4.75 mL, 26.67 mmol, 1.05 equiv) was 
added slowly down the side of the flask and stirred for 1 h at -78 °C.  Methanol (30 mL) was 
added slowly and the solution was stirred for 15 min at -78 °C.  The reaction was decanted into of 
vigorously stirring CH2Cl2 (50 mL) at RT, layered with saturated Na/K tartrate (100 mL) and stirred 
until the layers became clear.  The organic layer was separated and the aqueous layer was 
extracted 2x with CH2Cl2. The combined organic extracts were washed with brine and filtered 
through a sodium sulfate plug, which was then rinsed 2x with CH2Cl2.  Concentration and 
subsequent high vacuum yielded crude aldehyde which was dissolved in THF (10 mL) and used 
immediately.   
 
Both flasks were cooled to -78 °C and crude aldehyde was added by cannula to the prepared 
ylide.  The solution was stirred at -78 °C for 30 min, warmed to RT and stirred for an additional 30 
min.  The reaction was quenched with half saturated NH4Cl (50 mL) and extracted 3x with 
pentane, filtered through a sodium sulfate plug, rinsed 2x with pentane and carefully concentrated 
to give the crude alkene product. Flash chromatography: pentane afforded 26 as a clear oil (3.91 
g, 19.51 mmol, 77% over three steps.) 
 
Note: 26 is volatile under high vacuum. 
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1H NMR (CDCl3, 599 MHz) δ 5.77 (ddd, J = 17.3, 10.4, 6.9 Hz, 1H), 5.07 – 4.96 (m, 2H), 3.51 (dd, 
J = 9.8, 6.2 Hz, 1H), 3.41 (dd, J = 9.7, 7.0 Hz, 1H), 2.37 – 2.27 (m, 1H), 1.00 (d, J = 6.8 Hz, 3H), 
0.89 (s, 9H). 0.04 (s, 6H). 
13C NMR (CDCl3, 151 MHz) δ 141.4, 113.9, 67.9, 40.3, 25.9, 18.3, 16.0, -5.3, -5.4. 
EI HRMS: Calculated [M-CH3]+ 185.1356, found 185.1366. 
 
 
17, 27-33:  General cross metathesis of 18 and silyl ethers 19-26 
 
A 10 mL recovery flask was charged with 18 (1 equiv), silyl-ether (19-26, 1.5 equiv) and 
Hoveyda-Grubbs 2nd generation (Sigma, 24 mg, 0.04 mmol, 3 mol%) under a stream of N2.  An 18 
gauge needle was placed into the septum, venting to the atmosphere (in addition to positive 
pressure of N2) and the flask was heated to 60 °C for 12 h. Flash chromatography: 














































catalyst had decomposed completely (TLC) after 12 h, though it remained detectable on 
occasion.  Raising the temperature to 80 °C for an additional 2 h resulted in complete catalyst 
decomposition.  
 
S27: 81% yield at a 1.26 mmol scale. 
1H NMR (CDCl3, 599 MHz) δ 6.94 (dd, J = 15.9, 7.5 Hz, 1H), 6.14 (dd, J = 15.9, 1.1 Hz, 1H), 
3.59-3.53 (m, 1H),  2.87 (h, J = 6.9 Hz, 1H),  2.58-2.44 (m, 2H),  2.17-2.07 (m, 1H), 1.52-1.44 (m, 
1H), 1.43-1.34 (m, 2H), 1.20 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 
0.88 (s, 9H), 0.86 (ovlp t, J = 7.0Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (CDCl3, 151 MHz) δ 203.0, 181.5, 150.8, 127.9, 76.4, 41.5, 41.3, 37.0, 36.2, 26.8, 25.8, 
21.3, 18.1, 17.5, 16.7, 14.2, 9.6, -4.4, -4.5. 
HRMS: Calculated [M+H]+ 371.2612, found 371.2619. 
 
17: 78% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.94 (dd, J = 15.9, 7.4 Hz, 1H), 6.14 (dd, J = 15.9, 1.0 Hz, 1H), 
3.59-3.53 (m, 1H), 2.87 (h, J = 6.9 Hz, 1H), 2.58-2.44 (m, 2H), 2.17 – 2.08 (m, 2H), 1.52-1.44 (m, 
1H), 1.19 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.86 
(ovlp t, J = 7.0Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (CDCl3, 151 MHz) δ 202.9, 181.8, 150.8, 127.9, 76.4, 41.6, 41.3, 37.0, 36.2, 26.8, 25.8, 
18.1, 17.5, 16.7, 14.3, 9.6, -4.4, -4.5. 
HRMS: Calculated [M+H]+ 371.2612, found 371.2614. 
 
28:  77% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.90 (dd, J = 15.9, 7.9 Hz, 1H), 6.14 (d, J = 15.9 Hz, 1H), 3.56 – 
3.52 (m, J = 1H), 2.12 (h, J  = 7.2 Hz, 1H), 2.56 – 2.43 (m, 2 H),  2.12 (ddd, 14.4, 7.8, 6 Hz, 1H), 
1.50 – 1.33 (m, 2H), 1.19 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.05 (d, J = 6.8 Hz, 3H),  
0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 
13C NMR (CDCl3, 151 MHz) δ 203.0, 182.1, 150.2, 128.3, 76.6, 41.5, 41.2, 37.9, 36.2, 27.1, 25.9, 
25.8, 18.1, 17.4, 16.7, 15.4, 9.6, -4.3, -4.6. 
HRMS: Calculated [M+H]+ 371.2612, found 371.2612. 
 
29:  82% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.91 (dd, J = 16.0, 7.9 Hz, 1H), 6.14 (d, J = 15.9 Hz, 1H), 3.58 - 
3.51 (m, 1H), 2.87 (h, J = 7.2 Hz, 1H), 2.58 – 2.44 (m, 2H), 2.13 (ddd, 14.4, 7.8, 6 Hz, 1H), 1.52 – 
1.35 (m, 2H), 1.20 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.89 (s, 
9H), 0.86 (t, J = 7.4 Hz, 3H), 0.05 (s, 3H), 0.04 (s, 3H). 
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13C NMR (CDCl3, 151 MHz) δ 203.0, 181.7, 150.2, 128.3, 76.6, 41.5, 41.2, 36.9, 36.2, 27.1, 25.8, 
18.1, 17.5, 16.7, 15.4, 9.6, -4.3, -4.6. 
HRMS: Calculated [M+H]+ 371.2612, found 371.2609. 
 
 30:  66% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.91 (dd, J = 15.9, 7.7 Hz, 1H), 6.14 (d, J = 15.9 Hz, 1H), 3.76 (p, J 
= 6.0 Hz, 1H), 2.87 (h, J = 7.2 Hz, 1H), 2.53 (h, J = 7.8 Hz, 1H), 2.35 (h, J = 6.6 Hz, 1H), 2.12 
(ddd, J = 14.3, 8.2, 6.5 Hz, 1H), 1.41 (ddd, J = 13.8, 7.2, 6.5 Hz, 1H), 1.20 (d, J = 7.0 Hz, 3H), 
1.12 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 6.2 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.04 (s, J 
= 3H), 0.03 (s, J = 3H). 
13C NMR (CDCl3, 151 MHz) 203.9, 182.0, 150.4, 128.2, 71.3, 44.5, 41.2, 37.0, 36.3, 25.8, 21.0, 
18.0, 17.4, 16.6, 14.8, -4.4, -4.9. 
 
31:  77% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.90 (dt, J = 15.2, 7.4 Hz, 1H), 6.18 (d, J = 15.7 Hz, 1H), 3.95 (h, J 
=  15.7 Hz, 1H), 2.85 (h, J = 7.2 Hz, 1H),   2.57 - 2.49 (m, 1H), 2.38 – 2.30 (m, 1H), 2.12 (ddd, J = 
14.4, 7.8, 6 Hz, 1H), 1.41 (ddd, J = 13.9, 7.6, 6.2 Hz, 11H), 1.20 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 
6.1 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 0.87 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H). 
13C NMR (CDCl3, 151 MHz) δ 202.7, 181.9, 144.7, 130.4, 77.19, 67.6, 42.7, 41.3, 37.0, 36.2, 
25.8, 23.8, 18.0, 17.5, 16.6, -4.5, -4.8. 
HRMS: Calculated [M+H]+ 357.2456, found 357.2457. 
 
32: 77% yield at a 1.26 millimole scale.   
1H NMR (CDCl3, 599 MHz) δ 6.91 (dt, J = 15.3, 7.5 Hz, 1H), 6.18 (dt, J = 15.8, 1.2 Hz, 1H), 3.73 
(p, J = 5.8 Hz, 1H), 2.85 (h, J = 7.8 Hz, 1H), 2.59 – 2.45 (m, 1H), 2.41 (m, 2H), 2.12 (ddd, J = 
14.4, 7.4, 5.3 Hz, 4H), 1.51 – 1.44 (m, 1H), 1.41 (ddd, J = 13.9, 7.7, 6.2 Hz, 1H), 1.20 (d, J = 7.0 
Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 0.88 (ovlp t, J = 7.4 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 3H), 0.03 (s, 
3H). 
13C NMR (CDCl3, 151 MHz) δ 202.6, 181.9, 144.5, 130.4, 72.4, 41.3, 40.0, 37.0, 36.2, 29.9, 25.8, 
18.0, 17.5, 16.6, 9.5, -4.5, -4.5. 
HRMS: Calculated [M+H]+ 357.2456, found 357.2452. 
 
33:  51% yield at a 1.26 millimole scale. 
1H NMR (CDCl3, 599 MHz) δ 6.86 (dd, J = 15.9, 7.3 Hz, 1H), 6.18 (dd, J = 15.9, 1.2 Hz, 1H), 3.54 
(d, J = 6.4 Hz, 1H), 2.86 (h, J = 7.2 Hz, 1H), 2.60 – 2.47 (m, 1H), 2.12 (ddd, J = 13.8, 7.8, 6 Hz, 
1H), 1.41 (ddd, J = 13.9, 7.7, 6.1 Hz, 1H), 1.20 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.06 
(d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H). 
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13C NMR (CDCl3, 151 MHz) δ 203.0, 182.2, 150.2, 128.00, 66.9, 41.4, 39.4, 37.0, 36.2, 25.8, 
18.2, 17.5, 16.6, 15.6, -5.4, -5.4 















9-12:  General thioesterification and TBS deprotection of 17, 27-29. 
 
A round bottom flask was charged with seco-acid (17, 27-29, 1 equiv), Ph2S2 (Sigma, 1.1 equiv), 
and CH2Cl2 (0.1 M) and cooled to - 78 °C. PBu3 (Sigma, distilled neat, 1.3 equiv) was added 
dropwise and the reaction was stirred for 45 min at - 78 °C before being removed from the 
cooling bath and immediate quench with a saturated aq. CuSO4 solution and warming to RT. The 
organic layer was separated, and the aq. layer was extracted further with CH2Cl2 (2x), CH2Cl2 
layers combined and filtered through a sodium sulfate plug, rinsed 2x with CH2Cl2 and 
concentrated. Flash chromatography (silica topped with 1:1 SiO2:CuSO4): EtOAc/Hexanes (2:98 
to 4:96) afforded crude thioesters as a clear oils, which were used immediately in the subsequent 
step. 
 
An open polyethylene bottle was charged with crude thioester, MeCN (1 M) and cooled to 0 °C.  
H2SiF6 (Fisher, 25% in H2O, 0.8 equiv) was added and the reaction was stirred at 0 °C until 
complete by TLC.  The reaction was monitored by TLC and upon completion it was diluted with 
CH2Cl2 (10 mL) and carefully quenched with saturated sodium bicarbonate. The aqueous layer 
was extracted 2x with CH2Cl2. Filtration through a sodium sulfate plug then rinsed 2x with CH2Cl2 
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9: 90% at a 4 millimole scale. 
1H-NMR (599 MHz; d6-acetone): δ 7.46-7.43 (m, 5H), 6.93 (dd, J = 15.9, 8.0 Hz, 1H), 6.22 (dd, J 
= 16.0, 0.8 Hz, 1H), 3.68 (d, J = 5.7 Hz, 1H), 3.46-3.42 (m, 1H), 2.98 (h, J = 6.9 Hz, 1H), 2.84 (h, 
J = 7.1 Hz, 1H), 2.45-2.40 (m, 1H), 2.18-2.14 (m, 1H), 1.50 (dqd, J = 14.1, 7.2, 3.6 Hz, 1H), 1.43 
(dt, J = 13.7, 6.8 Hz, 1H), 1.39-1.31 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 
1.09 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; d6-acetone): δ 202.4, 200.7, 151.1, 135.3, 130.07, 129.95, 128.89, 128.79, 
75.9, 46.8, 43.6, 41.6, 37.7, 28.3, 18.3, 17.2, 14.9, 10.7 
HRMS: Calculated [M+H]+ 349.1832, found 349.1837.  
 
10: 91% at a 1.92 millimole scale. 
1H-NMR (599 MHz; d6-acetone): δ 7.46-7.43 (m, 5H), 6.93 (dd, J = 15.9, 8.0 Hz, 1H), 6.22 (dd, J 
= 15.9, 1.0 Hz, 1H), 3.68 (d, J = 5.7 Hz, 1H), 3.45 (dtt, J = 11.5, 5.8, 2.9 Hz, 1H), 2.98 (h, J = 6.9 
Hz, 1H), 2.84 (h, J = 6.9 Hz, 1H), 2.45-2.40 (m, 1H), 2.16 (dt, J = 14.0, 7.1 Hz, 1H), 1.51 (dqd, J = 
14.1, 7.2, 3.6 Hz, 1H), 1.43 (dt, J = 13.7, 6.9 Hz, 1H), 1.39-1.31 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 
1.13 (d, J = 6.9 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; d6-acetone): δ 202.4, 200.8, 151.1, 135.3, 130.09, 129.98, 128.92, 128.81, 
76.0, 46.8, 43.7, 41.6, 37.7, 28.4, 18.4, 17.2, 14.9, 10.7. 
HRMS: Calculated [M+H]+ 349.1832, found 349.1835.  
 
11: 77% at a 1.62 millimole scale. 
1H-NMR (599 MHz; d6-acetone): δ  7.43-7.39 (m, 5H), 6.93 (dd, J = 15.9, 8.3 Hz, 1H), 6.17 (dd, J 
= 15.9, 0.9 Hz, 1H), 3.63 (d, J = 5.5 Hz, 1H), 3.42 (dq, J = 8.9, 4.5 Hz, 1H), 2.95 (hex, J = 6.9 Hz, 
1H), 2.80 (dq, J = 14.3, 7.0 Hz, 1H), 2.43-2.38 (m, 1H), 2.13 (dt, J = 14.0, 7.1 Hz, 1H), 2.01 (dt, J 
= 4.4, 2.2 Hz, 1H), 1.47-1.32 (m, 1H), 1.19 (d, J = 6.9 Hz, 3H), 1.09 (d, J = 6.9 Hz, 3H), 1.07 (d, J 
= 6.9 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; d6-acetone): δ 202.3, 200.8, 150.3, 135.3, 130.1, 123.0, 129.6, 128.8, 76.3, 
46.8, 43.3, 41.5, 37.7, 28.6, 18.3, 17.3, 16.7, 10.6 
HRMS: Calculated [M+H]+ 349.1832, found 349.1829.  
 
12: 78% at a 1.76 millimole scale. 
1H-NMR (599 MHz; d6-acetone): δ  7.46-7.44 (m, 5H), 6.97 (dd, J = 15.9, 8.4 Hz, 1H), 6.20 (dd, J 
= 16.0, 0.9 Hz, 1H), 3.70-3.69 (m, 1H), 3.48-3.44 (m, 1H), 3.00 (h, J = 6.9 Hz, 1H), 2.87-2.81 (m, 
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1H), 2.47-2.41 (m, 1H), 2.16 (ddd, J = 14.0, 7.6, 6.6 Hz, 1H), 1.50-1.35 (m, 3H), 1.22 (d, J = 6.9 
Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; d6-acetone): δ 202.4, 200.7, 150.3, 135.3, 135.3, 130.1, 129.0, 129.9, 
129.6, 128.8, 76.3, 46.8, 43.4, 41.4, 37.8, 28.6, 18.3, 17.2, 16.7, 10.6. 
HRMS: Calculated [M+H]+ 349.1832, found 349.1851.  
 
 
41: An open 100-mL flask was charged with 40 (1.18 g, 3.6 mmol, 1.00 equiv), CeCl3!7H2O 
(Fisher, 1.342 g, 3.6 mmol, 1.0 equiv), technical grade MeOH (36 mL, 0.1 M), stirred until 
dissolved and cooled to -78 °C.  NaBH4 (Fisher, 0.14 g, 3.6 mmol, 1 equiv).  The resulting 
solution was stirred for 10 min at -78 °C and decanted into aq. HCl (1 M), the organic layer was 
separated and the aqueous layer extracted 2x with CH2Cl2.  The combined organic extracts were 
washed with brine and filtered through a sodium sulfate plug, which was subsequently rinsed 2x 
with CH2Cl2.  Concentration and subsequent high vacuum yielded colorless oil that was carried 
onto the next step without further purification. 
A 100-mL flask was charged with the crude allylic-alcohol, CH2Cl2 (36 mL, 0.1 M) and cooled to -
78 °C.  2,6-lutidine (Sigma, 0.50 g, 0.54 mL, 4.68 mmol, 1.3 equiv) was added followed by 
dropwise addition of TBSOTf (Sigma, 1.14 g, 0.99 mL, 4.32 mmol, 1.2 equiv) and the resulting 
solution was stirred -78 °C for 1 h before aq. NH4Cl (sat.) quench.  The organic layer was 
separated and the aqueous layer extracted 2x with CH2Cl2.  The combined organic extracts were 
washed with brine and filtered through a sodium sulfate plug, which was subsequently rinsed 2x 
with CH2Cl2.  Flash chromatography: EtOAc/hexanes (5:95) gave 41 as a colorless oil (1.38 g, 
3.234 mmol, 90%) 
 
1H-NMR (599 MHz; CDCl3): δ  5.69-5.66 (m, 1H), 5.39 (dt, J = 15.4, 2.3 Hz, 1H), 5.00 (ddd, J = 
8.8, 5.4, 3.2 Hz, 1H), 4.06 (s, 1H), 3.49 (s, 3H), 3.12 (dd, J = 10.3, 1.7 Hz, 1H), 2.61-2.55 (m, 1H), 
2.51-2.48 (m, 1H), 2.02-1.96 (m, 1H), 1.89-1.85 (m, 1H), 1.68-1.63 (m, 1H), 1.57-1.51 (m, 1H), 
1.35-1.30 (m, 1H), 1.25 (d, J = 6.8 Hz, 3H), 1.04 (ovlp m, 6H), 1.01-0.96 (m, 1H), 0.93-0.90 (m, 
15H), 0.03 (s, 3H), -0.01 (s, 3H). 
13C NMR (151 MHz; CDCl3): δ 175.2, 131.3, 127.5, 89.1, 77.3, 75.5, 62.7, 43.5, 37.6, 35.7, 32.63, 
32.59, 26.0, 24.6, 20.5, 18.3, 17.7, 16.3, 10.34, 10.22, -4.9, -5.2. 











    MeOH
2. TBSOTf, 2,6 lutidine
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42: An 100-mL flask was charged with 41 (1.48 g, 3.45 mmol, 1.00 equiv), CH2Cl2 (35 mL, 0.1 M) 
and cooled to -78 °C.  DIBAL-H (2.16 g, 15.21 g, 4.4 equiv) was added dropwise, and the solution 
was stirred at -78 °C for 5 min, warmed to 0 °C for ~ 1 min, and then recooled to -78 °C.  The 
reaction was partially quenched by dropwise addition of MeOH (5 mL) followed by an additional 
15 min at -78 °C, followed by aq. Na/K tartrate (sat.) and warming to RT.  The biphasic solution 
was stirred until the layers became clear.  The organic layer was separated and the aqueous 
layer extracted 2x with CH2Cl2.  The combined organic extracts were washed with brine and 
filtered through a sodium sulfate plug, which was subsequently rinsed 2x with CH2Cl2.  
Concentration and subsequent high vacuum yielded a colorless oil that was carried onto the next 
step without further purification. 
 An open 100-mL flask was charged with the crude diol and CH2Cl2 (7 mL, 0.5 M), and 
cooled to 0 °C.  Imidazole (Fisher, 0.28 g, 4.15 mmol, 1.2 equiv) was added followed by TBSCl 
(Oakwood, 0.57 g, 3.79 mmol, 1.1 equiv), and the resulting solution was stirred for 1 h at 0 °C 
before aq. NH4Cl (sat.) quench.  The organic layer was separated and the aqueous layer 
extracted 2x with CH2Cl2.  The combined organic extracts were washed with brine and filtered 
through a sodium sulfate plug, which was subsequently rinsed 2x with CH2Cl2.  Flash 
chromatography: EtOAc/hexanes (5:95) gave 42 as a colorless oil (1.69 g, 3.1 mmol, 90%) 
 
1H-NMR (599 MHz; CDCl3): δ 5.45 (t, J = 2.8 Hz, 2H), 3.86 (d, J = 4.6 Hz, 1H), 3.50 (t, J = 9.0 Hz, 
1H), 3.41 (dd, J = 9.6, 6.0 Hz, 1H), 3.37 (s, 3H), 3.00 (dd, J = 7.7, 2.2 Hz, 1H), 2.25 (dd, J = 11.2, 
6.4 Hz, 1H), 2.00 (s, 1H), 1.83 (dt, J = 13.1, 6.8 Hz, 2H), 1.72 (dt, J = 13.0, 6.2 Hz, 1H), 1.61 (dt, 
J = 12.2, 6.1 Hz, 1H), 1.52 (dtd, J = 14.2, 7.2, 3.8 Hz, 1H), 1.37 (dt, J = 14.8, 7.5 Hz, 1H), 1.00 (d, 
J = 6.9 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H), 0.89 (t, J = 7.6 Hz, 21H), 0.82 (d, J = 6.7 Hz, 3H), 0.78 
(d, J = 6.9 Hz, 3H), 0.02 (d, J = 27.6 Hz, 12H). 
13C NMR (151 MHz; CDCl3): δ 133.4, 132.9, 85.1, 77.8, 65.9, 60.3, 42.1, 37.40, 37.3, 36.9, 33.6, 
26.9, 25.9, 18.2, 18.2, 17.5, 16.5, 14.4, 10.52, 10.36, -3.9, -4.8, -5.3, -5.41. 
























43: A 100-mL round bottom flask was charged with 42 (0.93 g, 1.70 mmol, 1 equiv), PPh3 (AK, 
2.23 g, 8.5 mmol, 5 equiv), chloroactic acid (Sigma, 0.80 g, 8.5 mmol, 5 equiv), PhMe (17 mL, 0.1 
M), and then cooled to 0 °C.  DIAD (Sigma, 1.78 g, 1.67 mL, 8.5 mmol, 5 equiv) was added 
dropwise over 10 min, and the resulting solution was stirred at 0 °C for 10 min, RT for 12 h.  The 
solution was concentrated and purified by flash chromatography: Et2O/hexanes (1:99 to 4:96) 
gave 43 as a colorless oil (0.75 g, 1.207 mmol, 71%) 
1H-NMR (599 MHz; CDCl3): δ 5.49 (dd, J = 15.5, 6.6 Hz, 1H), 5.41 (dd, J = 15.5, 8.2 Hz, 1H), 
4.84 (q, J = 5.6 Hz, 1H), 4.04 (s, 2H), 3.95 (dd, J = 6.5, 3.5 Hz, 1H), 3.51 (t, J = 8.8 Hz, 1H), 3.42 
(dd, J = 9.6, 6.0 Hz, 1H), 3.37 (s, 3H), 3.03 (dd, J = 7.0, 2.7 Hz, 1H), 2.45-2.42 (m, 1H), 1.93-1.87 
(m, 1H), 1.86-1.80 (m, 1H), 1.73-1.68 (m, 1H), 1.68-1.62 (m, 1H), 1.59 (dq, J = 14.0, 6.8 Hz, 2H), 
1.01 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 7.7 Hz, 18H), 0.87-0.84 (m, 6H), 0.81 (d, J = 6.9 Hz, 3H), 
0.04 (s, 6H), 0.03 (s, 3H), -0.02 (s, 3H). 
13C NMR (151 MHz; CDCl3): δ 167.1, 133.9, 130.6, 84.8, 80.9, 76.5, 66.2, 60.1, 41.0, 39.9, 37.4, 
36.6, 33.0, 25.95, 25.91, 24.6, 18.25, 18.17, 16.80, 16.73, 16.1, 10.8, 9.7, -3.9, -4.8, -5.33, -5.40. 
HRMS: Calculated [M+Na]+ 643.3951, found 643.3949. 
 
44: A 100-mL round bottom flask was charged with 43 (1.16 g, 1.86 mmol, 1 equiv), THF (9 mL, 
0.05 M), and cooled to 0 °C.  TBAF (Sigma, 1 M in THF, 27.92 mL, 15 equiv) was added 
dropwise over 30 min, the resulting solution was warmed to RT and stirred for 48 h.  The reaction 
was mostly complete after 48 h (TLC), and quenched with CaCO3 (5.6 g, 55.8 mmol, 30 equiv) 
and H2O/EtoAC with 5 min additional stirring.  The organic layer was separated and the aqueous 
layer extracted 2x with EtoAc.  The combined organic extracts were washed with brine and 
filtered through a sodium sulfate plug, which was subsequently rinsed 2x with EtOAC.  Flash 
chromatography: acetone/hexanes (30:70) gave 44 as a colorless oil (0.51 g, 1.61 mmol, 86%). 
1H-NMR (599 MHz; d6-DMSO): δ 5.49 (dd, J = 15.5, 7.9 Hz, 1H), 5.37 (dd, J = 15.6, 6.2 Hz, 1H), 
4.42 (t, J = 5.1 Hz, 1H), 4.34 (d, J = 4.6 Hz, 1H), 4.24 (d, J = 5.3 Hz, 1H), 3.78 (q, J = 4.9 Hz, 1H), 
3.34-3.31 (m, 1H), 3.30 (s, 3H), 3.26-3.19 (m, 2H), 2.96 (dd, J = 6.2, 3.4 Hz, 1H), 2.16 (ttd, J = 
6.7, 6.3, 5.9 Hz, 1H), 1.81 (dp, J = 13.4, 6.7 Hz, 1H), 1.74-1.63 (m, 2H), 1.58-1.51 (m, 1H), 1.36-
1.21 (m, 2H), 0.95 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.4 Hz, 3H), 0.82-0.80 (ovlp m, 6H), 0.77 (d, J 
= 6.8 Hz, 3H). 
13C NMR (151 MHz; d6-DMSO): δ 132.7, 131.7, 84.8, 75.1, 73.6, 64.3, 59.6, 41.5, 37.2, 36.3, 
36.1, 32.5, 26.7, 17.0, 16.6, 15.8, 11.5, 10.5 
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44: A 9-dram round bottom flask was charged with 44 (0.44 g, 1.4 mmol, 1 equiv), MeCN/H2O (14 
mL, 0.1 M) and cooled to 4 °C.  TEMPO (Sigma, 0.22 g, 1.4 mmol, 1 equiv) and PIDA (AK 
scientific, 1.8 g, 5.6 mmol, 4.00 equiv) were added in single portions and the resulting solution 
was stirred vigorously and 4 °C.  The reaction was monitored by 1H NMR spectroscopy after 12 h 
(small aliquot added to excess MeOH, concentrated, and dissolved in CDCl3) for loss of the 
intermediate aldehyde. After 16 h, the reaction was decanted into MeOH and concentrated.  
Flash chromatography: EtOAc/hexanes (50:50) to AcOH/EtOAc/hexanes (1:50:49) gave 45 as a 
colorless oil (0.39 g, 1.19 mmol, 84%). 
1H-NMR (599 MHz; CDCl3): δ 6.97 (dd, J = 15.9, 7.6 Hz, 1H), 6.23 (d, J = 15.9 Hz, 1H), 3.46 (dt, 
J = 8.6, 4.4 Hz, 1H), 3.42 (s, 3H), 3.28 (dd, J = 7.1, 4.5 Hz, 1H), 2.87-2.81 (m, 1H), 2.57 (p, J = 
7.0 Hz, 1H), 2.42 (h, J = 6.4 Hz, 1H), 1.93 (ddd, J = 13.7, 9.4, 4.1 Hz, 1H), 1.87-1.70 (m, 3H), 
1.59-1.53 (m, 3H), 1.45 (dp, J = 14.6, 7.3 Hz, 1H), 1.17 (d, J = 6.9 Hz, 3H), 1.11-1.09 (m, 6H), 
0.97-0.95 (m, 6H). 
13C NMR (151 MHz; CDCl3): δ 203.9, 178.9, 148.2, 128.2, 86.9, 76.9, 61.0, 42.5, 42.0, 41.6, 35.1, 
34.3, 27.8, 17.8, 17.0, 16.0, 12.9, 10.1. 
HRMS: Calculated [M+Na]+ 351.2142, found 351.2140. 
 
 
46: A 50 mL round bottom flask was charged with 45 (0.42 g, 1.27 mmol, 1 equiv), EDC!HCl 
(Chem-impex, 0.36 g, 1.90 mmol, 1.5 equiv), HOBT (Sigma, 0.21 g, 1.52 mmol, 1.5 equiv), and 
the flask was cooled to 0 °C.  DMF (13 mL, 0.1 M) was added and the resulting solution was 
stirred at 0 °C for 30 min, followed by HSNAC (0.18 g, 1.52 mmol, 1.2 equiv), stirred at 0 °C for 
an additional 10 min before DMAP addition (cat., ~1 mg).  The solution was stirred at at 0 °C for 
an additional 10 min before warming to RT and 24 h additional stirring.  The reaction was diluted 
with EtOAc, washed with H2O. The organic layer was separated and the aqueous layer extracted 
2x with EtoAc.  The combined organic extracts were washed with brine and filtered through a 
sodium sulfate plug, which was subsequently rinsed 2x with EtOAC.  Flash chromatography 
[column topped with (SiO2:CuSO4)]: EtOAc (46) as a colorless oil (0.32 g, 0.77 mmol, 61%). 
 
1H-NMR (599 MHz; d6-acetone): δ 7.34 (s, 1H), 6.96 (dd, J = 15.9, 8.4 Hz, 1H), 6.22 (dd, J = 
15.9, 0.8 Hz, 1H), 3.77 (d, J = 5.3 Hz, 1H), 3.46 (dq, J = 8.6, 4.3 Hz, 1H), 3.36 (s, 3H), 3.35-3.26 
(m, 3H), 3.06-2.92 (m, 3H), 2.97-2.83 (m, 2H), 2.47-2.41 (m, 1H), 1.91 (ddd, J = 13.6, 9.6, 4.0 Hz, 
HO
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1H), 1.85 (s, 3H), 1.63-1.57 (m, 1H), 1.49-1.35 (m, 2H), 1.17 (d, J = 6.9 Hz, 3H), 1.20-1.15 (ovlp 
m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H), 0.95-0.92 (ovlp m, 6H). 
13C NMR (151 MHz; d6-acetone): δ 203.9, 202.4, 170.0, 150.1, 130.0, 87.5, 76.3, 61.0, 51.8, 
43.4, 41.6, 39.5, 36.1, 35.0, 29.2, 28.7, 22.8, 18.7, 17.3, 16.8, 13.7, 10.6 
HRMS: Calculated [M+H]+ 430.2622, 430.2628. 
 
49: A 4 dram vial was charged with 48 (0.022 g, 0.071 mmol, 1 equiv), CeCl3!7H2O (0.026 g, 
0.071 mmol, 1 equiv), and MeOH (0.7 mL, 0.1 M).  The resulting solution was stirred at RT until 
the solids dissolved, and subsequently cooled to -78 °C.  NaBH4 (0.003 g, 0.071 mmol, 1 equiv) 
was added in a single portion.  The reaction was stirred at -78 °C for 20 min before the solution 
was decanted into aq. HCl (1 M) and CH2Cl2.  The organic layer was separated and the aqueous 
layer extracted 2x with CH2Cl2.  The combined organic extracts were washed with brine and 
filtered through a sodium sulfate plug, which was subsequently rinsed 2x with CH2Cl2 and 
concentrated.  The crude allylic alcohol was used in the subsequent step without further 
purification. 
 A 4 dram vial was charged with the crude allylic alcohol (0.071 mmol, 1 equiv), CH2Cl2 
(0.7 mL, 0.1 M) and cooled to 0 °C.  NEt3 (0.009 g, 0.013 mL, 0.092 mmol, 1.3 equiv), 4-
nitrobenzoic anhydride (0.027 g, 0.085 mL, 0.085 mmol, 1.2 equiv), and DMAP (~1 mg, cat.) 
were added sequentially and the solution was stirred at 0 °C for 20 min, then quenched with aq. 
sodium bicarbonate (sat.).  The organic layer was separated and the aqueous layer extracted 2x 
with CH2Cl2.  The combined organic extracts were washed with brine and filtered through a 
sodium sulfate plug, which was subsequently rinsed 2x with CH2Cl2 and concentrated.  Flash 
chromatography: EtOAc/hexanes (5:95) gave 49 as a colorless solid (0.027 g, 0.059 mmol, 83%). 
1H-NMR (599 MHz; CDCl3): δ 8.33 (d, J = 8.8 Hz, 2H), 8.25 (d, J = 8.8 Hz, 2H), 5.57 (s, 1H), 5.43 
(dd, J = 15.5, 2.9 Hz, 1H), 5.29-5.25 (m, 1H), 4.62-4.58 (m, 1H), 3.41 (s, 3H), 3.05 (dd, J = 9.6, 
1.2 Hz, 1H), 2.77-2.71 (m, 1H), 2.44-2.38 (m, 1H), 2.06 (dt, J = 13.8, 7.1 Hz, 1H), 1.76-1.70 (m, 
3H), 1.61-1.55 (m, 2H), 1.30 (d, J = 6.9 Hz, 3H), 1.08 (d, J = 7.0 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 
0.94 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 174.2, 164.0, 150.6, 135.5, 131.9, 130.8, 128.3, 123.7, 85.4, 78.7, 
77.6, 59.7, 43.6, 41.4, 34.8, 34.3, 31.1, 24.6, 19.0, 17.0, 16.51, 16.40, 9.1 
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Structure Determination. 
 Colorless needles of 49 were grown from a hexanes solution of the compound at -30 deg. 
C.  A crystal of dimensions 0.26 x 0.01 x 0.01 mm was mounted on a Rigaku AFC10K Saturn 
944+ CCD-based X-ray diffractometer equipped with a low temperature device and Micromax-
007HF Cu-target micro-focus rotating anode (λ = 1.54187 A) operated at 1.2 kW power (40 kV, 
30 mA).  The X-ray intensities were measured at 85(1) K with the detector placed at a distance 
42.00 mm from the crystal.  A total of 2633 images were collected with an oscillation width of 1.0
° in ω.  The exposure times were 15 sec. for the low angle images, 75 sec. for high angle.  The 
integration of the data yielded a total of 98528 reflections to a maximum 2θ value of 136.48° of 
which 9383 were independent and 8176 were greater than 2σ(I).  The final cell constants (Table 
1) were based on the xyz centroids 44319 reflections above 10σ(I).  Analysis of the data showed 
negligible decay during data collection; the data were processed with CrystalClear 2.0 and 
corrected for absorption.  The structure was solved and refined with the Bruker SHELXTL 
(version 2008/4) software package, using the space group P2(1)2(1)2(1) with Z = 4 for the 
formula C25H35NO7.  There are two crystallographically independent molecules per asymmetric 
unit.  All non-hydrogen atoms were refined anisotropically with the hydrogen atoms placed in 
idealized positions.  Full matrix least-squares refinement based on F2 converged at R1 = 0.0518 
and wR2 = 0.1275 [based on I > 2sigma(I)], R1 = 0.0591 and wR2 = 0.1328 for all data.  
Additional details are presented in Table 1 and are given as Supporting Information in a CIF file.  
Acknowledgement is made for funding from NSF grant CHE-0840456 for X-ray instrumentation. 
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51: A 50 mL round bottom flask was charged with 50 (0.69 g, 1.45 mmol, 1 equiv), CH2Cl2 (15 
mL, 0.1 M) and cooled to -78 °C.  2,6-lutidine (Sigma, 0.40 g, 3.77 mmol, 2.6 equiv) was added 
followed by dropwise addition of TBSOTf(Oakwood, 0.92 g, 3.48 mmol, 2.4 equiv) and additional 
stirring for 1 h at -78 °C.  The reaction was quenched with aq. NH4Cl (sat),and  decanted into aq. 
HCl (1 M).  The organic layer was separated and the aqueous layer extracted 2x with CH2Cl2.  
The combined organic extracts were washed with brine and filtered through a sodium sulfate 
plug, which was subsequently rinsed 2x with CH2Cl2 and concentrated.  The silyl-ester survived 
this work-up and was subsequently hydrolyzed in MeOH (15 mL, 0.1 M) at 0 °C with K2CO3 (0.22 
g, 1.59 mmol, 1.1 equiv).  After 45 min, the reaction was diluted with EtOAc and washed with aq. 
HCl (1 M).  The organic layer was separated and the aqueous layer extracted 2x with EtoAc.  The 
combined organic extracts were washed with brine and filtered through a sodium sulfate plug, 
which was subsequently rinsed 2x with EtOAC.  AcOH/EtOAc/hexanes (1:10:89) gave 51 as a 
colorless oil (0.45 g, 0.75 mmol, 52%).  Note: rotamers were observed in CDCl3. Denoted in 
parentheses in the 13C. 
1H-NMR (599 MHz; CDCl3): δ 8.07-8.06 (m, 1H), 7.79-7.78 (m, 1H), 7.64-7.61 (m, 1H), 7.44-7.41 
(m, 1H), 6.93 (ddd, J = 15.9, 7.2, 3.0 Hz, 1H), 6.11 (dd, J = 16.0, 1.2 Hz, 1H), 5.04-4.98 (m, 2H), 
4.84 (qd, J = 8.0, 2.8 Hz, 2H), 3.77 (t, J = 5.2 Hz, 1H), 3.57-3.54 (m, 1H), 2.93-2.90 (m, 1H), 2.73-
2.68 (m, 1H), 2.49-2.46 (m, 1H), 2.03-1.98 (m, J = 3.3 Hz, 1H), 1.64-1.63 (m, 1H), 1.50-1.43 (m, 
1H), 1.34 (dp, J = 14.1, 7.1 Hz, 1H), 1.18-1.16 (m, 3H), 1.12 (dt, J = 9.3, 4.6 Hz, 1H), 1.07-1.05 
(m, 3H), 1.01 (d, J = 6.8 Hz, 3H), 0.92-0.84 (m, 15H), 0.04 (dd, J = 6.9, 1.8 Hz, 6H). 
13C NMR (151 MHz; CDCl3): δ 203.9, (150.26, 150.23), 147.1, 134.8, 133.6, (128.7, 128.36), 
128.34, 127.9, 124.7, 96.6, 83.9, (76.65, 76.61), 67.0, 41.62, (41.53, 41.48), (40.98, 40.95), 
(35.94, 35.90), 34.5, (26.62, 26.59), 25.9, (18.27, 18.24), 18.13, 16.5, 14.3, 9.7, -4.36, -4.51. 
HRMS: Calculated [M+Na]+ 616.3276, found 616.3275. 
 
52: A 25 mL flask was charged with 51 (0.050 g, 0.084 mmol, 1 equiv) and CH2Cl2 (0.8 mL, 0.1 
M).  Ghosez’s reagent (Acros, 0.025 g, 0.025 mL, 0.185 mmol, 2.2 equiv) was added dropwise 
and the resulting solution was stirred for 90 min at RT.  The solution was concentrated and 
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Concurrently, a second 25 mL flask was charged with Bis(2,2,2-trifluoroethyl) ethylphosphonate 
(0.076 g, 0.278 mmol, 3.3 equiv) and THF (0.8 mL) and cooled to - 98 °C (a deep bath of MeOH 
with temperature maintained by careful addition of liquid N2.)  LHMDS (Sigma, 1 M in THF, 0.28 
mL, 3.3 equiv) was added dropwise down the side of the flask and this solution was stirred at - 98 
°C for 10 min.  The acid chloride generated from 51 was dissolved in THF (0.4 mL, 0.2 M) and 
transferred dropwise to the lithiated phosphonate solution via cannula, down the side of the flask.  
The transfer was quantitated with additional THF (0.4 mL, 0.2 M) and subsequent dropwise 
cannula.  The resulting solution was stirred at - 98 °C for 2 h and quenched with aq. NH4Cl (sat.) 
The organic layer was separated and the aqueous layer extracted 2x with CH2Cl2.  The combined 
organic extracts were washed with brine and filtered through a sodium sulfate plug, which was 
subsequently rinsed 2x with CH2Cl2.  Flash chromatography: EtOAc/hexanes (10:90) provided a 
crude silyl-ether that was deprotected immediately in the following step. 
To an open 1.5 mL epi-tube was added crude silyl-ether and MeCN (0.16 mL, 0.5 M) and aq. HF 
(48%, 0.1 mL).  The reaction was monitored by TLC and upon completion it was diluted with 
CH2Cl2 (10 mL) and carefully quenched with saturated sodium bicarbonate. The aqueous layer 
was extracted 2x with CH2Cl2. Filtration through a sodium sulfate plug then rinsed 2x with CH2Cl2 
and concentrated.  Flash chromatography: EtOAc/hexanes (30:70) gave 52 (0.017 g, 0.023 
mmol, 27%).  Note: the epimeric center formed α to the phosphonate resulted in a complex 1H 
NMR spectrum, where the annotation is apparent and unselected for a single diasteromer. 
Assumed epimeric carbons are denoted in parentheses in the 13C. 
 
1H-NMR (599 MHz; d6-acetone): δ 1H-NMR (599 MHz; aceton-d6): δ  8.10-8.07 (m, 1H), 7.88-7.82 
(m, 1H), 7.79-2.75 (m, 1H), 7.60-7.57 (m, 1H), 6.95-6.89 (m, J = 8.0 Hz, 1H), 6.21-6.18 (m, J = 
0.9 Hz, 1H), 5.10-4.92 (m, 2H), 4.92-4.80 (m, 2H), 4.70-4.60 (m, 4H), 4.07-3.93 (m, 1H), 3.82 (t, J 
= 4.8 Hz, 0.5H), 3.72-3.66 (ovlp m, J = 6.6 Hz, 1.5H), 3.46-3.34 (m, 1.5H), 3.24-3.20 (m, 0.5H), 
3.07-2.97 (m, J = 6.8, 3.8 Hz, 1H), 2.80-2.77 (m, 1H), 2.44-2.36 (m, 1H), 2.03-1.98 (m, 1H), 1.59-
1.40 (m, 4H), 1.37-1.27 (m, 5H), 1.20-1.11 (m, 4H), 1.09-1.01 (m, 6H), 0.99-0.87 (m, 6H). 
13C NMR (151 MHz; d6-acetone): (209.32, 209.28), (207.27, 207.25), (206.2, 205.9), (204.06, 
203.95), (151.2, 150.9), (135.4, 135.1), (134.49, 134.40), (129.90, 129.73), (129.55, 129.47), 
(129.22, 129.09), (125.31, 125.29), (97.46, 97.37), (85.1, 83.3), (75.93, 75.80), (67.55, 67.46), 
(63.1, 62.87, 62.83, 62.77, 62.73), 50.1, (48.91, 48.89), (46.4, 46.1), (45.5, 45.2), (43.66, 43.63), 
(43.58, 43.56), (41.5, 41.3), (36.34, 36.27), (35.81, 35.71), (28.36, 28.31), (19.2, 18.9), (17.36, 
17.17), (14.89, 14.73), 12.9, (12.30, 12.26), 12.12, (11.27, 11.22), 10.6 
HRMS: Calculated [M+Na+] 758.2499, found 758.2500. 
 





All H2O was obtained from a Millipore Milli-Q system (serial P3MNO3809A) using Millipore Q-
Gard 2/Quantum Ex Ultrapure organex cartridges.  LB broth Miller was obtained from EMD and 
autoclaved before use.  Glycerol was obtained from EMD, HEPES was obtained from 
Calbiochem (Omnipur grade), Isopropyl-b-D-thiogalactopyranoside (IPTG) was obtained from 
Gold Biotechnology.  Kanamycin Sulfate (Kan) was obtained from Amresco.  ACS grade 
imidazole and NaCl were obtained from Fisher Scientific.  pH was determined on a Symphony 
SB70P pH meter (serial SN005695) calibrated according to manufacturer’s specifications.  Ni-
NTA agarose was purchased from Qiagen and pre-equilibrated with five column volumes of lysis 
buffer.  PD-10 columns were purchased from GE and pre-equilibrated with five column volumes 
of storage buffer.   Cells were lysed using a model 705 Sonic Dismembrator purchased from 
Fisher Scientific.  Optical density (OD600) was determined using an Eppendorf Biophotometer. 
 
Bap122 cells bearing plasmids for expression of respective PKS modules were taken from glycerol 
cell stocks stored at - 80°C and grown in LB (10mL) with Kan (50 mg/L), and grown overnight at 
37°C.  The following morning, LB (1L) containing Kan (50 mg/L) was inoculated with the entire 
overnight culture, and shaken at 37°C until they reached an OD600 of 0.6-0.7 at which point they 
were removed and allowed to cool to RT, then to 20 °C.  When an OD600 of 0.8 was reached, the 
cultures were induced with IPTG (300µM) and shaken at 180RPM at 20 °C for 18 hours.  Cells 
were pelleted at 5000g (4 °C) for 10 minutes. 
 
PKS Crude Cell Lysate Preparation 
 
Frozen cells were resuspended in 100 mL of storage buffer  [HEPES (50 mM), NaCl (150 mM), 
EDTA (1 mM), glycerol (20% v/v), pH 7.2] per 20 grams of pelleted culture broth via vortex.  Cells 
were lysed by addition of 1 mg/ml lysozyme immediately before sonication in a brine/ice at 70% 
power 100 x 5s with 15s rest periods.  Cellular debris was pelleted in a precooled (4 °C) 
centrifuge at 65,000g for 10 min.  Crude cell lysate was either used immediately or flash frozen in 
N2 and thawed on ice without discernible loss in activity.  Protein concentration was crudely 
normalized to that of purified protein though densitometry, and used without further manipulation. 
 
Pik TE Purification 
 
The following steps were conducted in <2 hours for maximum and reproducible enzymatic 
activity.  Cells were suspended in 5 mL of lysis buffer [HEPES (50 mM), NaCl (300 mM), 
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imidazole (10mM), glycerol (10% v/v), pH 8.0] per 20 grams of pelleted culture broth via vortex.  
Cells were lysed by addition of 1 mg/ml lysozyme immediately before sonication in a brine/ice at 
70% power 100 x 5s with 15s rest periods.  Cellular debris was pelleted in a precooled (4 °C) 
centrifuge at 65,000 g for 10 min.  Cellular debris was pelleted in a precooled (4°C) centrifuge at 
40,000 g for 10 min, and the supernatant was applied to 4 mL of Ni-NTA resin and allowed to drip 
through.  15 mL of wash buffer [HEPES (50 mM), NaCl (300 mM), imidazole (30mM), glycerol 
(10% v/v), pH 8.0] was added, the column was gently pressurized with a syringe, and the enzyme 
of interest was eluted with 15 mL of elution buffer [HEPES (50 mM), NaCl (300 mM), imidazole 
(300mM), glycerol (10% v/v), pH 8.0] with gentle syringe pressure.  Protein containing fractions 
were determined via Bradford assay and pooled.  Buffer exchange was performed using a PD-10 
column, and protein containing fractions were determined via Bradford assay and pooled, 
aliquoted, flash frozen in liquid N2, and stored at -80 °C. 
 
Incubation of 10-12 with PikAIII-TE 
Reaction conditions: sodium phosphate buffer (50 mM, 2.5% v/v glycerol, 50 mL total, pH = 7.2), 
pentaketide 10-12 (70 mg, 0.2 mmol, 4 mM) MM-SNAC (10 equiv, 40 mM), NADP+ (0.1 equiv, 0.4 
mM), glucose-6-phosphate (2.5 equiv, 10 mM), glucose-6-phosphate dehydrogenase (2 
units/mL), 2-vinylpyridine (20 mM), cell free PikAIII-TE (Crude cell estimated conc. ~15 µM, 4 µM 
in reaction, 0.1 mol %), 8 hours, stationary, RT.  
 
Workup and purification:  Quenched with acetone (2x volume, 100mL), placed in a -20 °C freezer 
for 1 h and filtered through a celite plug.  Remaining insoluble material was suspended in acetone 
and this solution was used to rinse the celite plug.  Acetone was removed through rotary 
evaporation and the aqueous layer was saturated with NaCl and extracted 3x EtOAc. Combined 


































then rinsed 2x with EtOAc and concentrated.  Flash chromatography: acetone/hexanes (8:92) 
afforded compounds 34-39. 
 
34 from pentaketide 10 (2.5 mg, 0.009 mmol, 4% yield)  
1H-NMR (599 MHz; CDCl3): δ 5.54 (dd, J = 15.7, 8.0 Hz, 1H), 5.39 (d, J = 15.7 Hz, 1H), 3.41 
(ddd, J = 8.7, 5.3, 3.6 Hz, 1H), 2.51 (dq, J = 19.0, 6.4 Hz, 2H), 2.34 (h, J = 6.8 Hz, 1H), 2.09-2.03 
(m, 1H), 1.91 (ddd, J = 13.3, 5.7, 4.1 Hz, 1H), 1.60-1.53 (m, 3H), 1.42-1.33 (m, 3H), 1.05 (d, J = 
6.8 Hz, 3H), 1.03 (d, J = 6.4 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 
6.8 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 211.9, 135.0, 131.7, 81.5, 76.7, 52.1, 44.6, 42.2, 39.8, 39.6, 27.2, 
15.6, 15.0, 14.4, 10.2, 7.9. 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1931. 
 
35 from pentaketide 10 (2.5 mg, 0.009 mmol, 4% yield)  
1H-NMR (599 MHz; CDCl3): δ  6.87 (dd, J = 15.9, 8.1 Hz, 1H), 6.18 (dd, J = 15.9, 0.8 Hz, 1H), 
3.57-3.52 (m, 1H), 2.77 (h, J = 6.9 Hz, 1H), 2.60 (dq, J = 14.0, 7.0 Hz, 1H), 2.55-2.42 (m, 3H), 
2.15-2.10 (m, 1H), 1.90 (s, 1H), 1.55 (dqd, J = 14.3, 7.2, 3.9 Hz, 1H), 1.47-1.39 (m, 1H), 1.24 (dt, 
J = 13.8, 6.7 Hz, 2H), 1.10 (d, J = 6.8 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H), 1.07-1.03 (ovlp m, 6H), 
0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 215.0, 203.2, 149.9, 128.4, 75.9, 43.7, 42.5, 41.4, 36.1, 34.5, 27.3, 
17.2, 16.7, 13.9, 10.4, 7.7 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1932. 
 
36 from pentaketide 11 (2 mg, 0.007 mmol, 3.5% yield)  
1H-NMR (599 MHz; CDCl3): δ 5.54 (dd, J = 15.7, 8.5 Hz, 1H), 5.42 (d, J = 15.7 Hz, 1H), 3.37 (dt, 
J = 7.9, 4.2 Hz, 1H), 2.55-2.48 (m, 2H), 2.30 (dq, J = 14.2, 7.0 Hz, 1H), 2.06 (dqd, J = 12.7, 6.5, 
4.1 Hz, 1H), 1.91 (ddd, J = 13.3, 5.8, 4.0 Hz, 1H), 1.60-1.53 (m, 2H), 1.44-1.37 (m, 2H), 1.06 (d, J 
= 6.9 Hz, 3H), 1.03 (d, J = 6.4 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.89 (d, J 
= 6.8 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 211.8, 136.1, 130.8, 81.5, 76.5, 52.0, 44.6, 42.4, 39.67, 39.52, 
27.4, 17.3, 15.1, 14.4, 10.0, 7.9. 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1930. 
 
37 from pentaketide 11 (2 mg, 0.007 mmol, 3.5% yield) 
1H-NMR (599 MHz; CDCl3): δ 6.83 (dd, J = 15.9, 8.7 Hz, 1H), 6.16 (d, J = 15.9 Hz, 1H), 3.48 (dt, 
J = 8.5, 4.4 Hz, 1H), 2.77 (h, J = 6.9 Hz, 1H), 2.62 (dq, J = 13.9, 7.0 Hz, 1H), 2.56-2.50 (m, J = 
17.8, 7.3 Hz, 1H), 2.47-2.40 (m, 2H), 2.15-2.10 (m, 1H), 1.62-1.53 (m, 1H), 1.46 (tt, J = 14.7, 7.4 
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Hz, 1H), 1.25-1.20 (m, 2H), 1.12 (d, J = 6.8 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H), 1.06-1.03 (m, 6H), 
0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 215.2, 203.2, 149.1, 129.3, 76.3, 43.8, 42.7, 41.3, 36.3, 34.6, 27.7, 
17.4, 16.6, 16.4, 10.1, 7.8. 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1930. 
 
38 from pentaketide 12 (1 mg, 0.004 mmol, 2% yield)  
1H-NMR (599 MHz; CDCl3): δ 5.54 (dd, J = 15.7, 8.5 Hz, 1H), 5.41 (d, J = 15.7 Hz, 1H), 3.37 (dt, 
J = 8.2, 4.3 Hz, 1H), 2.54-2.48 (m, 2H), 2.33-2.27 (m, 1H), 2.04 (dqd, J = 12.6, 6.4, 4.1 Hz, 1H), 
1.91 (ddd, J = 13.3, 5.9, 4.0 Hz, 1H), 1.59-1.51 (m, 3H), 1.43-1.37 (m, 2H), 1.06 (d, J = 6.9 Hz, 
3H), 1.02 (d, J = 6.4 Hz, 3H), 0.97-0.95 (ovlp m, 6H), 0.87 (d, J = 6.8 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 211.9, 136.0, 130.8, 81.5, 76.6, 52.1, 44.6, 42.3, 39.67, 39.61, 
27.5, 17.3, 14.9, 14.4, 10.1, 8.1. 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1931. 
 
39 from pentaketide 12 (1 mg, 0.004 mmol, 2% yield)  
1H-NMR (599 MHz; CDCl3): δ 6.91 (dd, J = 15.9, 8.0 Hz, 1H), 6.18 (d, J = 15.9 Hz, 1H), 3.48-3.47 
(m, 1H), 2.80-2.75 (m, 1H), 2.60-2.37 (ovlp m, 4H), 2.13-2.09 (m, 1H), 1.84-1.80 (m, 1H), 1.59-
1.52 (m, 1H), 1.47-1.40 (m, 1H), 1.26-1.22 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 
3H), 1.06-1.02 (m, 6H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (151 MHz; CDCl3): δ 214.9, 203.2, 149.0, 129.1, 76.3, 43.7, 42.3, 41.4, 36.0, 34.3, 27.6, 
17.08, 16.94, 15.9, 10.0, 7.8. 
HRMS: Calculated [M+Na]+ 291.1931, found 291.1932. 
 
Reaction conditions: sodium phosphate buffer (400 mM, 4 mL total, pH = 7.2), hexaketide 46 or 
47 (1.7 mg, 0.004 mmol, 1mM), 2-vinylpyridine (8 mM), purified Pik TE (10 µM in reaction, 1 mol 
%), 18 hours, stationary, RT.  
 
Workup and analysis:  After 18 h, reactions were directly extracted 3x EtOAc.  Combined organic 



























rinsed 2x with EtOAc and concentrated.  Crude reaction mixtures were analyzed by 1H NMR in 
d6-acetone and correlated to known compounds 40 and 45 (chapter 3) 
 
40: From hexaketide 47, 40 was the major product, with some 47 detectable but below reliable 
integration.  Estimated >95% conversion. 
45: From hexaketide 46, 45 was the only detectable product. 
 
Reaction conditions: sodium phosphate buffer (400 mM, 4 mL total, pH = 7.2), hexaketide 46 or 
47 (1.7 mg, 0.004 mmol, 1mM), 2-vinylpyridine (8 mM), purified Pik TE (10 µM in reaction, 1 mol 
%), 18 hours, stationary, RT.  
 
Workup and analysis:  After 18 h, reactions were directly extracted 3x EtOAc.  Combined organic 
layers were washed with brine and filtered through a sodium sulfate plug was performed then 
rinsed 2x with EtOAc and concentrated.  Crude reaction mixtures were analyzed by 1H NMR in 
d6-acetone and correlated to known compound 40 (chapter 3) 
 
40: From hexaketide 47, 40 was the only detectable product. 
45: From hexaketide 46, 48 was the only detectable product. 
 
As there is no authentic standard to confirm the structure of 48, a scaled up reaction (100 mL) 
under otherwise identical conditions provided 48 which was purified via flash chromatography: 
EtOAc/hexanes (10/90) afforded compound 48 (0.028 g, 0.09 mmol, 90%). 
 
1H-NMR (599 MHz; CDCl3): δ 6.59 (dd, J = 16.3, 8.0 Hz, 1H), 6.06 (d, J = 16.3 Hz, 1H), 4.48 
(ddd, J = 9.6, 7.1, 5.0 Hz, 1H), 3.45 (s, 3H), 3.18 (dd, J = 8.9, 1.8 Hz, 1H), 2.77-2.65 (m, 3H), 
2.08-2.02 (m, 1H), 1.80-1.75 (m, 2H), 1.62 (ddd, J = 14.3, 8.1, 5.9 Hz, 1H), 1.26 (d, J = 7.0 Hz, 
3H), 1.16-1.12 (ovlp m, 1H), 1.13 (d, J = 6.7 Hz, 3H), 1.09 (d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.9 Hz, 
3H), 0.93 (t, J = 7.4 Hz, 3H). 
HS
Pik TES148C



























13C-NMR (151 MHz; CDCl3): δ 204.6, 173.5, 146.8, 128.8, 86.2, 80.8, 60.2, 42.8, 42.4, 39.7, 36.6, 
34.1, 25.0, 17.4, 16.2, 15.60, 15.45, 9.5 
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